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Abstract
The role of NF-kB regulation of eosinophil apoptosis and survival;
Implications for the pathogenesis of Hodgkin's disease
In inflammatory diseases such as asthma inappropriately recruited or activated
eosinophilic granulocytes may cause damage to the tissue in the respiratory tract by
release of their toxic contents. This can be resolved by efficient removal of activated
eosinophils from inflammatory sites. Ligation of specific cell surface receptors and the
consequent triggering of diverse signal transduction pathways control eosinophil
functional responsiveness and physiological programmed cell death or apoptosis. During
apoptosis eosinophils undergo a series of characteristic changes (e.g. shrinkage,
chromatin condensation, expression of cell surface phosphatidylserine) to shutdown their
secretory capacity of toxic cell contents and marks them for 'silent' removal from
inflamed sites by macrophages. However, the precise role of apoptosis in eosinophilic
inflammatory disease and other diseases where eosinophils are observed in abundance
(e.g. Hodgkin's disease) has not been fully elucidated.
Apoptosis is regulated by extracellular stimuli, such as TNFa, FasL, and their cell
surface receptors by activating various death pathways such as the caspase pathway.
However, the pro-inflammatory cytokine TNFa can also trigger the NF-kB pathway for
transcriptional activity which is responsible for synthesis of survival and pro¬
inflammatory proteins. There is a delicate balance between these dual pathways, pro-
survival and pro-apoptotic, generated by TNFa. Inhibition of TNFa -mediated NF-kB
activation ultimately un-masks the caspase-dependent pro-apoptotic properties of TNFa.
In particular, the role ofNF-kB activation in the regulation of eosinophil survival and the
potential contribution of apoptosis to eosinophils presence found in Hodgkin's disease
was investigated.
Activation ofNF-kB is mediated by signal-induced phosphorylation via the IKK
complex by TNFa and degradation of its inhibitor, licBa in the cytoplasm. Degradation
of IxBa in the cytoplasm by TNFa and translocation ofNF-kB into the nucleus were
determined by immunofluorescence and western blotting analysis. Various
pharmacological reagents (e.g., the fungal metabolite gliotoxin and the proteasome
inhibitor Mgl32) and the HIV-1-TAT transduction peptide linked with IxBa were used
to stabilise and over-express IxBa in the cytoplasm resulting in the prevention of
translocation ofNF-kB into nucleus. The 11 amino acid TAT peptide linked with super-
suppressive form of IxBa (lKBa.32,36) was for the first time produced and transduced
into eosinophils, HeLa and A549 cell lines, and resulted in an inhibition ofNF-kB.
Inhibition of TNFa mediated iKBa degradation and NF-kB activation by gliotoxin,
Mgl32 and TAT- IkBo.32,36 induced significant eosinophil apoptosis and prevented NF-
kB regulated IL-8 production. It was notable however that the effect of TAT-hcBa32,36
I
was donor dependent, in that some populations of eosinophils failed to undergo enhanced
apoptosis, suggesting the involvement of other pathways distinct from NF-tcB.
Hodgkin's disease (or Hodgkin's lymphoma) is characterised by a minority (about 1% of
tumour mass) of neoplasic cells, the so called Hodgkin-Reed-Sternberg (FIRS) cells, and
where the 'tumour' mass is comprised of predominantly recruited eosinophils. However,
the mechanisms responsible for this eosinophil accumulation are currently unknown. In
vitro, eosinophils cultured with supernatant derived from HRS cells caused a profound
survival of eosinophil (e.g., supernatant treated eosinophils survived up to 6 times longer
than non-treated eosinophils). This effect was blocked by various NF-kB inhibitors which
caused eosinophil apoptosis, indicating the potential of NF-icB as a target for anti-tumour
therapy in Hodgkin's disease.
In summary, these data strongly suggest the important role ofNF-kB in controlling
eosinophil responsiveness and apoptosis which may provide alternative therapeutic
agents for the treatment of eosinophilic diseases, including asthma, eczema, rhinitis and
Hodgkin's disease where eosinophils are present in abundance.
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Chapter layout and aims are;
Chapter 1; General Introduction. This introduction summarises the knowledge to date
on the function of eosinophils in inflammatory diseases. Then the mechanism regulating
apoptosis and the NF-icB pathway is summarised.
Chapter 3; The methodology to investigate the function of NF-kB in granulocytes.
Methodology of studying granulocyte apoptosis was investigated. This is continuous
work from our previous publication Ward et al., 1999 (see appendix for the paper).
Chapter 4; The inhibition of NF-kB un-mask the ability of TNFa to induce
apoptosis in eosinophils. This study was investigated by the usage ofNF-kB inhibitors,
gliotoxin and Mgl32. This chapter is based on my previous publication, Fujihara et al.,
2002, (see appendix for the paper.)
Chapter 5; Use of TAT-IxBa for the inhibition of NF-kB in HeLa, A549 and
eosinophils, and its effect on eosinophil apoptosis. This study was investigated by the
usage of the transduction peptide HIV-1-TAT linked with IkBoc to inhibit specifically
NF-kB in HeLa, A549 cells and eosinophils. The effect ofNF-kB inhibition and
apoptosis in eosinophils are investigated.
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Chapter 6; Hodgkin's disease and eosinophilia. The observation of enhanced survival








Eosinophils are thought to be key cells involved in host defence and are particularly
effective against helminth parasite worm infections (Buttervvorth et al., 1975, Gleich
and Adolphoson, 1986). On the other hand, excessive eosinophil recruitment or
activation at inflammatory sites likely causes surrounding tissue damage by liberation
of their granules toxic contents and by release of pro-inflammatory cytokines and
chemokines. Therefore, effective removal of eosinophils from inflammatory sites may
be a key factor for successful resolution of the inflammatory process.
Eosinophils are terminally differentiated leukocytes which are derived from bone
marrow, where approximately the mean turn over of eosinophils is approximately
2.2x10s cells/kg/day (Parwaresch et al., 1979). In healthy donors, 2-5% among the
peripheral leukocytes are eosinophils. Once in the circulation, the half life of
eosinophils is approximately 18 hours. However, the half-life of eosinophils is
prolonged during specific circumstances, including inflammation. A typical view of
eosinophils under light microscopy is shown in figure 4-2-5-A and B (chapter 4).
Eosinophils are approximately 8pm in diameter, containing typically a bi-lobed
nucleus, which can be stained with blue dye, haematoxylin. In the cytoplasm one-fifth
is occupied with ovoid granules, stained orange by eosin, which appear according to
the maturation status of the cells.
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Eosinophil and parasite
The role of cell-mediated response against helminths is mostly dependent on the
activation of eosinophils which release toxic granules to damage the outer surface of
the helminths. Helminths are large multicellular organisms. Several Schistosoma
species are responsible for the chronic, debilitating and sometimes fatal disease
schistosomiasis. Eosinophils are thought to be the first defence against helminthic
infection. Once helminthic infection occurs in a human subject, the total IgE levels can
exceed those seen in asthmatic and atopic dermatitis patients, sometimes up to 40 x
109/ 1 (Yazdanbakhsh, 1996). As shown in figure 1-1-1, activation of Th2 pathway
releases Th2 cytokines, IL-4, IL-13 and IL-5, which results in activation and
degranulation of eosinophils. Eosinophil degranulation is activated by the binding of
IgA and IgG to the eosinophil. The complement cascade also results in the
degranulation of eosinophils. C3a is an eosinophil chemoattractant and binding of C3a
promotes release of EPO, EDN and ECP which may be enhanced by IL-3 and IL-5
(Takafuji et al., 1994, and 1996, Bach et al., 1990). Once eosinophils are activated
their toxic contents MBP, ECP and EDN are released which damage the outer surface
of parasites. For example, MBP increases membrane permeability (Young et al., 1986)
and perturbation of the lipid bilayer of the target cells (Wasmoen et al., 1988).
Eosinophil granules
Granules are categorised as secondary granules, small granules, primary granules and
lipid bodies. (See table 1-1-1 for summarised contents of granules in eosinophil.)
These granules contain not only many highly toxic proteins with powerful enzymatic
activity but also certain cytokines which can promote the inflammatory response. For
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Table 1-1-1; Summary of contents of eosinophil granules (modified
from Giembycz and Lindsay, 1999)
Eosinophilic toxic proteins are important for defence against parasites, however, if
toxic contents are released in the host tissue, when eosinophils are activated, this will
contribute to the progress of inflammation. For instance, MBP (Kroegel et al., 1987),
ECP and EPO (Frigas et al., 1981) are known to be toxic to mammalian cells and may
produce pathological changes through alteration of lipid membranes in vitro.
In particular, in asthma, primed eosinophils release ECP, EDN, MBP and oxygen free
radicals may be one of the direct causes of airway remodelling. Increased air wall
thickness and decreased airway caliber were observed when airway sections were
incubated with EPO from PAF-activated eosinophils (Rabe et al., 1994). MBP is
thought that to bind to anionic domains of target parasites resulting in the pertubation
of the lipid bilayer. In vitro, MBP increases [Ca2+]i in bovine tracheal smooth muscle
(TSM) (Wylam et al, 1998) and guinia pig TSM contractions (Streck et al., 1996). In
primate both MBP and EPO induce AHR (Gundel et al, 1991). In asthmatic subjects,
MBP (Frigas et al., 1981) and elastase (Lungarella et al., 1992) were found in
significantly increased amounts in the airway, which indicates the airway tissue
damage done by those proteases.
Another function of eosinophils is the production of some pro-inflammatory proteins
including IL-1 (Weller et al., 1993), IL-4 (Moqbel et al., 1995, Nonaka et al., 1995),
IL-6 (Hamid et al., 1992), IL-8 (Braun et al., 1993, Kita et al., 1995) TNFa (Costa et
al., 1993), GM-CSF (Weller et al., 1992), IL-5 (Broide et al., 1992, Dubucquoi et al.,
1994). The synthesis of the proteins is dependent on the activation of intracellular
signalling cascades including activation of key transcription factors. Some of these
cytokines trigger the activation of inflammatory cells including eosinophils thereby
contributing to an amplification of the inflammatory response and disease progression.
1.1.2. Intracellular signalling pathways
Eosinophils are one of the cell types where tyrosine cascades is crucial for cell
activation and survival. IL-5, IL-3, GM-CSF (Simon et al, 1997), which all share
receptors partially, platelet-activating factor (PAF) (Miike et al., 2000), interferon-y
(IFN-y) (Ochiai et al., 1999) activates Lyn, JAK2 kinases, PI-3, Syk and Src homology
2 phosphatase 2 tyrosine phosphatase (SHPTP-2). Blocking phosphorylation of JAK2
by specific inhibitors induces eosinophil apoptosis, indicating tyrosine cascades that
are crucial for eosinophil survival (Yousefi et al., 1996, Pazdrak et al., 1997). IL-5
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induced activation of ERK1 and ERK2 resulting in leukotriene C4 synthesis (Bates et
al., 2000).
The three MAP kinase families, extracellular regulated kinases (ERKs), the c-jun N-
terminal kinases/ stress-activated protein kinases, and p38 MAP kinases have common
functions including cellular activation in various cell types, including eosinophils. The
ERKs are activated mainly by mitogens such as growth factors and G-protein coupled
receptor agonists whereas c-jun N-terminal kinase and p38 are activated by various
cellular stresses. Activated p38 phosphorylates and stimulates down stream kinase,
mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) (Rouse et
al., 1994). In summary, IL-5-induced activation of those cascades and pathways exert
an anti-apoptosis effect in eosinophils (Owen et al., 1989, Rothernberg et al., 1989,
Pazdrak et al., 1995, Yousefi et al., 1996).
Distinct from tyrosine cascades, as previously shown from my study (Fujihara et al.,
2002) (see chapter 4 and appendix for the paper) and others (Yamashita et al., 1999)
NF-kB regulates eosinophil activation (e.g. production of IL-8) and survival. Applying
NF-kB inhibitors factors such as the proteasome inhibitor Mgl32 and the fungal
metabolite gliotoxin significantly induced eosinophil apoptosis and suppressed the
production of IL-8, indicating that NF-kB is an important transcription factor that
regulates cellular activation and apoptosis. (See NF-kB section in 1.5 and the




Neutrophils are the first cell type to be recruited at sites of bacterial or fungal infection
and are thought to contribute to the progression of damage to healthy tissue. For
instance, in adult respiratory destress syndrome (ARDS), neutrophils may damage
tissue through H2O2 generation (McGuire et al., 1982). Recent evidence suggests that
not only eosinophils but also neutrophils are involved in asthma pathogenesis. For
instance, in non-allergic asthma substances, such as nitrogen dioxide and ozone
(Coffey et al., 1996, Fahy et al., 1995) and respiratory tract infection (Lamblin et al.,
1998) induces an influx of neutrophils into the airways. Study of status asthmaticus by
Tonnel et al., (2001) showed dramatic increases in neutrophils and neutrophil elastase
in bronchoalveolar lavage (BAL). Also, the level of EPO and gelatinase (MMP9) were
increased in those samples, indicating that eosinophil degranulation also plays a role in
the neutrophil influx seen in status asthmaticus patients.
1.3. Inflammatory diseases
1.3.1. Inflammation and allergy
Inflammatory diseases such as asthma, eczema and other allergic diseases are
increasing in both developed and developing countries. In Western countries 155
million individuals (up to 10 to 20 % of children's population) are affected by asthma
and eczema (reviewed by Sampson et al., 2000).
Inflammation is a local response to injury, involving vasodilatation and increased
permeability of capillaries in damaged areas largely due to release of substances such
as histamine and serotonin from mast cells. Vasodilation also helps recruitment of
inflammatory cells, such as macrophages, T cells, B cells and particularly
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granulocytes, which have the potential to cause damage and destroy surrounding tissue.
Neutrophils are the first cells to migrate at inflammatory sites to defend against
invading micro-organisms and are often seen at acute inflammatory sites, where
eosinophils are more commonly seen at sites of parasitic infection and are associated
with chronic allergic diseases.
Allergic reaction (hypersensitivity) and inflammation
Hypersensitivity is classified into four types, but it is important to realise that a great
deal more complexity exists due to the vast array of secondary effects which cross the
boundaries of the classification scheme.
Type I hypersensitivity is IgE-mediated and its initiation time is between 2-30
minutes. The Ag induces cross-linkage of IgE bound to mast cells and basophils with
release of vasoactive mediators. This typically manifests as systemic anaphylaxis, or
localised anaphylaxis (e.g., hay fever, asthma, hives, food allergies, eczema). When a
host body is exposed to an allergen (such as grass, ragweed, penicillin, local
anaesthetics, nuts, seafood, bee venom, wasp venom, house dust mite, mold spores,
animal hair and dander) B cells are activated to form IgE-secreting plasma cells. The
secreted IgE molecule binds IgE-specific Fc receptors on mast cells and blood
basophils. Upon a second exposure to the allergen, the bound IgE is cross-linked,
triggering the release of pharmacologically active mediators, such as histamine,
serotonin, platelet-activating factor (PAF), LT, prostaglandins, TNFa, IL-1, IL-5, GM-
CSF, from mast cells and basophils. These mediators cause smooth-muscle
contraction, increased vascular permeability, and vasodilation which results in the
allergic reaction such as asthma.
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Type I hypersensitivity is commonly identified and assessed by skin testing. If a person
is allergic to the allergen, local mast cells will degranulate. The release of histamine
and other mediators produces a wheal and flare within 30 min. Similarly,
radioallergosorbent test (RAST) or radioimmunosorbent test (RIST) are commonly
used for type I hypersensitivity test. Several drugs block the release of allergic
mediators by interfering at various biochemical steps which are involved in the
activation and degranulation of mast cells. For example, disodium chromoglycate
7+
prevents Ca influx into mast cells. Theophylline, which is commonly administered
orally or through inhalers to asthmatics, blocks phosphodiesterase, which catalyses the
conversion of cAMP to 5'-AMP. The resulting prolonged increase in cAMP levels
blocks degranulation. A number of drugs stimulate the beta-adrenergic system by
stimulating beta-receptors. Epinephrine is commonly administered during anaphylactic
shock. It acts by binding to beta receptors on bronchial smooth muscles and mast cells,
elevating the cAMP levels within these cells. The increased levels of cAMP leads to
relaxation of the bronchial muscle and decreased mast-cell degranulation.
Corticosteroids and other anti-inflammatory drugs also have been used to reduce type I
reactions.
Type II hypersensitivity is an antibody-mediated cytotoxic reaction, initiation time is
between 5 and 8 hours after exposure to the allergen. The mechanism involves the
production of antibody which directs against cell-surface destruction via complement
activation or antibody-dependent cell-mediated cytotoxicity (ADCC). Typical
manifestations are blood-transfusion reactions, erythroblastosis fatalist, autoimmune
haemolytic anaemia. Type III hypersensitivity reaction is immune complement-
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mediated hypersensitivity where has an initiation time is between 2- 8 hours. Antibody
and antigen complex deposited in various tissue induce complement activation and an
inflammatory response. Typical manifestations are localized arthus reacations, serum
sickness, rheumatoid arthritis, systemic lupus erythematousus. Type IV
hypersensitivity in sensitised CD4+ TDTh cells which release cytokines that activate
macrophages or Tc cells which mediate direct cellular damage by lytic enzyme
released by activated macrophages. Its initiation time is 24- 72 hours as 'delayed'
reaction. Typical manifestations are contact dermatitis, tubercular lesions, and graft
rejection.
T cells and B cells in inflammation
The developmental process that results in generation of antibody-secreting B cells can
be divided into two phases; an antigen-independent phase, which occurs in the bone
marrow, and an antigen-dependent phase, which occurs in the periphery. Following
release of mature B cells from the bone marrow, the subsequent steps in B-cell
development and differentiation occur in the periphery and require antigen. Activated
B cells can undergo class switching resulting in expression of isotypes other than IgM
and IgD on the membrane. As a result, memory B cells often express membrane IgG,
IgA, or IgE.
IL- 4 and 13 are the type 2 cytokines which have a broad spectrum of reactivity,
especially mediating IgE synthesis (See figure 1-1-1). Both IL-4 and IL-13 shear the
alpha chain of the IL-4 receptor (IL-4Ra). Th2 cells, mast cells, basophils and
eosinophils are capable for producing IL-4, however, the relevant source of IL-4 for
IgE synthesis in allergic reaction is unclear.
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EL-4 exerts different effects on B cells at different stages in the cell cycle. On resting B
cells - IL-4 acts as an activating factor - inducing the resting cells to enlarge in size and
increase their expression of Class II MHC.Then it acts as a growth factor, driving the B
cells to proliferate. Finally, IL-4 acts as a differentiation factor by regulating the class
switch to IgGl and then to IgE "switch-inducing factor"
Ligand initiated binding on IL-4Ra activates the signalling cascade signal transducer
and transcription -6 (STAT-6) for transcription and synthesis of mRNA. However,
other receptors such as CD40 and CD80/ 86 cause a switch to IgE synthesis. The
interaction of CD40-CD154 (T cells) activates NF-kB to enhance further IgE
production by Stat-6 pathway (Warren et al., 1999)
A shift in the class switching in B cells occurs by recombination between the VhDhJh
region and downstream constant regions specific for each class in heavy chain DNA.
The constant region for the chain (C) lies upstream of the constant regions for all the
other heavy chains. Thus an IgM-producing B cell (at antigen-independent phase) can
switch to the production of immunoglobulin classes under certain stimuli to activate B
cells. However, a cell producing IgG cannot switch to IgM production because its
DNA has previously undergone a recombination event which eliminates the C region.
1.3.2. Asthma and inflammatory cells
Asthma is an inflammatory disease of the airways of the lungs. The airways narrow
due to smooth musculature contraction and airways hyperreactivity (AHR) with
mucous hypersecretion. Accumulation of eosinophils in the lungs is a common feature
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of asthma, although neutrophilia has been reported in fatal acute asthma (Fahy et al.,
1995).
Asthma and eosinophils
Tissue eosinophilia is a characteristic of asthma and there appears to be a positive
correlation between the AHR and number of eosinophils found in the BAL fluid and
peripheral blood of patients with asthma (Bousquet et al., 1990, Bradley et al., 1991).
In the airway, activated eosinophils release toxic products such as MBP, ECP, EDN
and oxygen free radicals, which damage the surrounding tissue resulting in the
contraction of bronchial smooth muscle (Rabe et al., 1994), increased vascular
permeability (Collins et al, 1993) and induction ofAHR (Leff, 1994).
The mechanisms regulating -asthma are complex and involve various types of cells
such as neutrophils, T cells, B cells, mast cells, macrophages, epithelial cells,
myofibroblasts, smooth muscles, and especially eosinophils (Bousquet et al., 1990,
Djukanovic et al., 1990). These cells are recruited by released cytokines and
chemokines from many cells at the inflammatory sites. For instance, in BAL fluid
increased amounts of IL-4 (Shi et al., 1990), IL-5 (Webb et al., 2000), IL-13, TNFa
(Luttman et al, 1999), MCP-4, IL-16 (Taha et al., 2001), MCP-1, MIP-oc, RANTES
(Alam et al., 1996) have been reported. Furthermore, recruited inflammatory cells
interact with other cells such as endothelial cells via ICAM-1 and VCAM-1 (Granger
and Kubes, 1994, Bochner and Schleimer, 1994) resulting in the activation of the
cells.
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Administration of IL-13 in the airways of mice increases AHR, BAL eosinophil influx,
serum IgE and mucus secretion. These actions were reversed by blocking the IL-13
receptors (Uills-Karp et al., 1998, Criinig et al., 1998). In addition, IL-13 was
demonstrated to mediate PSGL-1/ P-selectin dependent adhesion of eosinophils to
HUVECS (Woltmann et al., 2000). Furthermore, both IL-4 and EL-13, which share a
common IL-4-receptor a subunit, stimulate epithelial cell release of eotaxin, a known
strong eosinophil chemoattractant (Li et al., 1999) and can activate B cells to release
IgE which is captured by Fc receptors (FcsRI and FcsRII) on eosinophils.
The recruitment of eosinophils occurs at the capillary level where flow is slow enough
to allow cells to roll through endothelial cells. The mechanism of infiltration and
accumulation of inflammatory cells at inflammation may be due to release of various
chemoattractants from surrounding cells in the tissue, such as fibroblasts, and
inflammatory cells themselves. Furthermore, following the recruitment of those
inflammatory cells, there may be some substances released resulting in high cellular
activation and enhanced survival of inflammatory cells. As a consequence activated
inflammatory cells are able to successfully escape from the normal induction of
apoptosis which results in clearance of dying cells by macrophage phagocytes. Table
6-1-7-A summarise the eosinophilic chemoattractant cytokines and chemokines are
listed according to their molecular weight.
Among various cytokines and chemokines as shown in table 6-1-7-B, some
chemokines, such as eotaxin, IL-8, TRAC, RANTES, and cytokines, such as TNFa,
TGF(3, IL-2, IL-3, IL-5, GM-CSF and IL-13 modulate various aspects of eosinophil
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Table 1-3-2; The summary of eosinophil surface molecules and their
binding receptors (modified from Gimbycz and Lindsay, 1999).
and eotaxin. Eosinophil activators are most of the chemokines and cytokines such as
IL-3, IL-5, GM-CSF, IL-13, TNFa, TGFp. In addition, cytokines which are known to
influence eosinophil survival include IL-3, IL-5, GM-CSF, IL-13, TNFa. The selective
and existing chemoattractants near inflammatory sites cause the eosinophils to be
primed and to interact with endothelial cells through particular interaction with surface
molecules for cell rolling (see table 1-3-2).
The expression of adhesion molecules on the surface of eosinophils is essential for
migration. The summary of eosinophil adhesion molecules is shown in table 1-3-2.
Selective migration occurs in three steps; rolling of eosinophils along the surface of the
vessels, firm adhesion of eosinophils with endothelial cells and transmigration of
eosinophils into tissues. Various evidence suggests that for eosinophil rolling,
expression of L-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) are essential
for interaction to E- and P-selectin on the surface of endothelial cells. Especially, P-
selectin is more potent for eosinophil rolling (Symon et al., 1996) binding to PSGL-1
(Patel and McEver, 1997). In vivo, P-selectin deficient mice reduced the infiltration of
eosinophils in the lungs and BAL after allergen-challenge (Broide et al., 1998b).
Several studies have demonstrated that the expression of very late activation antigen 4
(VLA-4), CR3 and lymphocyte function-associated antigen 1 (LFA-1) on eosinophils,
VCAM-1, ICAM-1 and E-selectin on endothelial cells are particularly important for
adhesion of eosinophils to endothelial cells (Walsh et al., 1990, Kyan Aung et al.,
1991a,b, Weller et al., 1991, Nakajima et al., 1994). In asthmatic individuals ICAM-1
and HLA-DR are significantly expressed in eosinophils and epithelial cells
respectively in BAL (Hansel et al., 1991, Mengelers et al., 1994) and VLA-4, CR3,
LFA-1 in eosinophil rich mucosa and ICAM-1, VCAM-1 and E-selectin on the luminal
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membrane of endothelial cells (Ohkawara et al., 1995). IL-5, which is highly expressed
in asthmatic airways (Leff et al., 1991) downregulates L-selectin but upregulates
beta2-integrins on the surface of eosinophils. On the surface of endothelial cells, the
ligands for eosinophil surface integrins are the immnoglobulin supergenes (e.g.,
ICAM-1 ,VCAM-1). IL-4 (Schleimer et al., 1992) and IL-13 (Sironi et al., 1994,
Bochner et al., 1995) upregulate VCAM-1 expression on endothelial cells. The
expression of adhesion molecules may cause some functional activation in eosinophils.
VLA-4-mediated adhesion interacts with VCAM-1 and fibronectin. Upon VLA-4
stimulation, eosinophils augment PAF- and A23187-induced LTC4 release (Anwar et
al, 1994, Munoz et al, 1996), fMLP-induced ECP release (Neeley et al., 1994), IL-3,
GM-CSF- induced eosinophil survival (Anwar et al., 1993) and NADPH oxidase
release by the interaction of VLA-4/VCAM-1 (Nagata et al., 1995a) and VLA-
4/fibronectin (Neeley et al., 1994). In monkies, anti-ICAM-1 antibody reduces the
number of eosinophils in BAL, and AHR after bronchial airway challenge by
methacholine (measuring PC100) (Wegner et al., 1990). This data indicates that the
infiltration ofprimed eosinophils is an important part ofAHR in asthma.
Anti-IL-5 antibody and asthma
IL-5 has a variety of influences on eosinophils. IL-5 promotes the terminal
differentiation of eosinophils in bone marrow, prolongs the viability of mature
eosinophils and primed eosinophils. Several studies demonstrate that there is a
correlation between between IL-5 expression and eosinophil influx, eosinophil counts
in the peripheral blood and severity of asthma (Corrigan and Kay, 1990, reviewed by
Hamelmann and Gelfand, 2001).
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Leckie et al., (2000) has demonstrated that a single intravenous infusion of monoclonal
anti-IL-5 antibody did not protect against the allergen-induced late asthmatic response
and did not have any effects on baseline or post-allergen airway hyperresponsiveness
(AHR), despite a dramatic decrease in peripheral blood and sputum eosinophil count.
However there is slight protection seen in histamine PC20 in pre-allergen challenge at
day 8. This data indicates a disassociation between eosinophil number in peripheral
blood and sputum, and AHR. Eosinophil numbers are one of the indications of the
progress of inflammation and asthma (Green et al., 2002). However, in Leckie's study
peripheral blood and sputum eosinophil number were examined but not eosinophil
number in BAL or bronchial tissue, nor the level of activation of eosinophils, which
may be the more direct indication of residual eosinophil numbers in the airways. In
other studies, infusions of humanised anti-IL-5 monoclonal antibody (mepolizumab) to
mild atopic asthmatics decreased airway eosinophil numbers (Food-Page et al., 2003),
the marker of airway remodelling (Food-Page et al., 2003), hyper-eosinophilic
syndromes in tissue (Garrett et al., 2004), bone marrow eosinophil maturation
(Menzies-Gow et al., 2003) and peripheral eosinophil number (Food-Page et al., 2003,
Garrett et al., 2004, Buttner et al., 2003). However, in these studies there is no direct
evidence of improvement of symptoms of asthma. In subjects with severe persistent
asthma treated with oral or high dose of inhaled steroids, infusion of humanised anti-
human IL-5 antibody (SCH55700) has improved FEV1 and circulation of eosinophil
counts (Kips et al., 2003).
In vivo, there are contrasting results on the function of eosinophils and AHR. Direct
evidence of a link between local IL-5 and eosinophilia in the airways has been
demonstrated in mice (Lee et al., 1997). Hamelmann et al., (1997, 2000), Eum et al.,
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(1995) have demonstrated a correlation between the influx of eosinophils and AHR
after aerosolised MCH challenges. In IL-4 deficienct mice, adeno-IL-5 transfection
before allergen challenges result in a high influx of eosinophils in BAL and an increase
in AHR. These results indicate the role of IL-5 as eosinophil chemoattractant to BAL
and an inducer of AHR. The contrasting results on the relation between IL-5 and
eosinophils may be due to the experimental protocols, antibody amount, different
species and so on.
On the other hand several studies have indicated the disassociation between eosinophil
numbers and AHR, e.g., in guinea-pig (Mauser et al., 1993) and mice (Mathur et al.,
1999).
The inflammatory response is characterised by the appearance of not only eosinophils
but also CD4+ Th2 cells, mast cells and eosinophils in bronchial biopsies and in BAL
fluid of asthmatic patients (Robinson et al., 1992, Robinson et al., 1993, Azzawi et al.,
1992). Cortiocosteroids (Gauvreau et al., 1996), cyclosporin A (Sihra et al., 1997),
systemic anti-IgE (Fahy et al., 1997) and leukotriene antagonists (Taylor et al., 1991)
are able to suppress late asthmatic reactions which are generated by different types of
cells. The activity of low numbers of residual eosinophils in the airway could be the
target for eosinophil-directed treatment, a separate process to suppression of the late
asthmatic reaction. However, the activation state of eosinophils should be equally
considered, which can be measured by the level of eosinophilic proteins (e.g., ECP,
MBP, IL-8) and transcription activation factors as shown in this thesis. In Leckie's
study, despite reduction of eosinophil numbers from peripheral blood and sputum, the
activation state of eosinophils in BAL or sputum is unstated. One could hypothesise
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that even low numbers of eosinophils, if highly activated, may be enough to cause
damage to the airway and further progression of airway remodelling. Therefore, the
number of residual eosinophils and other inflammatory cells in the airways is the one
of the indications but the activation state has to be examined.
The difference between the in vivo data in different species and Leckie's study may be
a result of different sensitisation and challenge protocols or interpretations of altered
AHR. For example, human asthma is more chronic and includes the potential for
airway remodelling. In vivo studies are more controllable than the human trials. For
example, intravenous antibody quantity in human may not be high enough to obtain the
similar results from in vivo studies.
1.3.3. Leukotriene and asthma
Leukotriene (LT) is a potent biological lipid mediator derived from arachidonic acid
(See figure 1-3-3). The cleavage of arachidonic acid by phospholipase A2 can be
metabolised to eicosanoids and 5-hydroperoxy-eicosatetraenoic acid (5-HETEP) to
LTA4 by 5-lipoxynase. LTC4 synthetase catalyses the conjugation of glutathione with
LTA4. LTC4 is the major product of the 5-lipoxynase (5-LO) in human. In vitro
eosinophils stimulated combination with Ca2+ ionophore A23187 and eosinophil
priming factors (e.g., IL-3, IL-5, GM-CSF, TNFa, PAF) produce substantial amounts
of LTC4 (reviewed by Giembycz and Lindsay 1999).
5-LO is located in the cytosol at rest, but after cell adherance or stimulation with Ca2+
ionophore A23187, 5-LO translocated to the nuclear envelope in neutrophils (Brock et





















Figure 1-3-3; The pathway of leukotriene production.
1993). On the other hand, in non-stimulated rat alveolar macrophages and basophilic
leukaemic cells (Cofficy et al., 1992, Brock et al., 1994), 5-LO is localised to the
nuclear envelope, where it may be associated with the SHS3 domain of cytoskeletal
proteins (Lepley and Fitzpatrick, 1994). These observations may suggest involvement
of 5-LO for transcriptional activities.
In vitro, LT exert its effect to induce EL-4 from eosinophils (Banderia-Melo et al,
2002), induction of replication smooth muscle (Palmberg et al., 1991, Rajah et al.,
1996) and no induction of eosinophil apoptosis (Murray et al., 2003) (see Table 1-3-3-
A). On the other hand, various stimuli induce LT production from eosinophils
(Triggiani et al., 2003, Munoz et al., 2000, Banderia-Melo et al., 2002, Cromwell et
al., 1988, Shaw et al., 1984) and lung fibrobrast (Chibana et al., 2003) (see Table 1-3-
3-B). LT receptor antagonist (LTRA) demonstrate some roles in inhibition of primed
cellular activation in eosinophils (Braccioni et al., 2002, Virchow et al., 2001, Suzuki
et al., 2003, Nagata et al., 2002, Thomet et al., 2001), in peripheral blood
mononucleated cells (PBMNC) (Ichiyama et al., 2003) and neutrophils (Koyama et al.,
2000, Sato et al., 1999) (see Table 1-3-3-C).
Eosinophils and mast cells produce substantial amounts of LTC4 from endogenous
arachidonic acid in the airways (Shaw et al., 1984). Markedly in aspirin intolerant
patients, approximately 70% of all LTC4 synthetase-positive cells in biopsy samples
from airway tissue were EG2+ stained eosinophils (Cowburn 1998). In asthma, LT is
mainly released from primed eosinophils, mast cells and basophils and is a potent
mediator for bronchocontraction and inflammation in the airways and increased
permeability of the endothelial membrane leading to edema, enhanced secretion of
18


























Table 1-3-3-A. The summary of recent publications of the effect of LT on various
cell types in vitro. I; increase, D; decrease
authors experiment stimuli cell type effect
Triggiani M
2003































I. LTC4 from eo,
LTB4 from neu.
Table 1-3-3-B. The summary of recent publications of the effect of various stimuli
on various cell types to induce the production of LT in vitro. I; increase, D; decrease,
NA; not affected
authors experiment stimuli cell type effect
Braccioni F
2002



















































Table 1-3-3-C. The summary of recent publications of the effect of various LT
receptor antagonist (LTRA) on various cell types in vitro. I; increase, D; decrease,
PB; peripheral blood





















D. eo in sputum, PB
D. asthma symptoms
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Table 1-3-3-D. The summary of recent publications of the effect of various LT
receptor antagonist (LTRA) in clinical trial I; increase, D; decrease, P2A; beta-2
agonist, PEF; peak expiratory flow.
authors experiment stimuli cell type effect
Wu AY in vivo montelukast lungs, BAL, D. total cell no, eo,
2003 blood neu, lymph
D. IL-4,-5,-13,
eotaxin in lungs
D, IL-4, -5, eotaxin
in BAL
D. IL-5, IgE serum
no challenge studies!
Finsenes F in vivo montelukast BAL, lungs D. total cell no, eo,
2002 lymph
D. degree of inflam
D. ET-1, IFNg (?)
NC. TNF, IL-8




Ihaku D in vivo montelukast BAL D. eo, neu, IL-





in vivo LTB4A BLTR requirement
for PMN
chemoattractant
Kawada N in vivo ltd4 5-LO KO I. eo
2001
Hendrson in vivo montelukast BAL D. eo influx
2002
Table 1-3-3-E. The summary of recent publications of the effect of various LT
receptor antagonist (LTRA) on various cell types in vivo. I; increase, D; decrease,
NO; n.ot conclusive, KO; knock out.
mucus (Marom et al., 1986) and increase in bronchial hyerresponsiveness (Adlroth et
al., 1986, O'Hickey SP et al., 1991), increasing prolifereation of airway smooth
muscle (Cohen P et al., 1995, Panettieri RA et al., 1998) and airway epithelial cells
(Leikauf GD et al., 1990) and induce collagenase expression in human lung fibroblasts
(Medina LJ et al., 1994).
LT receptor antagonist (LTRA) is selectively modify the leukotriene pathway, have
exerted their effects as anti-asthma drugs in mild- moderate asthmatics improving
PC20, PEF reducing eosinophils numbers in BAL induced sputum and peripheral
blood (reviewed by Lipworth, 1999, reviewed by Holgate et al., 1996, Currie et al.,
2003, Diamantz et al., 1999, Minocuchi et al., 2002, Pizzichini et al., 1999, Tohda et
al, 1999, Hood et al., 1999, Leff et al., 1996, Wenzel et al., 1990) (see Table 1-3-3-
D). In vivo, administration of montelukast protects against asthma symptoms in
ovalbumin (OVA) challenged mice significantly by reducing the airway eosinophil
infiltration and the degree of inflammation (Henderson et al., 2002) and other anti¬
inflammatory effects (Wu et al., 2003, Finsenes et al., 2002, Ihaku et al., 1999, Chiang
et a., 1999) (see table 1-3-3-E). On the other hand, OVA-sensitised 5-LO knockout
mice have attenuated methacholine responsiveness, airway eosinophilia and IgE
response after the challenge (Irvin et al., 1997, Kawada et al., 2001). These data
suggest the potent role of LT in pathogenesis of asthma.
1.3.4. The role of eosinophils in airway causing smooth muscle contractions.
Eosinophils contain cationic proteins (e.g., eosinophil cationic protein (ECP), major
basic protein (MBP), eosinophil-derived neurotoxin (EDN)), eicosanoids, leukotrienes,
pro-inflammatory cytokines (e.g., TNFa, IL-4, IL-8) and chemokines in their granules.
If those products are released on inappropriate time, it causes host tissue damage. In
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case of asthma, primed eosinophils release ECP, EDN, MBP and oxygen free radicals
may be one of the direct causes of airway remodelling. Increased air wall thickness and
decreased airway caliber were observed when airway sections were incubated with
EPO from PAF-activated eosinophils (Rabe et al., 1994). MBP is thought to bind to
anionic domains of target parasite membrane resulting in the pertubation of the lipid
bilayer. In vitro, MBP increases [Ca2+]i in bovine tracheal smooth muscle (TSM)
(Wylam et al, 1998) and guinea pig TSM contractions (Streck et al., 1996). In
primates both MBP and EPO induce AHR (Gundel et al, 1991).
Eosinophils also release cytokines and chemokines such as TNFa, IL-8 and IL-4,
which causes the influx of pro-inflammatory cells. This can contribute to the further
progression of asthma, which is associated with airway remodelling and smooth
muscle contraction.
1.4. Apoptosis
1.4.1. Morphology of apoptosis
Apoptosis or programmed cell death is essential for normal development and
homeostasis to maintain physiological processes. Apoptosis is very different from
necrosis, which induces swelling and rupturing of the plasma membrane, leading to the
release of intracellular contents and causing damage to surrounding tissue and
amplification of inflammation. Characteristic features of apoptosis include the
shrinkage of the cells, exposure of phosphatidylserine on the outer plasma membrane,
mitochondrial breakdown, bubble-like blebs on the cell surface and chromatin
condensation (Wyllie, 1980). Apoptosis results in disassembly of the cell into








Figure 1-4-2 ; Apoptosis and the NF-kB pathway triggered by
TNF superfamiiy receptors
1.4.2. Extracellular stimuli for the apoptosis pathway
Various extracellular stimuli from UV light to cytokines can induce cell apoptosis.
TNFa and Fas ligand (Fas L) are pro-apoptotic agents which bind to the TNF
superfamily of receptors; TNF receptor (TNFR) 1, TNFR2 and FAS. The
TNF superfamily share a death domain (DD), which initiates caspase pathways leading
to apoptosis (Itoh and Nagata, 1993, Tartaglia et al., 1993, Boldin et al., 1995). (See
figure 1-4-2 for a summarised diagram.) The interaction of the intracellular complex
leads to two major pathways, death or survival pathways. The interaction between
TRAF1, TRADD and FADD results in the activation of caspase-8, which is the
initiator of the downstream caspase pathway (Hsu et al., 1995, Chinnaiyan et al.,
1995). On the other hand, TRADD also activates TRAF2 and RIP to trigger the IKK
pathway leading to NF-kB and JNK activation (Natoli et al., 1997). (See the following
section for NF-kB activation pathway.) Therefore, the TNF superfamily can decide the
fate of the cells by triggering death or survival pathways.
1.4.3. Caspase-death pathway
Caspases (cysteinyl aspartate-specific proteinases) were first implicated in apoptosis by
genetic analysis in the nematode C. elegans (Ellis and Horvitz, 1991) and later shown
to be a common feature in mammalian cells controlling the fate of the cells
(Thornberry et al., 1992). Caspases are expressed ubiquitously as latent pro-enzyme
forms which are activated by cleavage at aspartic acid residues. This process initiates
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The first group of the caspase cascade to be activated is caspase-8, -9, -10 after
stimulation by FasL or TNFa through the TRADD and FADD complex. Caspase-8 is
the initiator caspase for this cascade and not only activates other capspases, such as
caspase -3, -6, -7, but also cleaves Bid to tBid which activates Bax on surface of
mitochondria. (See figure 1-4-3 for the summarised diagram.) Accumulation of other
pro-apoptotic Bcl-2 family members (Goping et al., 1998, Antonsson et al., 2001,
Gross et al., 1999) on the surface ofmitochondria causes opening of pores in the outer
and inner membrane of mitochondria to release cytochrome c which activates caspase-
9, which initiates the activation ofApaf-1. Caspase-9 and Apaf-1 activation are the last
steps of the caspase pathway for the biochemical execution of the cells (Slee et al.,
1999).
1.5. Granulocyte apoptosis
Granulocytes undergo constitutive apoptosis. However, at chronic inflammatory sites,
induction of apoptosis in granulocytes may be beneficial for the successful resolution
of inflammation. Apoptotic granulocytes retain intracellular contents, such as cytotoxic
proteases, thereby preventing tissue damage. Apoptotic granulocytes are subsequently
cleared by tissue macrophages (Savill et al., 1989, Savill et al., 1990, Savill et al.,
1992).
Eosinophils possess relatively low number of mitochondria and level of expression of
cytochrome c (Dewson et al., 2001). Although, there are controversial reports on the
expression of Bel- homologous protein in eosinophils, high level of expression of pro-
apoptotic protein, Bax, Bcl-XS (Dewson et al., 2001, Druihe et al., 1998) and anti-
apoptotic protein Bcl-XL (Druihe et al., 1998), Bcl-2 Dibbert et al., 1998, Plotz et al.,
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1998) are reported. Dewson et al., (2001) demonstrated co-localisation of Bax and
mitochondria in IL-5 deprived condition in caspase independent manner. On the other
hand, IL-5 prevents Bax translocation and release of cytochrome c and following
caspase activation resulting in an anti-apoptoic effect. The on going contradictory
debate continues, however, asIL-5 induced expression of anti-apoptotic Bcl-2 (Dewson
et al., 1999, Ochiai et al., 1997) may attenuate constitutive apoptosis in eosinophils.
Interestingly other types of cells such as alveolar epithelial cells (Walsh et al., 1999,
Sexton et al., 2001) and macrophages have been demonstrated to clear apoptotic




NF-kB is a family of transcription factors that regulate genes involved in controlling
apoptosis but also mediating much pro-inflammatory gene expression (see review by
Baeurerle and Baltimore, 1996, Baldwin, 1996, May and Gosh, 1998). The NF-kB
family contains the proteins p65/Rel A (Nolan et al., 1991), c-Rel (Wilhelmsen et al.,
1984) or Rel B (Ryseck et al., 1992), p50/ NF-kB 1 (Gosh et al, 1990, Kieran et al.,
1990) or p52/ NF-kB2 (Bours et al, 1990, Neri et al., 1990). NF-kB transcriptional
activity is controlled by inhibitory proteins, IkB, of which the most important may be
IkBcx, IkBP and IkBc. The IkB family contain ankyrin repeat domains (ARD) and
share the function of retaining NF-kB in the cytoplasm. IkBcx is the major form of IkB
in most cells in vertebrates. IkBoc is a 37KDa protein that binds to NF-kB in the
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TNF IL-1
production ofNF-kB up-regulated proteins
Figure 1-6-1; Schematic representation of components of the NF-kB
signal transduction pathway. (Modified from Mercurio and Manning 1999)
cytoplasm. Therefore, NF-kB is prevented from nucleus translocation for gene
expression.
NF-kB activation is regulated by the state of IkBcc in the cytoplasm. (See figure 1-6-1.)
The fate of IkBoc is dependent on its phosphorylation and ubiquitination. The pro¬
inflammatory cytokines TNFa and EL-ip initiate a signalling cascade via their
receptors on the cell surface and activate two IkB kinases, IKK-1 (or IKK-a) and IKK-
2 (or IKK-(3), which lead the phosphorylation on serines 32 and 36 on IkBcx (DiDonato
et al, 1997, Regnier et al., 1997). IKK1 and DCK2 are signal transduction kinases,
containing an amino-terminal kinase domain and carboxy-terminal region with two
protein interaction motifs, a leucine-zipper and a helix-loop-helix motif (Mercurio et
al., 1997). Phophorylated IkBoc is selectively ubiquitinated on lysine 21 and 22 by an
E3 ubiquitin ligase and finally degraded by the 26S proteasome (Chen et al., 1995).
Once IicBa is degraded, NF-kB is free to translocate in the nucleus where it can
activate gene expression.
1.6.2. Inhibition of NF-kB for the induction of apoptosis
The pro-inflammatory cytokine TNFa can trigger at least two pathways; a pro-survival
pathway via the NF-kB pathway for transcriptional activity and a pro-apoptotic
pathway via caspase cascades. There is some evidence demonstrating that TNFa-
induced inhibition ofNF-kB un-masks the caspase-dependent pro-apoptotic properties
of TNFa. Beg et al., (1996) demonstrated that fibroblasts and macrophages from RelA
deficient (RelA-/-) mice have reduced viability when these cells were stimulated with
TNFa, however RelA +/+ cells were unaffected. Similarly transfection of S32 and S36
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mutated hcBa, which is the super-suppressive form of h<fia, into human fibrosarcoma
cell lines (Wang et al., 1996), primary mouse and human fibroblasts and Jurkat cells
(Van Antwerp et al., 1996), increases TNFa mediated apoptosis. Furthermore, it was
demonstrated that disruption of the NF-kB pathway with dominant-negative TRAF2
enhances TNFa-induced apopsosis (Hsu et al, 1996). These results strongly suggest
that inhibition ofNF-kB enhances TNFa cytotoxity.
A possible explanation for these observations are that NF-kB may produce anti-
apoptotic proteins which would protect the cells from the cytotoxic effect of TNFa.
These proteins therefore may not only be house keeping proteins but may also be
inhibitory proteins preventing apoptosis. For instance, NF-kB upregulates TNFa
superfamily receptor complexes, such as TRAF-land TRAF-2, and the family of
inhibitor of apoptosis (LAP), such as XLAP, c-IAPl, c-IAP-2 (Stehlik et al., 1998,
Deveraux et al., 1997, Deveraux et al., 1998), which inactivate caspases resulting in
survival. TNFa therefore regulates the delicate balance between pro- and anti-
apoptotic pathways in cells. Therefore, inhibition ofNF-kB plays an important role in
the regulation of apoptosis a process that may be applicable regulation of inflammatory
cell numbers.
1.6.3. Inflammation and NF-kB
NF-kB upregulates the production of many cytokines including IL-1, IL-2, IL-2R, IL-
6, IL-8, G-CSF, GM-CSF and TNFa from various types of cells (reviewed by Baererle
and Henkel, 1994). These cytokines not only cause recruitment of inflammatory cells,
but can also activate those accumulated inflammatory cells and surrounding cells,
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resulting in promotion of the inflammatory process. (See chapter 6 introduction for
eosinophils chemoattractant cytokines.) For instance, p50 (-/-) mice are incapable of
mounting eosinophilic airway inflammation due to lack of production of IL-5, eotaxin,
MUM a, MIP-ip (Yang et al., 1998), indicating NF-kB involvement in eosinophil
accumulation in the airway. Also, in eosinophils, genes for granule proteins EDN and
ECP were upregulated by NFAT-1, which is a sub family of NF-kB (Handen et al.,
1997). Therefore, inhibition of NF-kB is one of the primary therapeutic targets for the
resolution of inflammation. Some anti-inflammatory drugs, such as aspirin and
salicylates (Yin et al., 1998), helenalin (Lyss et al., 1997), curcumin (Jobin et al.,
1999), dexamethasone (Ray and Prefontaine, 1994, Caldenhoven et al., 1995), have
been shown to suppress NF-kB activation.
Inhibition of NF-kB suppresses production of pro-inflammatory cytokines. On the
other hand, inhibition of NF-kB enhances the cytotoxity of TNFa in certain cells. If
apoptosis is induced in granulocytes at inflammatory sites by pharmacological
reagents, it may offer another approach for the successful resolution of inflammation.
In addition, inhibition of NF-kB will result in the suppression of pro-inflammatory
cytokine generation another beneficial effect that would be important for successful
resolution of inflammation.
1.7. Summary and aims of this thesis
In this thesis, the role ofNF-kB activation in the regulation of eosinophil survival and
the potential contribution of apoptosis to the massive eosinophil presence found in




2.1. - 2.13. Methods and Materials
2.1. Granulocyte Isolation
2.1.1. Granulocyte Isolation
Normal or mildly atopic donor venous blood was collected and anticoagulated {4ml
3.8% sodium citrate/ 36ml blood} and centrifuged (350g, 20 min, room temperature).
This gives two layers, an upper layer containing platelet-rich plasma (PRP), and a
lower layer containing a mixture of erthyrocytes and leukocytes. The PRP was
removed and used to prepare autologous serum in glass tubes by the addition of CaCh
{22pl of 1 M CaCl2 per 1ml PRP} at 37°C. To sediment the erythrocytes, 5ml of 6%
dextran (pre-warmed to 37°C) was added to the pelleted cells and the volume made up
to 50ml with 0.9 % saline (pre-warmed to 37°C) and mixed. The cells were allowed to
sediment for 30 min at room temperature resulting in formation of two distinguishable
layers; a bottom layer containing mainly sedimented erythrocytes and an upper
leukocyte-rich layer. The leukocyte-rich layer was aspirated, centrifuged (350g, 6 min)
and the supernatant discarded. The resulting leukocyte pellet was resuspended in 2.5ml
of 55% isotonic Percoll (9:1 v/v Percoll: 10 x PBS) in 1 x PBS without divalent
cations. Discontinous Percoll gradients were prepared by overlaying 2.5ml of 68%
Percoll onto 2.5ml of 79% isotonic Percoll. Leukocytes were then resuspended in 55%
Percoll and overlayed to form the final layer of the gradient. The gradients were
centrifuged (720g, 20 min) and polymorphonuclear cells harvested from the 68%/79%
Percoll interface. Mononuclear cells sedimented at the 55%/68% Percoll interface.
Purified cells were washed sequentially in PBS without divalent cations twice and cell
yield assessed using a haemocytometer. Although the above density gradient
centrifugation method does not separate neutrophilic from eosinophilic or basophilic
granulocytes, the harvested polymorphonuclear cells generally consisted of <3%
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eosinophils, and basophils were rarely seen. Preparations of granulocytes containing
>5% eosinophils were used for preparation and study of eosinophils as described in
section 2.1.2. Cell viability was assessed by trypan blue exclusion and was routinely
>99%.
2.1.2. Eosinophil isolation
Eosinophils were prepared from polymorphonuclear cells, isolated as described above
(2.1.1). Separation of eosinophils from neutrophils was achieved through negative
selection by immunomagnetic separation using the murine anti-neutrophil antibody
3G8 (anti-CD16; a gift from Dr J. Unkeless, Mount Sinai Medical School, New York)
and coated sheep anti-mouse IgG-Dynabeads. Anti-CD16-Dynabeads were prepared
under sterile conditions by combining anti-CD16 with Dynal M450 sheep anti-mouse
dynabeads (typically 20ml supernatant of 3G8 ~1ml beads). The antibody/bead mixture
was rotated at 4°C for at least 20 min to allow antibody binding. The coated beads
were then sequentially washed 4 times in PBS without divalent cations (4°C) and the
beads retrieved using a stationary contact (3 min) with a magnet (Dynal Magnetic
Particle concentrator, MPC-1).
Granulocytes, isolated as in Section 2.1.1. were incubated with washed 3G8-
Dynabeads at a bead:granulocyte ratio of 3:2 on a rotary mix at 4°C for 10 min and the
beads with attached neutrophils were magnetically separated by stationary contact (3
min) with a magnet. This procedure was repeated once. Purity was assessed by light
microscopy of cyto-centrifugated cells, stained with Diff-Quik1M. Purified eosinophils
(> 98%) were washed and centrifuged (220g, 5 min) twice in PBS without divalent
cations, before cell yield was assessed by haemocytometer counts.
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2.2. Assessment of Eosinophil Apoptosis
2.2.1. Morphological assay
Eosinophils in Iscove's DMEM supplemented with 10% autologous serum were
cultured in Falcon flat-bottomed flexible 96 well plates at 37 °C in a 5% CO2
atmosphere at 2 x 106/ml. Cells were cultured for a set time in the absence or presence
of test agents as described in each experiment. Cells were cyto-centrifuged, fixed in
methanol, stained with Diff-Quik™ and counted using oil immersion microscopy (xlOO
objective) to determine the proportion of cells with distinctive apoptotic morphology.
At least 500 cells were counted per slide. All experiments were performed at least 3
times and each treatment done in duplicate. The results are expressed as the mean %
apoptosis (except experiments performed during Hodgkin's disease study, see 6.2.1.).
Trypan blue assay was routinely performed to check the viability of the cells.
2.2.2. Annexin V binding
Stock annexin V was diluted 1:200 with binding buffer {2.5mM CaCl2 in Hank's
balance salt solution} and 20pl of 3.0 x 106 cells/ml cells were added. Following 10
min incubation at 4°C, samples were fixed by the addition of 100pl of 3%
paraformaldehyde in PBS before analysis using an EPICS Profile II.
2.2.3. DNA ladder
Cells (5.0 x 106) were washed with PBS and lysed with 500pl of 7M guanidium
hydrochloride. Using a Qiagen mini-prep kit, DNA was isolated according to the
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manufacturer's instructions. After DNA was isolated, DNA was run on an 1% agarose
gel with lpg/ml EtBr in TBS. Gel was analysed on UV light.
2.3. Western blotting
2.3.1. Preparation of cytoplasmic extracts
Following incubation at 37 °C with the indicated reagents cells were washed with ice
cold PBS and the cells lysed at 4 °C for 15 min with Nonidet P-40 (NP-40) lysis buffer
{50 mM NaF, 5 mM Nad^O?, 1 mM Na3V04, 10 mM |3-glyceropyrophosphate, 0.5 %
(v/v) Nonidet P-40, 2 mM EDTA, 16.8 mM Na2HP04, 3.2 mM NaFEPC^} containing
complete protease inhibitor cocktail EDTA free (Boehringer) for eosinophils and
{0.5mM ABSEF, lOpg/ml aprotinin, 2mM levamisole, 10pg/ml leupeptin, ImM
sodium orthovanadate, 0.5mM benzamidine, 10pg/ml pepstatinA, ImM
phenanthroline, ImM PMSF} for neutrophils. The cell fragments were then
centrifuged (4300g, 10 min, 4 °C) and the supematants containing the cytoplasmic
extracts collected. The protein loading was controlled by cell number either total
protein amount per condition. Each time WB was probed with ponsour staining to
determine the equal loading.
2.3.2. Western blot analysis
The cell extracts were diluted with 3 x sample buffer {5.7% (wt/v) SDS, 14% P-
mercaptoethanol, 150mM Tris HC1, pH 6.7; 30% (v/v) glycerol} and heated at 95°C
for 3 min before running on 10 % (wt/v) SDS -polyacrylamide gel. Electophoretically
separated proteins were transferred on PVDF microporous membranes. Non-specific
binding was blocked with PBS containing 5% non fat dry milk and 0.1% Tween 20
and probed with the indicated antibodies. As a positive control, protein extracted from
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Jurkat cell extract was also run on the gels. Immunodetected proteins were visualised
by ECL™ detection reagents.
2.4. Immunohistochemistry
2.4.1. Staining for immunohistochemistry
Eosinophils (2.5 x 106/ml) were incubated in Iscove's DMEM containing 5% FCS for 2
hours at 37°C before treatment with the indicated agents and time. The cells were cyto-
centrifuged, air dried for 10 min and then fixed with 4% (w/v) p-formaldehyde/PBS for
10 min and washed 3 times with PBS. The cells were permeabilized and non-specific
binding was blocked in buffer containing 0.2% (w/v) Triton X-100 in DAKO Protein
Block Serum Free buffer at room temp for 30 min. The cells were incubated with rabbit
polyclonal p65 antibody (1:100 dilution) in DAKO Antibody Diluent with 0.2 % Triton
X-100 for 1 hour. The cells were washed 3 times in DAKO Antibody Diluent with 0.2
% Triton X-100 and then incubated (1:100 dilution) with Alexa™ 488 (goat anti-
mouse) IgG antibody for 1 hour in DAKO Antibody Diluent with 0.2 % Triton X-100
then washed 3 times in the same buffer. The nucleus was stained with 0.1% propidium
iodide with 2% RNAse in PBS at 37°C for 30 min followed by washing (x 3) with PBS
before applying a glass coverslip.
2.4.2. Confocal microscopy and image analysis
Images are from single confocal sections, 0.3pm thick, taken through the center of the
nucleus, on a Leica TSC 4D confocal microscope using a 63x objective lens. p65
nuclear translocation was determined with a Leica DMRB microscope using a 40 x NA
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0.7 objective lens and Kappa integrating monochrome CCD camera. Image analysis
was integrated with image capture as described before (Dptala et al., 1998). The image
analyzer captures an image of the green p65 fluorescence and using an automated
macro-program developed for this application on a Leica Q550IW image analyser and
uses the binary images of the propidium iodide staining as a mask to measure only the
p65 fluorescence of the nuclei. The image analyser then detects the green fluorescence
(488nm excitation, 530nm emission) and subtracts the binary image of the red
fluorescence (570nm excitation, 620nm emission) to give a binary mask for the
cytoplasm.
2.5. ELISA for IL-8 Measurement
The ELISA (enzyme-linked immunosorbent assay) was performed using IL-8
recombinant protein as a standard and IgG anti-human IL-8 according to the
manufacturer's instructions (R&D systems).
Briefly, lOOpl of IL-8 mAB (4pg/ml in TBS) per well on a flat bottom EIA/RIA Plate
and left over night. The plate was washed three times with TBS 1% Tween 20, and
blocked with TBS 1%BSA for 1 hour. After blocking, samples were incubated with
standard samples (typically concentrations of 20ng/ml, lOng/ml. 5ng/ml etc.,) for 2
hours. The plate was then washed three times with TBS 1% Tween 20, and incubated
with detection antibody {biotinylated 20ng/ml in sample buffer; 0.1% BSA in TBS}
for 2 hours. The plate was then washed three times with TBS 1% Tween 20, and
incubated with 0.005% streptavidin-HRP in sample buffer for 20 min. The plate was
then washed three times with TBS 1% Tween 20, and incubated with TMB lOOpg/ml
in lOOmM sodium acetate-citrate pH 4.9 with 0.015 % H2O2 for 20 min in the dark.
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Then, 1M H2SO4 is added to stop the reaction. The plate was read on a Microplate
Reader 450 (BioRad Laboratories) at a wave length of 595nm.
2.6. Cloning TAT-IicBa
pcDNA
pcDNA IicBaWT and pcDNA IkBcc32,36 were gifts from Prof Hay, University of St
Andrews. pcDNA IkBccWT is full length wild type IkBoc, pcDNA IicBa32,36 is the
full length IkBoc but mutated at amino acid 32 and 36 serine to alanine. pGEX2T,
containing glutathione S-transferase (GST) gene, was obtained from Pharmacia (See
figure 5-2-1-A for plasmid map).
E.coli
E.coli DH5a (genotype; O80d/aeZDM15, recAl, end A1 gyr A96, thi-1, hsd R17 (r,
-, mk+), sup E44, relAl, deoR, D(/acZYA-argF)U169) was used for mainly DNA
preparation.
E.coli B834 (F-,ompT,hsdSB, (rB-,mB-)dcm,gal) was used for protein purification.
TAT
amino acid; YGRKKRRQRRR (Nagahara et al., 1999)
TAT oligoenucleotides, containing BarmHl cut sites, were obtained from MWG-
Biotech, phosphorylated at 5'.
TAT top; 5' GA TCTTAT GGC CGC AAA AAA CGT CGC CAG CGT CGC CGT G 3'
TAT bottom; 3' A ATA CCG GCG TTT TTT GCA GEG GTC GCA GCG GCA CCT AG 5'
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2.6.1. Insertion of pcDNA IkBccWT and pcDNA IkBo32,36 into pGEX2T
Aim; to producepGEX2T containing GST-IkBcc or GST-IkBo.32,36 gene
Isolation of pcDNA and cut off pGEX2T
pGEX2T contains high level expression of genes as fusions with GST gene from
Schitsoma japonicum, which forms an affinity tail on the protein products of genes
inserted into the multiple cloning site. pGEX2T was digested by BamHl {5 pg DNA,
5pl 10 x Buffer E (Promega), 2 pi BarmHl (Promega)}, pcDNA IkBcxWT and pcDNA
IicBa32,36 were digested by EcoRI {5pg DNA, 5pl 10 x Buffer (Promega), 2pl EcoRI
(Promega)} and BamHI at 37°C for 3 hours. Digested DNA was run on a 1% agarose
gel with lpg/ml EtBr. Efficiently digested pcDNA was extracted from the gel under
UV light and purified with using a Qiagen Gel Extraction Kit, according to the
manufacturers instructions. Final concentration of DNA was determined for the
ligation.
2.6.2. Ligation and insertion into DH5a
Ligation was set up for typically, xl, x3, x6, x9, x20, x30 of pcDNA against digested
pGEX2T for several hours at 20 C {lOOng pGEX2T DNA, lpl lOx ligase buffer
(Promega), 0.5pl T4 DNA ligase (Promega), 6.5pl H2O}. DH5a, competent cells, were
heat shocked at 42 C for 3 min for DNA insertion {lOOpl of cells (from the stock of
the cells OD600nm=0.6) to 5pl of ligated DNA}. Cells were cultured with {400pl
Luria-Bertani (LB), 20mM glucose} on a shaker for 37 C for 1 hour. Then the cells
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were seeded onto the plates {LB, 50pg/ml Ampicillin (AMP), 0.7% agar} and
incubated for 37 C for several hours.
2.6.3. Selection of the colony by PCR and DNA sequencing
After the incubation several colonies were selected for 5ml culture {LB, 50pg/ml
AMP} growing for several hours on the shaker at 37 C. After growing the cells, mini
prep (Qiagen) was perfomed to determine for PCR and DNA sequence, and a small
volume of protein purification was performed to determine the colony which contains
the appropriate DNA.
2.6.4. PCR
Primer; GC rich E14A down; GCG GGG GCC CGC CAT GGC CCA (Professor Hay,
Uniyersity of St Andrews).
PCR was proceeded for 35 cycles, 94°C 5min, 94°C 5min, 55°C 5min, 72°C 3min,
72°C lOmin.
2.6.5. DNA sequence
DNA sequence was determined using an ABI PRISM™ 377 DNA Seqeuencer by Alex
Huston at the DNA sequence Unit, St Andrews University. (See chapter 5, result
section figure 5-2-2 for a successful GST-TAT-IkB(x insertion.)
2.6.6. Protein purification for small volumes
See protein purification session (2.7.) as follows. A small volume of the cells, such as
in 5ml medium culture, was used.
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2.6.7. Selection of the colony
The right colony was selected depending on the results obtained from PCR, DNA
sequence and protein purification procedures. If it was necessary maxi prep (Qiagen)
was performed.
2.6.8. Insertion of double stranded TAT into pGEX2T containing IkBgcWT or
IkBcx32, 36
Aim; to produce pGEX2T containing GST-TAT-IkBa or GST-TAT-IkBcc 32,36 gene
Anealling single strand TAT oligonucleotides into double stranded DNA.
Single stranded TAT oligonucleotides were anealled with lOx hibridisation buffer {1M
NaCl, lOOmM Tris pH 8.0, lOmM EDTA} for 50pM top and bottom oligonucleotides
at 100°C for 3 min then allowed to cool down to room temperature. Double stranded
TAT DNA was inserted into pGEX2T containing hcBa or IicBa32,36 as described
above (see 2.6.1. and 2.6.2.).
2.7. Protein Purification
2.7.1. Protein expression in B834
The DNA containing GST-TAT-IkBcc or GST-TAT-IicBa32,36 were transformed into
chemically competent E.Coli B834 by heat shock as described above. After several
hours incubation on an agarose plate, a few colonies were selected for growing in
500ml cultures {LB, 50pg/ml AMP}. (DNA sequence or PCR were obtained.) B834
cells were cultured on the shaker at 20-37 C, depending on the speed of their growth.
When OD600nm was between 0.6 and 0.8, 0.5mM IPTG was added. After 2 to 3 hours
of growth the cells on the shaker at 20 C cells were harvested . Some cells were kept in
a glycerol stock (10%) at -70 C. The remaining the cells were lysed with Buffer A
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{50mM Tris pH8.0, 500mM NaCl, 0.1% P-mercaptoethanole} at 4°C (all the process
must be handled at 4°C after this process except enzyme digestion) and sonicated until
the medium colour gets clear. 1% Triton-X was added and centrifuged for 5 min at
6000g. The supernatant was used as cell lysate.
2.7.2. Protein purification through column
GST-beads in the column was washed with Buffer A {50mM Tris pH8.0, 500mM
NaCl, 0.1% P-mercaptoethanole} before applying the cellular lysate to the column
(this allows GST-TAT-IkBcx binding to GST beads in the column). lOmM glutathione
was applied to the column and 1ml flow-through fraction was collected. The peak
protein fraction was measured using the Bradford assay at 595nm. (This peak fraction
should contain GST-TAT-IicBa) Thrombin 2 units/mg protein used to digest the peak
fraction (to cut off GST from'TAT-hcBcc), for 1 hour at room temperature. A protein
gel (10% acrylamide SDS gel) was run to check the efficiency of digestion by
thrombin, stained with comassie blue. The Q-sepharose beads in the column was
washed with Buffer B {50mM Tris pH8.0, 250mM NaCl, 0.1% P-mercaphtoethanol}.
Thrombin digested protein fraction (TAT-IicBa) was diluted with 250mM NaCl with
Buffer C {50mM Tris pH8.0, 0.1% P-mercaptoethanol} for application to the Q-
sepharose column. (This allows TAT-IicBa binding to Q-sepharose beads and to elute
away GST.) Buffer D {50mM Tris pH8.0, 625mM NaCl, 0.1% P-mercaphtoethanol}
was applied and flow-through was collected, and the protein measured at 595nm using
the Bradford assay (Peak fraction should contain TAT-IkBoc). TAT-IkBoc was
examined by 10% SDS gel and mass spectrometry by slow crystalisation (Dr Botting,
St Andrews, see fig5-2-3) were performed to be confirm correct protein determination.
Protein was kept in 10% glycerol at -70°C.
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2.8. Denaturing the protein
TAT-IkBoc or TAT-IkBo.32,36 protein (300- 500pg) were dialysed with 8M urea
against DMEM for 3 hours. Medium was changed every hour. After the dialysis 20mM
HEPES was added and the protein kept at -70°C with 10% glycerol.
2.9. Luciferase assay
Luciferase-reporter-gene-inserted cells (Arenzana-Seisdedos et al., 1997) were used to
examine the expression of NF-kB following treatment with TAT-IicBaWT or TAT-
IxBa 32,36.
HeLa cells; 57A (Professor Hay, University of St Andrews), maintained in 10%
FCS in DMEM
Epithelial cells; A549 (Professor Hay, University of St Andrews), maintained in
10% FCS in DMEM
Jurkat cells; a5.1 (Professor Hay, University of St Andrews), maintained in 10%
FCS in RPMI 1640 (Gibco)
Six-well plates were used to culture adherent cells. Cells were stimulated with various
stimuli and 5-6 hours later the cells were washed with ice cold PBS and harvested with
lysis buffer {25mM Tris pH 7.8, 8mM MgC12, ImM DTT, 1% TritonX-100, 15%
glycerol}. Cellular lysate (100pl) was read using a luminometer with injecting 100 pi
luciferase buffer {ImM ATP, 0.25mM luciferin, 1% BSA made up in lysis buffer}.
Protein amount was measured using the Bradford assay to detennine luciferase
activity/ protein amount (RLU/mg).
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2.10. Labelling TAT with FITC
Fluorescent Isothiocyanate (FITC) was incubated, in a ratio of 40-80pg per mg of
protein, with TAT-IkBoc, recombinant IkBoc, GST-TAT for 1 hour at room
temperature, overnight at 4°C in the dark. After the incubation, protein was dialysed
against buffer {lOmM Tris, 150mM NaCl, pH8.2}, over night at 4°C with four
changes ofbuffer. After dialysis protein concentration was measured.
2.11. Gel shift assay
After cells were lysed to obtain cytoplasmic extracts, the nuclei were washed twice
with cytoplasm lysis buffer {50 mM NaF, 5 mM Na4P207, 1 mM Na3V04, 10 mM (3-
glyGeropyrophosphate, 0.5 % (v/v) Nonidet P-40, 2 mM EDTA, 16.8 mM NaaHPO,},
3.2 mM NaH2P04, containing complete protease inhibitor cocktail EDTA free
(Boehringer)}. The nuclei were then lysed with ice cold nucleus lysis buffer {300mM
NaCl, 50 mM NaF, 5 mM Na4P207, 1 mM Na3VC>4, 10 mM (3-glyceropyrophosphate,
0.5 % (v/v) Nonidet P-40, 2 mM EDTA, 16.8 mM Na2HP04, 3.2 mM NaH2P04,
containing complete protease inhibitor cocktail EDTA free} for 15 min on ice and
centrifuged (23,000g for 10 min at 4°C). The nuclear extract was obtained and its
protein concentration was measured.
10pg of nucleus extract was incubated with 18pl binding buffer {25mM Hepes, ImM
EGTA, 3.5mM Spermidine, 6mM MgCl2, 0.15% NP-40, 10% glycerol}, 2pl {lOOmM
DTT, lpl lOmg/ml BSA, lpl 0.5mg/ml poly dAT, lpl lOmg/ml BSA, lpl 0.5mg/ml
poly dGC} for 15 min on ice. Then lpl of 33P (10,000cpm, approx) labelled DNA
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containing an NF-kB recognition site (see below for various oligonucleotides) was
added for 15 min at room temperature before being assayed by electrophoresis on 6%
non-denaturing polyacrylamide gels. After electrophoresis, gels were dried on 3MM
paper (Whatman) and visualised using a phosphoimager.
The NF-kB oligonucleotides were as shown below;
Oligonucleotides;
16bp WTkB;
5' CTG GGGACTTTCC AGG 3'
3' GAC CCCTGAAAGG TCC 5'
HIV-R;
5' GATCTG GGGACTTTCC AGG 3'
3' AC CCCTGAAAGG TCCCTAG
Promega;
5' AGT TGA GGG GAC TTT CCC AGG C 3'
3' TCA ACT CCC CTG AAA GGG TCC G 5'
2.12. Hodgkin's disease studies
2.12.1. Hodgkin-Reed-Sternberg (HRS) cell lines
Six different HRS cell lines (L428, L540, L591, KMH2, HDLM2, HDMYZ) were
maintained in RPMI1640 with heat inactivated 10% Foetal calf serum (FCS), except
HDMYZ in RPMI 1640 with heat inactivated 20% FCS. These suspension cells were




HRS cells were centrifuged at 350g for 5 min and supernatants were taken for further
incubation with eosinophils or neutrophils. Supernatant was collected from different
passages on several separate occasions. Typically 10% of supernatant in final a volume
during granulocytes culture was investigated (see 6.2.1. for more details).
2.12.3. Isolation of substances by molecular weight from the supernatant from
HRS cells.
Centriplus®, centrifugal filter devices, (Millipore) was used to separate the molecules
from HRS supernatants with molecular weight lOKDa, 30KDa, 50KDa. Centrifugation
was proceeded according to the manufacturer instructions.
2.13. Statistical Analysis
Statistics analysis was performed by Newmans-Kuels procedure. The row value was
calculated for mean value where standard error of the mean was taken to evaluate the
statistical significance. From standard deviation (defied as statistic that communicates
the average of the deviation of the scores from the mean in a set of data, computed by
obtaining the square root of the vatienc.) and the standard error of the mean difference
from each condition were taken to evaluate the statistical significance. These values
were obtained using T-test (p<0.05) and value was determined its significance.
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2.14. Materials
The following reagents were kindly donated as gifts:
• murine anti-neutrophil antibody 3G8 from Dr J. Unkeless, Mount Sinai Medical
School, New York,
anti-TAT AB from Dr Eric Vives, Institute de Genetique Moleculaire de
Montpellier, Montpellier, France
pcDNA IkBocWT and pcDNA IicBa32,36, anti-hcBa antibody 10B (Jaffray et al.,
1995) and AP were gifts from Professor Hay, University of St Andrews.
Further materials were purchased from the following companies:
5 Prime->3 Prime, Inc: Pancreatic Rnase A (DNase-free) (5-888777)
Affiniti Research Products Ltd, Mamhead, Exeter, UK: z-VAD-fmk methyl ester,
Agar Scientific LTD: PAP PEN (L4197)
ALEXIS Biochemicals : MG-132 (N-cbz-Leu-Leu-leucinal)
Amersham Pharmacia Biotech, UK Ltd, Buckinghamshire, UK: horse radish
peroxidase-conjugated donkey anti-rabbit secondary antibody, [gamma-32P], [gamma-
33P] ATP (3000 Ci/mM), Ultrapure dNTP set 2'-deoxynucleoside5'-triphosphate (27-
2035), Percoll, Poly di/dc. Poly di/dc 5U (27-7880), ECL detection reagents (RPN
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2105, RPN 3004), dNTP (27-2080-01), dATP (27-2050-01), dCTP (27-2060-01),
dGTP (27-2070-01)
Baxter Healthcare Ltd, Baillieston, Glasgow, Scotland, UK: Diff QuikIM stain.
Solution I (Eosin G in phosphate buffer, pH 6.0), Solution II (Thiazine blue in
phosphate buffer; pH 6.0), saline solution 0.9% (sterile).
Boehringer Mannheim, Germany: Annex in-V-FLUOS
Cambridge Bioscience, Cambridge, UK: Alexa 488 goat anti-rabbit (A-11034)
Cell Signalling Technology, Beverly, MA, UK: polyclonal rabbit anti-IicBa antibody
Costar: EIA/RIA Plate flat bottom high binding (3590) for ELISA
DAKO Ltd Cambridgeshire, UK: Horse radish peroxidase-conjugated, goat anti-
mouse, Anti-mouse AB; peroxidase-conjugated goat anti-mouse IgG (P0447), anti-
sheep AB, peroxidase-conjugated rabbit anti-sheep immunoglobulins (P 0163),
DAKO® antibody diluent (S0809), DAKO® Antibody Diluent (S080981), DAKO®
protein block serum-free (X0909)
DAKO® Protein Block Serum-Free (X090980); DAKO
Dynal UK, Wirral, UK: Dynabeads M-450 sheep anti-mouse IgG. Supplied as 4 x 108
beads/ml in PBS pH 7.4 with 0.1% human serum albumin and 0.2% sodium azide.
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Euronenetics: Anti-CD16 mAB, 5D2 clone (M1389)
Genzyme Diagnostics, Kent, UK: GM-CSF (1000 U/ml in PBS) was stored at -70°C.
Gibco Life Technologies, Paisley, Scotland, UK: Iscove's Dulbecco's modified
Eagles medium, without supplements with L-glutamine (Iscove's MDM); Hanks
Balanced Salt Solution (HBSS); RPMI1640; foetus calf serum; culture supplements
penicillin (50 U/ml)/streptomycin (50 U/ml); L-glutamine (200 mM); and 30 % (w/v)
acrylamide/bis solution.
Life Technologies : BenchMark™ Prestained protein ladder (10748-010)
Martindale Pharmaceuticals Ltd, Romford, UK: calcium chloride:
Melford Lab Ltd; IPTG
Millipore: CENTRIPLUS® YM-10, CENTRIPLUS® YM-30, CENTRIPLUS® YM-
50; Immobilon-P PVDF
Organon Laboratories Ltd, Cambridge, UK: Dexamethasone.
Phoenix Pharmaceuticals Ltd, Gloucestershire, UK: Sodium citrate solution (3.8%).
Piece chemical company: BCA Protein Assay Reagents (Kit) (0023223)
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Promega Corporation, Southampton, UK: SignaTECT™ cAMP-Dependent Protein
Kinase (PKA) Assay System, T4 DNA Ligase; T4 Polynucleotide Kinase (M4101),
NF-kB consensus ologonucleotide, DNA Polymerase I Large (Klenow) Fragment
(M2201),
QUIAGEN: QIAGEN® Plasmid Kits (12143, 12145)
R&D Systems Europe Ltd, Oxon, UK: TNFa (stock solution 10p.g/ml); mouse IgGi
anti-human IL-8 monoclonal antibody (stock solution 500pg/ml), biotinylated anti
human IL-8 polyclonal antibody (stock solution 50p.g/ml), human IL-8, Anti-IL-13
AB; monoclonal anti-human neutralizing IL-13 antibody (MAB213), TNFa; TNF(3,
IL-5, GM-CSF
Roche Diagnostics GmbH: Complete mini-EDTA free protease inhibitors (1836170)
Santa Cruz Biotechnology, Inc: Anti-hcBa antibody,C21, Anti-IicB-P antibody, Anti-
IKK1 antibody, IKKa(B-8), (sc-7606), Anti-p50 antibody, NF-kB p50 H-119 (sc-
7178), Anti-p50 antibody, NF-kB p50 N-19 (sc-1191), Anti-p65 antibody, NF-kB p65
H-286 (sc-7151), Anti-SUMO-1 antibody,C-9, (sc-6375)
Shandon, Pittsburgh, PA, USA: Shandon Filter Cards
Sigma; other reagents not on this list purchased by Sigma
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The methodology to investigate the function of
NF-kB in granulocytes.
3.1. Introduction
The study of specific intracellular proteins in granulocytes, by biochemical or
molecular approaches has some technical difficulties due to the high amount of
proteases and their short lives. (The half life of neutrophils and eosinophils are 12
hours and 2-4 days, respectively.) Of these cells in fact, compared to studies in other
cell lines, fewer biochemical and molecular studies have been demonstrated. For
example in the NF-kB area, Cassatella's group has demonstrated IkBcc degradation
and NF-kB activation in neutrophils (McDonald et al., 1997, McDonald et al.,
1998a, McDonald et al 1998b, McDonald and Cassatella 1997). Our study (Ward et
al, 1999) demonstrated the importance ofNF-kB in neutrophil apoptosis, and others
have demonstrated NF-kB gel shift assay for neutrophil adhesion molecules
(Rahman et al., 1999), phagocytosis (Vollebregt et al., 1998) and activation
(Shenkar and Abraham 1999). In eosinophils Yamashita et al., (1999) showed for
the first time the immunofluorescent staining of p50, and our study (Fujihara et al.,
2002, see chapter 4) demonstrated the expression of hcBa and p65 in the cytoplasm
and nucleus. Despite the huge therapeutic interest, these are the only NF-kB related
published reports in granulocytes (in both neutrophils and eosinophils).
In this chapter the methodology used to study NF-kB in neutrophils and eosinophils
is investigated. In neutrophils the usage of different antibodies, culture conditions
and expression of IkBcx are shown. The expression of IkBo. in neutrophils is
extension of the study we published recently (Ward et al., 1999) to investigate the
effect of various NF-kB inhibitors on neutrophil apoptosis. On the other hand, in
eosinophils, expression of p50, p65, hcBa and IkBP are shown in this chapter. Then
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in the following chapters (4, 5 and 6), the role ofNF-kB in apoptosis and survival in
eosinophils is thoroughly investigated.
++1 I I I++++++++++++
3.2. Results;
3.2. Morphological assessment of granulocyte apoptosis
As described in the methods chapter (see 2.1.1.) neutrophils or eosinophils were
freshly isolated. In vitro granulocytes undergo spontaneous apoptosis. Typical half
life of neutrophils is 12 hours, whereas in eosinophils it is an average 1-3 days, but
is dependent on the donor*. Figure 4-5-A and B in chapter 4 shows typical
apoptotic eosinophils, which were cultured without any stimulus for 4 (4-5-A) and
30 hours (4-5-B) and stained with Diff Quick (For typical apoptotic neutrophils, see
figure 3 in Appendix, Ward et al., 1999). Apoptotic eosinophils clearly exhibit
condensed nuclei and shrinkage of cytoplasm. Furthermore, another apoptosis
marker, Annexin V binding and eosinophils apoptosis is shown in chapter 4, figure
4-2-5C.
*However, it has been observed that some eosinophils from atopic donor (this
experiment was performed in GlaxoSK) survived up to 7-10 days without any
stimuli in vitro. This suggest that eosinophils from some individuals may have more
resistance towards apoptosis but survive longer for some reason, perhaps high
cellular metabolism, such as high activity of survival pathway, protein synthesis and
inhibition of apoptosis pathway. It is more likely that atopic patients or allergy
suffers may have more resistance towards ongoing apoptosis. However, the precise
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correlation studies has not yet be performed. As next project, apoptosis rate,
peripheral blood eosinophil count, level of IgE in peripheral blood, if asthmatic the
measurement of FEVl and PC20 to methacholine, adenosine monophosphate,
histamine challenge, allergy symptom scores etc., should be studied. Please see
5.5.3. for the possibilities of different responses in donor dependent manner to
TAT-IkBcc in apoptosis rate.
3.3. The methodology and study on NF-kB in neutrophils.
Molecular or biochemical experiments using neutrophils in vitro involves some
technical difficulties that may not arise in cell line work. This is not only because of
the neutrophil's short life span, but also that they contain high quantities of granules
with proteases that may disturb the target cellular contents during the isolation
process. To obtain the target cellular contents, in this case IicBa from cytoplasm
extract, various methods have been attempted as follows.
3.3.1. Protease inhibitors
Strong protease inhibitors are required for the isolation of cellular contents from
neutrophils due to the high amount of proteases contents in granules. Cassatella et
al., (1998) have suggested the usage of Diisopropyl Fluorophosphate (DFP) for
neutrophilic lysate preparation for Western blotting and gel shift assay. DFP is a
strong cysteine inhibitor but also highly neurotoxic and required extra caution to
handle in the laboratory. We (kindly with the help of Dr James Pryde, CIR,
University of Edinburgh) had tried and the results were clear that DFP blocked
protease activities (data not shown here, but shown in Pryde et al., 2000) and
obtained the target intracellular protein without any trace of degradation or
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disruption by proteases. However, in practical terms, it was impractical to continue
this procedure for each experiment with extra safety equipment, e.g. wearing gas
masks, and concluded that the strong cocktails of protease inhibitors, which can be
used normally in the laboratory, were used instead. The effect of the cocktail of
protease inhibitors was, however, limited resulting in the occasional failure of
isolation of the target proteins due to proteolysis in neutrophils.
3.3.2. Isolation of the target proteins for Western blotting analysis.
To obtain the cellular protein, neutrophils can be lysed in various ways; the standard
NP-40 lysis methods, homogenisation (Pryde et al., 2000) and nitrogen cavitation
methods (Cassatella et al., 1998b). Homogenisation and a series of centrifugations
can isolate various neutrophilic contents (e.g., cell membrane, granules,
mitochondria etc.,) and would be the most favourable method to isolate neutrophilic
contents without disturbing granule contents. Although, homogenisation may be the
best option for isolation, it requires a substantial amount of neutrophils. Therefore,
for my experiments, it was concluded that this was not the most suitable method due
to lack of the number of cells. In addition, due to a lack of equipment, we did not
have a chance to try nitrogen cavitation methods.
As described in the methods section, in my experiments, NP-40 lysis methods,
which disrupt the cellular membrane resulting in a burst of the cellular contents, was
used for both neutrophil and eosinophil work. This method may disturb the granule
contents, but would be controlled by the strong protease inhibitors. The NP-40
method with strong protease inhibitors may not be favourable for the isolation of
neutrophilic contents. However, considering the practical reasons and cell numbers,
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it was concluded to be an optimal method for the following investigation for the
IkBcx expression in neutrophils.
Summary
For practical reasons use of a strong protease cocktail and NP-40 lysis method
were used for the following neutrophil and eosinophil experiments.
3.4. Various anti IkBoc antibodies
To determine the expression of IkBcx by Western Blotting (WB) analysis, various
anti- IicBa antibodies were tested in neutrophil experiments. The characterisation of
those antibodies are as shown below in table 3-4. 'IkBcx' by New England Bio Lab
(see 3.13.) were used for eosinophil experiments as shown in the following sections.
name clone animal recognition
sites
supplier or gift from
10B mono¬
clonal






Prof Hay, University of
St Andrews
C-21 poly rabbit a.a. 297-317 Santa Cruz
IkBoc poly rabbit a.a. 27-38 New England Bio Lab
Table 3-4; Various anti-lKBa antibodies have different
recognition sites on IicBa. *Jaffary et al., 1995.
3.5. Expression of IkBcc from neutrophils cultured in PBS or medium
containing 10% autologous serum.
In the resting state of the cells, the transcription factors NF-kB are held by IkBcx in
the cytoplasm for the prevention of translocation into the nucleus for the following
51














Figure 3-5; Expression of IkBoi from neutrophils cultured in PBS
or medium containing 10% autologous serum. Purified neutrophils (5.0
x 106 cells/ ml) cultured in PBS or Iscove's DMEM containing 10% autologous
serum for 30 minutes. Cells were lysed for cytoplasmic extract amd examined by
WB. Different anti-IxBa antibodies, 10B and C-21 are used to determine the
expression. IkBoi is usually expressed as 37KDa.
transcription activities (see introduction 1.6.1. and figure 1-6-1). Upon certain
stimuli, such as TNFa, LPS and IL-1, IkBcx is phosphorylated and then degraded by
26S proteasome and result in the release of NF-kB into the nucleus. To investigate
the IkBoc expression in the cytoplasm as an index to measure NF-kB activation (i.e.,
the degradation of IkBoc indicates NF-kB translocation into the nucleus). The
expression of IicBa in neutrophils was examined by WB analysis.
Figure 3-5 shows IkBoc expression in neutrophils. Neutrophils were cultured in PBS
or Iscove's medium containing 10% autologous serum (M+S) for 30 minutes and
lysed for cytoplasmic extract for WB analysis. The membrane was probed with 10B
antibody first. Then it was stripped and probed with C-21 antibody. The anti-IicBa
antibody 10B (monoclonal, recognition site a.a. 24-48) recognises three different
bands (55K, 37K and 30KDa) in both PBS and M+S. In contrast anti-hcBa antibody
C-21 (polyclonal, recognition site is a.a. 267-317) recognised only two bands (55K
and 37KDa) in M+S condition, but not in PBS, although it was the same membrane.
Another anti-lKBa antibody, AP (polyclonal, recognises a whole length of IkBcx),
had also recognised three bands the same as 10B (see figure 3-9). The different band
expression by different antibodies are not fully understood. However, antibody AP
and 10B do recognise the same bands although their recognition sites were
different. Therefore, it was concluded that AP and 10B were to be used for the
following WB analysis but not C-21. (Because C-21 recognise the different bands.)
The three bands (55K, 37K and 30KDa) were repeatedly detected in the following
neutrophil WB. Ordinary hcBa in many cells is 37KDa, which is indicated as 'IkBcc'
in all the figures in this chapter. However, the mechanisms and functions of 55K
and 30KDa are yet to be elucidated. More details are discussed in 3.10.and
discussion 3.16.
Summary
. The antibodies 10B and AP (also see figure 3-8) detect the same three bands
(55K, 37K and 30KDa) in neutrophils.
It was concluded that 10B would be used for the following neutrophil WB
experiment.
C-21 recognises only two bands (55K and 37K) in medium containing serum.
C-21 did not recognise any bands from PBS cultured cells.
3.6. Expression of IkBcc from neutrophils cultured in medium with or without
10% autologous serum.
It has been noted that IkBoc expression in neutrophils by WB is generally better in
the cells cultured in medium containing 10% autologous serum than ones without
serum or in PBS. Figure 3-6 shows the IicBa expression from neutrophils cultured
in the medium with or without 10% autologous serum. Apart from 60 minutes, all
other time points showed better IkBcc expression from the cells cultured in serum
containing medium. The mechanism of the better signal on WB is not known. This
could be because of activation of IkBoc in the cytoplasm in PBS condition either
experimental artefact that IicBa protein may have been degraded as proteolysis
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Figure 3-6; Expression of IkBcc from neutrophils cultured in
medium with or without 10% autologous serum. Purified neutrophils
(5.0 x 106 cells/ ml), which had been cultured in Iscove's DMEM with or without
10% autologous serum for the time indicated. Cells were lysed for cytoplasmic
extract and examined by WB. Anti-IxBa antibodies (10B) are used to determine
the expression.
during the separation of lysate. To determine the real answer, direct measurement of
NF-kB activation is required as a future project.
Autologous serum contains various substances which may influence various
intracellular factors including protease activities. This may affect the preparation
process of obtaining lysate (e.g., inhibition of protease activities) or some protection
against proteolytic problems (See discussion 3.16.)
In order to gain better signals of IicBa expression by WB, it was concluded that
neutrophils would be cultured in medium containing 10% autologous serum.
Summary
. Neutrophils cultured in medium containing 10% autologous serum demonstrate
better IkBcc expression byWB.
Further experiments on neutrophils were performed with medium containing
10% autologous serum.
3.7. 55KDa IkBoc is not SUMO-IkBcc complex in neutrophil cytoplasm.
As shown in figure 3-5, three bands of 'hcBa' in neutrophils were expressed by WB.
Those three bands of IkBcc were recognised by anti-IicBa antibody 10B and AP. So
far this pattern has not been observed or reported in other cell types, such as HeLa,
A549 and also in eosinophils using the same isolation methods. Usually ItcBa is
detected as one band at 37KDa in many cells.
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Recently, it has been shown that SUMO (SUMO; small ubiquitin-like modifier)
linked IicBa is expressed in the cytoplasm at about 55KDa by WB (Desterro et ah,
1998) in HeLa cells. When IicBa is modified by SUMO-1, SUMO-IicBa complex is
resistant from degradation by the proteasome (Desterro et ah, 1998), resulting in the
inhibition ofNF-kB.
In neutrophils this 55KDa band is detected commonly. Thus, to investigate if
55KDa band is due to SUMO-IkBoc complex, neutrophil lysate on WB was to
assessed by anti-SUMO antibody. The result is shown in figure 3-7. In Jurkat cells
the 55KDa band is recognised as SUMO positive, possibly a complex of SUMO-
IkBoc, but not in neutrophils. Therefore, it was concluded that this neutrophilic
55KDa band is not due to SUMO-hcBa.
Summary
Neutrophilic 55KDa band is not SUMO-IkBcc.
3.8. Expression of IicBa in 15°C treated neutrophils
As previously described by Pryde et al. (2000), isolated neutrophils treated at 15°C
for 20 hours undergo substantial low percentage of apoptosis, while constitutive
apoptosis may reach nearly 80% when cells were kept at 37°C. After the treatment
of 15°C, when the cells were subsequent warming up to 37°C , rapid apoptosis was
observed (e.g., 100% apoptosis at 120 minutes, while 15°C treated cells resist at




Figure 3-7; 55KDa IicBa is not SUMO- IkBgc complex in
neutrophil cytoplasm. Purified neutrophils (5.0 x 106 cells/ ml) cultured in
Iscove's DMEM containing 10% autologous serum for 30 minutes. Using anti-
SUMO antibodies, 55KDa IkBcx is denied to be SUMO conjugated IicBa while in






Figure 3-8; Expression of IicBa from 15°C treated neutrophils.
Purified neutrophils (5.0 x 106 cells/ ml) cultured in Iscove's DMEM containing
10% autologous serum for 30 minutes, indicated as 'C' or cultured at 15°C for 20
hours (Pryde et al., 2000). In 15°C treated cells, IicBa is expressed as only one
band at 37KDa. In contrast, neutrophils incubated for 30 minutes in the medium
express three bands of IkBo. (but only two are shown). Anti-IxBa antibody, 10B,
was used.
lower metabolic activities, such as reduction in membrane lipid fluidity, a decrease
in the rate of protein translation, and an inhibition of vesicular tracking and
neutrophil respiratory burst activities (Liu et al., 1996). Pryde et al., (2000) has
shown the inhibition of pro-caspase 3 in the cells which has been treated at 15°C but
reversed this inhibition to the active state when cells were warming up to 37°C.
Also, this action was reversed with the addition of zVAD, a protease inhibitor,
suggesting the crucial role of caspase pathway for neutrophil apoptosis in
temperature dependent manner.
Neutrophils were incubated for 15°C for 20 hours (Pryde et al., 2000) resulting in
their apoptosis being arrested. These cells were harvested and subjected to WB
analysis for expression of IkBcc. Figure 3-8 demonstrates that 15°C treated
neutrophils express only one band, 37KDa of hcBa, which was recognised by 10B.
The explanation of different IkBcx expression between one band and three bands in
the different treatments is unknown. However, this may suggest lower cellular
metabolism (Liu et al., 1996) or arrest of caspase pathways may be involved with
cleavage of IicBa. (30k Da) or conjugation of some proteins onto IkBoc (55k Da).
(See discussion 3.16. for more details.)
Summary
It is possible to detect only one band of ordinary IkBoc, 37KDa, in neutrophils if
cells were incubated at 15°C for 20 hours to arrest spontaneous apoptosis.
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Figure 3-9; Expression and degradation of IkBo, by TNFa
stimulation. Purified neutrophils (5.0 x 106 cells/ ml) cultured in Iscove's
DMEM containing 10% autologous serum with or without TNFa (lOng/ml) for 30
minutes. Cells were lysed for cytoplasm extract and being examined by WB.
Different anti-IicBa antibodies, 10B and AP are used to determine the expression.
Both antibodies detect three bands of bcBa. Upon TNFa stimulation, the two
bands (37K and 30KDa) were degraded.
3.9. Degradation of IidBa by TNFa
When TNFa stimulates cells, IicBa is phosphorylated and this results in the
degradation of IicBa by the proteasome. As demonstrated in figure 3-9, IicBa
degradation upon TNFa (lOng/ml) stimulation occurs in neutrophils. They are
detected by anti-IicBa antibodies 10B and AP. The two bands, 30K and 37KDa are
degraded while 55KDa band remains in the cytoplasm. Normally bcBa is expressed
as 37KDa, thus, degradation of 37KDa of IicBa is expected. However, the cause of
degradation of 30KDa of h<Ba upon TNFa stimulation is unknown.
Summary
Using different antibodies, 37KDa and 30KDa bands of IicBa are detected to be
degraded upon TNFa stimulation.
The 55KDa band of IicBa remains in the cytoplasm upon TNFa stimulation.
3.10. DcBa in neutrophils
To assess the function of IicBa in neutrophils, neutrophils were cultured with
different stimuli, such as TNFa (lOng/ml), LPS (500ng/ml), gliotoxin (lOOng/ml),
Mgl32 (20pM) and caspase-3 inhibitors (50pM). The results are shown in figure 3-
10. Anti-IicBa antibody, 10B, was used in this experiment. In control condition (C)
medium containing 10% autologous serum (M+S) showed better signals (stronger
signals) compared to PBS or medium only. All other conditions contain 10%
autologous serum. In all non-treated control conditions (PBS, M, M+S), three bands
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Figure 3-10; Expression and degradation of IKBa. Purified neutrophils
(5.0 x 106 cells/ml) cultured in Iscove's DMEM containing 10% autologous serum
were treated with different stimuli for 30 minutes before TNFa (lOng/ml) and LPS
(500ng/ml) were added for a further 30 minutes. 'C' indicates control condition
without any stimulation. 'M' and 'S' indicate medium and serum respectively.
Cells were lysed for cytoplasmic extract and examined by WB, with using anti-
IkBoc antibody, 10B. TNFa and LPS degrades two bands of IxBa, while gliotoxin
(glio) prevents those degradations and proteasome inhibitor, Mgl32 (Mg) (20pM),
prevents only one band degradation. Caspase-3 inhibitor (C-3) (50pM) did not
affect the expression of IxBa.
Upon TNFa and LPS stimulation, two bands of IkBcc, 37K and 30KDa, were
degraded. The degradation of 37KDa hcBa leads to the activation ofNF-kB. These
results correlate with our previous work (Ward et al., 1999, see appendix) where
induction of NF-kB activation by gel shift assay stimulated with TNFa and LPS
was shown. 30KDa IicBa also is able to be degraded by stimulation with TNFa and
LPS, but the mechanism and function of its degradation is unknown.
In this experiment, gliotoxin and proteasome inhibitor Mgl32 were used as NF-kB
inhibitors. These NF-kB inhibitors were preincubated with cells for 30 minutes
before TNFa or LPS were added. Then after a further 30 minutes, cells were
incubated with TNFa or LPS in the indicated conditions.
As described in 4.1.4. in chapter 4, gliotoxin is an epipolythiodioxoperazine
produced by the fungus Aspegillus fumigatus, which exhibits immune suppressive
activity both in vitro and in vivo and selectively inhibits NF-kB activation (Pahl et
al., 1996). We (Ward et al., 1999) have also shown that gliotoxin inhibits NF-kB in
neutrophils and induces apoptosis, which is enhanced by co-culture with TNFa.
Figure 3-10 demonstrates that gliotoxin prevented iKBa degradation by itself or
with TNFa or LPS stimulation. Although TNFa and LPS showed degradation of
37K and 30KDa of hcBa, gliotoxin prevents TNFa - or LPS- induced degradation.
These results indicate the inhibition of NF-kB, which was also showed previously
from our results (Ward et al., 1999).
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Similarly, the proteasome inhibitor Mgl32 inhibited the degradation of 37KDa
IkBcl However, interestingly, the 30KDa IicBa was not prevented from degradation
on co-culture with TNFa and LPS. This may indicate that 30KDa IkBoc may be
degraded by a different mechanism but not by 26S proteasome.
On the other hand, caspase-3 inhibitors did not prevent TNFa- or LPS- induced
degradation of 37K and 30KDa hcBa.
Although 37K and 30KDa of hcBa were degraded by stimulation with TNFa or
LPS, the 55KDa band of IicBa still remains unaffected.
Summary
In unstimulated resting state, three bands (55K, 37K and 30KDa) of IicBa were
recognised.
• Both 37K and 30KDa IrcBa were degraded under TNFa or LPS stimulation,
suggesting activation ofNF-kB.
Gliotoxin inhibited TNFa- or LPS- induced degradation of 37K and 30KDa of
IicBa.
• Mgl32 inhibited the degradation of 37KDa IicBa only when TNFa and LPS
were added.
. 37KDa iKBa was degraded by the 26S proteasome.
30KDa IicBa may not be degraded by the 26S proteasome.
30KDa IicBa may be degraded by some mechanism that gliotoxin can inhibit.
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Caspase-3 inhibitors did not show any influence on hcBa degradation upon
stimulation with TNFa and LPS.
3.11. Neutrophil apoptosis induced by various NF-kB inhibitors
To investigate the effect of various NF-kB inhibitors on constitutive neutrophil
apoptosis, neutrophils were exposed to Mgl32 (20pM), PDTC (300pM) and
curcumin (20pM) for up to 20 hours. All these drugs has been shown to inhibit NF-
kB, (Moynagh et ai, 1994, Singh et al., 1995, Arenzana-Seisdedos et ai, 1995)
therefore, these drugs have been tested on constitutive neutophil apoptosis. The
results are shown in figure 3-11 (see appendix for neutrophhil apoptosis induced by
gliotoxin).
The usage of other NF-kB inhibitors were essential since gliotoxin which may
influence other pathways. It is necessary to use various types of inhibitors because
some might be non-specific to the certain intracellular pathway. This is the reason
why we had developed TAT-IicBa as a specific tool to investigate NF-kB in
eosinophils (see chapter 5 for more details).
The proteasome inhibitor, Mgl32 prevents degradation of IkBoc (37KDa and
30KDa) (figure 3-10), and induce apoptosis (figure 3-11). At 20 hours Mgl32
induces to up to 100% neutrophil apoptosis whereas control condition induces about
65%. This suggests that inhibition ofNF-kB may be the one of the direct causes of
induction of apoptosis in neutrophils.
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Control MG-132 Curcumin PDTC
Figure 3-11; Effect of various NF-kB inhibitors on neutrophil
apoptosis. Purified neutrophils (5.0 x 106 cells/ ml) cultured in Iscove's DMEM
containing 10% autologous serum, were exposed to various NF-kB inhibitors,
Mgl32 (20pM), curcumin (20pM) and PDTC (300pM) for 20 hours. After
incubation, cells were harvested and assessed morphologically for apoptosis. All
values represent mean + S.E. of n=6 experiments, each perfomed in triplicate
(P<0.02). * represents significance (p<0.05) from control.
As other NF-kB inhibitors, curcumin, which is known as anti-inflammatory
reagents and suppression ofNF-kB (Jobin et al., 1999) and PDTC (Moynagh et ai,
1994) (examined only at 20 hours time point in figure 3-11) were used as to
investigate their effect on induction of neutrophil apoptosis (figure 3-11). Both
curcumin and PDTC exerted their effect to induce apoptosis, although limited
(especially curcumin at 12 hours, there is small difference but statistically
significant from the control) compared to Mgl32 or gliotoxin.
For statistical analysis please refer 2.13.
Summary
. Mgl32 itself induces neutrophil apoptosis.
Curcumin and PDTC induce neutrophil apoptosis.
3.12. The existence of NF-kB (p50 and p65) in eosinophils.
Unlike using cell lines, to study eosinophil also involves some technical difficulties,
such as purified cell numbers, proteases and the eosinophil's short life. Despite these
technical difficulties, eosinophils were studied by WB and immunofluorescence
staining in this thesis. These studies show for the first time the role and function of
NF-kB in eosinophils. In this chapter, expression of p50, p65, IicBa and hcBp in







Figure 3-12; Expression of p50 and p65 in eosinophils. Purified
eosinophils (3.0 x 106 cells/ ml) were lysed for cytoplasmic extract and examined
by WB. Anti-p50 and p65 antibodies were used to determine the expression.
To investigate whether eosinophils possess any dimers of NF-kB, cytoplasmic
lysate was examined by WB, probing with p50 and p65 antibodies. p50 and p65 are
predominantly common heterodimers of NF-kB. The results are shown in figure 3-
12. As for the first time by WB it is demonstrated that eosinophils possess both p50
and p65. In this thesis, p65 was examined as one of the dimers of NF-kB by WB
and by immunofluorescence microscopy (see chapter 4 and 5).
Summary
. Eosinophils do possess both p50 and p65.
3.13. IkBcc degradation by TNFa in eosinophils
To investigate the expression of bcBa in eosinophils, eosinophil cytoplasmic extract
was examined by WB and probed with anti-IxBa antibody. As shown in figure 3-
13, for the first time, hcBa expression was shown in the cytoplasm of eosinophils.
Unlike neutrophils, IkBcx in eosinophils is indeed expressed only as 37KDa.
IkBoc is expressed in the cytoplasm in the resting state (0 min). Upon TNFa
stimulation for various time points, iKBa is degraded. Thus, these results indicate
that NF-kB activation in eosinophils stimulated with TNFa.
Summary
• Eosinophils possess h<Ba in the cytoplasm.
. h<Ba is expressed as a 37KDa.
IxBa in eosinophils is degraded by TNFa stimulation.
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Figure 3-13; Expression and degradation of IkBgc, by TNFa
stimulation. Purified eosinophils (3.0 x 10 cells/ ml) cultured in Iscove's
DMEM containing 10% autologous serum, were treated with TNFa (lOng/ml) for
the time indicated. 'J' indicates cytoplasmic extract from Jurkat cells. Cells were
lysed for cytoplasmic extract and examined by WB. Only one band of IicBa
(37KDa) is expressed and degraded by TNFa stimulation.
3.14. IkBP in eosinophils
The common isoforms of the family of IkB in mammalian cells are IkBcc,
IkBP, and IicBe, which all contain ankyrin repeats and hold NF-kB in the
cytoplasm. IkBoc is the most abundant isoform of IkB. On the other hand, IkBP is a
relatively minor form of IkB and also believed to undergo signal-induced
phosphorylation, ubiquitination, and degradation (DiDonato et al., 1996). However,
the kinetics of IkBP degradation is significantly slower than hcBa (Thompson et al.,
1995), indicating the lower efficiency of ubiquitination and phosphorylation than
IkBa.
In figure 3-14, for the first time, IkBP (45KDa) expression in eosinophils is shown.
Since the mechanism of IkBP degradation is not known especially in eosinophils, in
this experiment a time point of 30 minutes was chosen for investigation. There was
no degradation or other specific changes observed at 30 minutes, which may not be
the most suitable time point for any changes. However, as IkBP is thought to be the
minor form of IkB further experiments were not performed.
Summary
. IkBP is expressed in eosinophil cytoplasm.
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Figure 3-14; Expression of IkBJ3. Purified eosinophils (3.0 x 106 cells/ ml)
cultured in Iscove's DMEM containing 10% autologous serum, were treated with
TNFa (lOng/ml), gliotoxin (G) (lOOng/ml) or gliotoxin and TNFa (G/T) for 30
minutes each. 'J' indicates cytoplasm extract from Jurkat cells. Cells were lysed
for cytoplasmic extract and examined by WB.
3.16. Discussion
Neutrophils and eosinophils are derived from the same myeloid precursor yet are
different in their nature and metabolism for cellular activities. In this chapter the
work presented on the neutrophil is a part of the study from our previous publication
(Ward et ai, 1999) to investigate further expression of IkBoc which is an index of
measuring NF-kB activation. On the other hand, in eosinophils, for the first time the
expression of p50, p65, IicBa and IkB(3 were shown. In the following chapters (4, 5
and 6), the role of NF-kB in eosinophil survival and apoptosis pathways were
investigated.
Neutrophil experimental conditions
Neutrophils have been known to be one of the most difficult cells for biochemical
studies due to their high content of proteases which can disturb the target protein
during its preparation. Therefore, inhibition of proteases is one of the key targets for
experimental methods. As shown, various antibodies and conditions express
different signals. Therefore, various conditions of the neutrophil culture have been
attempted to obtain consistent results. For example, for unknown reasons, when
neutrophils were cultured with medium containing serum, the signals on WB
analysis was enhanced compared to the ones without. Autologous serum contains
various substances including anti-apoptotic agents which may prevent protease
activation. This may have influenced the preparation of lysate; e.g., protease
activities may have inhibited as the result in the better signals. This reason might
also occur with when cells were incubated at 15°C for 20 hours. Both conditions
exert as anti-apoptosis, therefore, inhibition of protease activity might stabilise the
intracellular protein, resulting in better expression on WB. However, to overcome
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protease problems, as McDonald and Cassatella (1998) suggested, nitrogen
cavitation and the usage of DFP might be essential for isolation of intracellular
protein from neutrophils. However, to set up those methods in our laboratory were
concluded to be beyond practical usage and not suitable despite the fact that they
might be the best option for neutrophil experiments.
IkBcc in neutrophils
As it has been shown, expression of IkBcc in neutrophils showed three distinct
bands 55K, 37K and 30KDa, which are not seen in the other types of cells. For
example in eosinophils, only 37KDa of IkBcx is expressed. The 55KDa band was
demonstrated not to be SUMO-conjugated IicBa. In addition, the stimulation with
TNFa or LPS, 55KDa band is undegradable. If this is a real IkBcx band, some
conjugated protein may protect from TNFa- or LPS-induced degradation. In that
case it could be that 55KDa IicBa is a super suppressive form of IicBa.
Interestingly, this band (as well as 30KDa band) was never observed in the cells
cultured at 15°C for 20 hours. Therefore, it could be due to some apoptotic pathway
involved with protein conjugated with IicBa. Therefore, the 55KDa band was
denied to be a non-specific band such as IgG, which is expressed around 55K-
60KDa, because of the lack of expression in 15°C treated cells.
On the other hand, the 37KDa band of IicBa was expressed and degraded as be
expected. It was degraded by TNFa and LPS stimulation and prevented by gliotoxin
and Mgl32. The exact mechanism of inhibition of NF-kB by gliotoxin is currently
unknown (see chapter 4 discussion for the hypothesis of function of gliotoxin).
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However, it may work through disruption of the IKK complex therefore, no
phophorylation on IicBa occurs. Thus, this could be the reason for over-expression
of IkBc* in the cytoplasm.
The 30KDa band was also degraded by stimulation by TNFa and LPS. The
degradation was prevented by gliotoxin but curiously not the proteasome inhibitor
Mgl32. This might suggest that this 30KDa band is degraded by a different
mechanism distinct from the 26S proteasome.
These studies are extended from our previous studies (Ward et al., 1999) and
confirmed the inhibition of NF-kB by over-expression of hcBa in the cytoplasm by
various NF-kB inhibitors.
Eosinophils
Biochemical experiments on eosinophils may not be as technically challenging as
neutrophil works, therefore, the choice of antibodies, conditioned mediums,
protease inhibitors are wider than used for neutrophil works. However, the
difficulties of working with eosinophils are the cell number and the isolation
methods. It was not guaranteed after the isolation each time that the desired number
of the cells were harvested. In addition, the percentage of eosinophils from the
granulocyte population is dependent on the donor. To obtain consistent results, the
eosinophil works presented here in the following chapters have been taken mainly
from 'high eosinophilic' donors.
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These results show for the first time the existence of p50, p65, IkB« and IkBp in
the cytoplasm of eosinophils. Like other types of cells, eosinophils do possess NF-




The inhibition of NF-kB un-masks the ability of
TNFa to induce apoptosis in eosinophils.
4.1. Introduction
4.1.1. Eosinophil apoptosis
In inflammatory diseases such as asthma inappropriately recruited or activated
eosinophilic granulocytes may cause damage to the tissue in the respiratory tract by
release of their toxic contents (e.g., MBP, free O2 radicals, etc.,) (see introduction
1.1.1. for eosinophilic toxic granules contents). Thus, eosinophil-mediated epithelial
cell damage in the respiratory tract and surrounding tissue is likely to contribute to
the pathogenesis and propagation of asthma and other inflammatory diseases such
as allergic rhinitis.
Such inflammation may be resolved by efficient removal of activated eosinophils
from inflammatory sites. Ligation of specific cell surface receptors and the
consequent triggering of diverse signal transduction pathways control eosinophil
functional responsiveness (Stern et al, 1992) and physiological programmed cell
death or apoptosis (Stern et al, 1996). During apoptosis eosinophils undergo a series
of characteristic changes (e.g. shrinkage, chromatin condensation, expression of cell
surface phosphatidylserine) to shutdown their secretory capacity of toxic cell
contents and marks them for 'silent' removal from inflamed sites by macrophages
(Savill et al., 1989) and other cells including epithelial cells (Walsh et al., 1999).
Apoptosis is regulated by extracellular stimuli, such as TNFa, FasL, and their
receptors by activating various death pathways such as the caspase pathway (see
introduction 1.4.2. for more details). However, the pro-inflammatory cytokine
TNFa can also trigger the NF-kB pathway for transcriptional activity which is
responsible for synthesis of survival and pro-inflammatory proteins. There is a
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delicate balance between these dual pathways, pro-survival and pro-apoptotic,
generated by TNFa. Therefore, inhibition of TNFa -mediated NF-kB activation
ultimately un-masks the caspase-dependent pro-apoptotic properties of TNFa (Beg
and Baltimore, 1996, Wang et al., 1996, van Antwerp et al., 1996).
4.1.2. TNFa in granulocytes
TNFa is capable of priming neutrophils; rendering them more susceptible to
activation upon subsequent exposure to other neutrophil secretagogues (OTlaherty
and Rossi, 1993, O'Flaherty et al., 1991). Furthermore, TNFa can influence
apoptosis in many cells including granulocytes (Ward et al., 1999, Murray et al.,
1997, Temkin and Levi-Schaffer 2001); effects that may be controlled by activation
ofNF-kB (Ward et al., 1999). For example, apoptosis is promoted when neutrophils
are exposed to TNFa for short periods of culture (i.e., 2-8 hours) in a concentration-
dependent manner. When apoptosis is assessed after 20 hours of TNFa exposure
apoptosis is delayed (Murray et al., 1997).
In human eosinophils TNFa has been shown to exert an anti-apoptotic effect that
signals partly via the p38 MAP kinase pathway (Tsukahara et al., 1999) and more
recently Temkin and Levi-Schaffer (2001) showed that TNFa mediated eosinophil
survival occurs via ligation of both TNF receptor subtypes and through the
generation of the eosinophil survival factor GM-CSF; an effect that seems to
involve activation ofNF-kB.
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4.1.3. NF-kB in eosinophils
We (Ward et al., 1999) and others (Temkin and Levi-Schaffer 2001, McDonald et
al., 1997) have shown that NF-kB is present in neutrophils and in eosinophils
(Fujihara et al., 2001, Yamashita et al., 1999), however role of NF-kB in the
regulation of eosinophil derived chemokine production and apoptosis remains
poorly understood.
Inflammatory cells have the capacity to synthesise and respond to NF-kB regulated
pro-inflammatory cytokines. Eosinophils have the capacity to release inflammatory
mediators derived from lipid metabolism and are capable of synthesising pro¬
inflammatory cytokines (e.g., IL-8, TNFa, GM-CSF, IL-5, etc.,) (reviewed by
Giembycz and Lindsay, 2000) many of which are regulated totally or partially by
NF-kB.
NF-kB is held in the cytoplasm by being bound to an inhibitory protein from the
IkB family where 37KDa hcBa is the major form. Activation ofNF-kB is mediated
by signal-induced phosphorylation via the IKK complex by TNFa and degradation
of its inhibitor, hcBa in the cytoplasm. Degradation of hcBa in the cytoplasm and
translocation of NF-kB into the nucleus is induced by stimuli such as TNFa. (See
figure 1-6-1 in introduction.) In this study to elucidate the role of NF-kB in
eosinophils, the expression of iKBa in the cytoplasm and translocation of p65 was
determined with the use of the NF-kB inhibitors, gliotoxin and Mgl32.
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4.1.4. Gliotoxin and Mgl32 as NF-kB inhibitors
In this chapter, Mgl32 and gliotoxin were used for inhibition ofNF-kB.
Gliotoxin
Gliotoxin is produced by the fungi Candida albicans and Aspergillus fumigatus, and
can cause several prominent biological effects, including immunosuppression. This
fungal infections are sharply increasing and causes 40% of deaths in patients with
acute leukaemia at some hospitals (Bodey et al., 1992). Gliotoxin causes
immunosuppression by disturbing the function and apoptosis of T cells, B cells
(Mullbacher and Eichner, 1984), thymocytes and spleen cells (Sutton et al., 1994),
and macrophages (Waring et al., 1988).
Gliotoxin belongs to the epipolythiodioxopiperazine class of secondary metabolites.
In vitro, it has been shown that at relatively low concentrations, it exerts its effect as
a specific NF-kB inhibitor (Pahl et al., 1996) but at higher concentration, it disturbs
the covalent interaction of disulphide formation in polypepties (reviewed byWaring
and Beaver, 1996). Moreover, gliotoxin raises cyclic AMP and PKA activation and
phosphorylation of histone H3 to induce apoptosis in thymocytes and certain cell
lines (Waring et al., 1997). The mechanism and function of gliotoxin to cause
immunosuppression is not fully understood. However, the suppression of NF-kB
activation resulting in inhibition of pro-inflammatory mediator formation is a likely
explanation. Furthermore, inhibitor of NF-kB may be the mechanism for the
apoptosis seen in some cells following gliotoxin treatment.
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Mgl32
On the other hand, upon phosphorylation of IkBcc, 26S proteasome degrades hcBa
for releasing of NF-kB into nucleus for the trascriptional activation. Proteasome
inhibitors are broadly used for the study ofNF-kB (Traenchkner et al., 1994). When
proteasome inhibitors are applied to cells, no degradation of hcBa occurs and
results in the accumulation of IkBcx in the cytoplasm thereby retaining NF-kB in the
cytoplasm. In this thesis, specific proteasome inhibitor Mgl32 (z-Leu-Leu-Leu-
CHO) (Bush et al, 1997) was used.
+ 1 I I I II++1I I I I I++++
In this chapter, the role of NF-kB in eosinophils was investigated using gliotoxin
and Mgl32 as inhibitors ofpathway.
The aim of this chapter
. To investigate the role ofNF-kB in eosinophil apoptosis.
. To investigate if inhibition ofNF-kB induces eosinophil apoptosis.
To investigate the expression of hcBa in the cytoplasm in eosinophils.
To investigate the translocation pattern of p65 in eosinophils.
To investigate NF-KB-dependent IL-8 synthesis.
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4.2. - 4.5. Results
4.2. TNFa induced IicBa degradation in the cytoplasm in eosinophils
Upon appropriate cell stimulation, IicBa is rapidly phosphorylated via the IKK
complex and undergoes degradation by the 26S proteasome thereby permitting NF-
kB to translocate from the cytoplasm to the nucleus. Since phosphorylation and
subsequent degradation of IkBcc is a prerequisite for NF-kB activation, the amount
of IkBcc in cytosolic extracts of eosinophils was examined by Western blotting
(WB) analysis as an index of the NF-kB activation. NF-kB inhibitors, gliotoxin
(lOOng/ml) and Mgl32 (20pM) were incubated with eosinophils for 30 min prior to
the addition of TNFa (lOng/ml) for a further 30 min. Then cells were harvested for
the following experiments.
In quiescent un-stimulated cells, IicBa appeared as a single band of 37KDa, that
disappeared following TNFa stimulation indicating degradation of IicBa as shown
in figure 4-2-1 panel A. This TNFa-induced IicBa degradation was prevented by
gliotoxin (lane 4). Furthermore, panel B shows the expression of p65 in the
cytoplasm. The absence of p65 in the cytoplasm following TNFa stimulation (lane
2), is due to the translocation of p65 into the nucleus; an effect reversed by
gliotoxin. Figure 4-2-2 demonstrates the evidence of translocation of p65 into the
nucleus by immunofluorescent confocal microscopy analysis. Anti-p65 antibody
conjugated with FITC (green) is observed in the cytoplasm in control conditions.
Nuclei are stained with propidium iodide (red). Upon TNFa stimulation, p65 is
translocated to the nucleus resulting in the formation of a yellow colour due to











Figure 4-2-1; Western blot analysis of cytoplasmic IkBcx, and p65.
Eosinophils were stimulated with TNFa (lOng/ml), gliotoxin (lOOng/ml) for 15
min in Iscove's DMEM at 37°C and cytoplasmic extract prepared and analyzed by
western blotting with anti-IxBa antibody, and anti-p65 antibody. Panel A shows
cytoplasmic ItcBa expression. Upon TNFa stimulation the IxBa band disappears
indicative of proteosomal degradation, treatment of the cells with gliotoxin
stabilizes IicBa in the cytoplasm both in the absence and presence of TNFa. For a
positive control Jurkat cell cytoplasmic extracts were included (Lane 5). Panel B,
shows the amount cytoplasmic p65. The loss of p65 expression in the cytoplasm
with TNFa stimulation correlated with IicBa loss and suggests translocation of
p65 into nucleus, a process blocked by gliotoxin. The blots are representative of at
least 3 separate experiments.
c TNFa
Figure 4-2-2; Confocal microscope images of p65 expression in
eosinophils stimulated with TNFa with and without gliotoxin. Eosinophils
were stimulated for 45 min in Iscove's with TNFa (lOng/ml) and gliotoxin (lOOng/ml).
Anti-p65 antibody was FITC labeled (shown as green) and the nucleus was stained with
propidium iodine (shown as red). Upon TNFa stimulation p65 translocate into the nucleus,
resulting in an enhanced yellow color. Gliotoxin, with or without TNFa, dramatically
inhibits p65 nuclear translocation.
4-2-1 WB analysis, which showed IkBcx degradation and absence of p65 in the
cytoplasm. Similarly, gliotoxin reversed the effect of TNFa. As shown in figure 4-
2-2, addition of gliotoxin prevented TNFa-induced translocation of p65, which
correlates with the results of figure 4-2-1 which shows the over-expression of IkBcc
and presence of p65 in the cytoplasm.
Summary
• IkBoc is degraded upon TNFa stimulation.
Gliotoxin prevents TNFa-induced IicBa degradation.
p65 is absent under TNFa stimulation in the cytoplasm.
The absence of p65 in the cytoplasm by TNFa is prevented by gliotoxin.
. p65 translocates into nucleus following TNFa stimulation.
• Gliotoxin prevents TNFa-induced p65 translocation into nucleus.
4.3. Immunohistochemical analysis ofNF-kB translocation in eosinophils
In order to provide compelling evidence for subcellular movement of p65 in
eosinophils, quantitative immunohistochemical analysis of TNFa induced
translocation of p65 was performed. Quantification of translocation is depicted in
figure 4-3 A, B, and C where the immunofluorescent images are analyzed on a
Leica Q550IW image analyser to detect p65 amount in the cytoplasm and nucleus
and the results expressed as a ratio. In other words, area of green (anti-p65-
antibodies-FITC) in the cells was measured by the image analyser, then, the area
occupied by nuclei was detected by the presence of propidium iodide (red). The
results in the area stained with green in nuclei or cytoplasm was calculated and
shown as the ratio of p65 translocation into nucleus in figure 4-3. At least 1,000
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Figure 4-3; Quantitative analysis of p65 translocation to the
nucleus. Computer analysis of p65 expression in the nucleus was measured
as the ratio of p65-FITC nuclear fluorescence versus cytoplasmic fluorescence
in each cell. At least 300 cells were counted per condition and the data is
represented as mean ± SEM determined for each experiment independently.
Eosinophils were incubated in Iscove's DMEM with the indicated stimuli
(panels A and B) for 45 min and with TNFa for the indicated times (panel C).
A, the effect of gliotoxin (lOOng/ml) on activation by TNFa (lOng/ml). B, the
effect ofMgl32 (20pM) on p65 translocation into the nucleus. C, time-course
of the effect ofTNFa (lOng/ml). D. the effect of TNFa-induced translocation



























Figure 4-3-D; Quantitative analysis of p65 translocation to the nucleus
cells were assessed per condition. The standard error bar represents the error of the
p65 translocation in each view which are typically 200 cells per view.
Figure 4-3 A and B clearly demonstrate the induction of translocation of p65 into
the nucleus by TNFa. On the other hand, gliotoxin and Mgl32 reverse TNFa-
induced p65 translocation. Panel C demonstrates the time-course of translocation of
p65 stimulated with TNFa. Maximum induction of TNFa stimulated p65
translocation in eosinophils isolated from this particular donor occurred at after 60
min exposure to TNFa. Following this time point, NF-kB levels in the nucleus
gradually decrease, perhaps reflecting rapid re-synthesis of IicBa and consequent
removal of NF-kB from the nucleus (Arenzana-Seisdedos et al., 1995). Although
different levels of basal and stimulated p65 distribution were observed between
individual donors, substantial p65 translocation by TNFa stimulation was observed
(figure 4-3-D). The response of the rate of p65 translocation stimulated by TNFa
was donor dependent. However, the majority of donors had p65 translocation
stimulated by TNFa except one donor (donor 4). Donor 4 recorded symptom scores
as 'severe allergic rhinitis' on that day when the blood was taken. This could
explain why basal activation of p65 was so high to compare with others but the
stimulation with TNFa did not have any further activation ofNF-kB.
Summary
p65 translocation into nucleus occurs upon TNFa stimulation.
TNFa-induced translocation of p65 is prevented by gliotoxin and Mgl32.
Maximum induction of TNFa-induced translocation of p65 occurred in this
particular donor at 60 min.
Different donors showed different rates of p65 translocation into nucleus
stimulated by TNFa.
4.4. NF-kB activation mediates IL-8 production by human eosinophils.
It is established in many cell types (McKay and Cidlowski, 1999, Roebuck 1999)
that IL-8 production is tightly controlled by NF-kB and eosinophils have the
capacity to synthesise (Yamashita et al., 1999). In other words, measuring IL-8 is
indirect way to determine NF-kB activation. Because IL-8 is the important pro¬
inflammatory cytokine of the family of CXC chemokines, that strongly attracts and
activates neutrophils, T lymphocytes. But the effect of IL-8 on eosinophils
themselves may be still controversial (Petering et al., 1999) although eosinophils
express CXCR1 and CXCR2 (reviewed by Nagase et al., 2001). However, IL-8 is a
strong pro-inflammatory cytokines, and upregulated by NF-kB, the determination of
IL-8 was thought to be appropriate for this project. The production of IL-8, which is
another indicator ofNF-kB activation, was measured by ELISA.
Figure 4-4 demonstrates that TNFa is a powerful stimulator of IL-8 production in
eosinophils even at the early time point of 90 min, a time point chosen since there is
no gliotoxin-induced apoptosis that could influence IL-8 production (data not
shown). The production of IL-8 was dramatically suppressed by gliotoxin at a
concentration that effectively inhibits NF-kB activation at this time point. This data
correlates with figure 4-2-1 and 4-2-2 which demonstrate overexpression of hcBa in
the cytoplasm and p65 translocation into the nucleus. Although in figure 4-2-1 the
overexpression of IicBa in the cytoplasm is seen, it is likely that basal level ofNF-
*
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Figure 4-4; Effect of gliotoxin on TNFa induced IL-8 release from
eosinophils. Eosinophils were stimulated with TNFa (10 ng/ml) for 90 min in
the absence and presence of gliotoxin (lOOng/ml) and the IL-8 concentrations in
the cell supernatants determined by specific ELISA. The data are expressed as
the mean ± SEM of 4 separate experiments using eosinophils isolated from
different donors. Significant difference (p<0.05) from the control is indicated by
kB activation occurs during the resting state. This is why although un-stimulated
control condition produce some of IL-8. On the other hand, stimulation with
gliotoxin may suppress the basal level of NF-kB activation. Therefore, the more
suppression of IL-8 production by gliotoxin is shown. There is no significant
apoptosis at this time point.
Summary
• TNFa induces IL-8 production.
TNFa-induced IL-8 production is prevented by gliotoxin.
Gliotoxin may suppress the basal level ofNF-kB activation.
4.5. NF-kB regulates eosinophil apoptosis
It has been shown that the TNFa-induced activation of NF-kB is inhibited by
gliotoxin and Mgl32. To investigate ifNF-kB inhibition could induce apoptosis and
un-mask the pro-apoptotic ability of TNFa the following experiments were
performed. Figure 4-5-A demonstrates the effect of gliotoxin and Mgl32 on
TNFa-induced apoptosis. TNFa alone and gliotoxin alone cultured with
eosinophils for 4 hours caused little morphological apoptosis, however when
eosinophils were cultured in the presence of TNFa plus gliotoxin there was a
dramatic induction of characteristic pyknotic nuclei typical of eosinophil apoptosis.
Our preliminary data indicated that it requires a significant amount of time (> 3










Figure 4-5-A; The effect of gliotoxin and TNFa on eosinophil
apoptosis. Cytocentrifuge preparations were made of eosinophils incubated for 4
hours at 37°C in medium alone (control), TNFa (lOng/ml), gliotoxin (lOOng/ml),
and combination of these reagents. The rates of apoptosis in this experiment are
control 5%, TNFa, gliotoxin 26.5% and gliotoxin/TNFa 47.5%.
Figure 4-5-B; The effect of Mgl32 and TNFa on eosinophil
apoptosis. Cytocentrifuge preparations of eosinophils incubated for
30hours at 37°C in medium alone (control), TNFa (lOng/ml), Mgl32
(20p.M), and combination of these reagents. The rates of apoptosis in this











Figure 4-5-C; The effect of giiotoxin and TNFa on eosinophil apoptosis.
Eosinophils were incubated for 4 hours at 37°C in medium alone (control), TNFa
(lOng/ml), gliotoxin (lOOng/ml), and a combination of these reagents and incubated
with FITC- labelled recombinant human annexin V to determine the phosphatitylserine
expression on the cell surface. Flow cytometric traces from a typical experiment are
depicted with the percentage of cells in the annexin-V high population being 7.0% in
control, 9.8% in TNFa, 28.5% in gliotoxin and 50.8% in TNFa plus gliotoxin treated
samples.
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Figure 4-6; Effects of the caspase inhibitor, zVAD-fmk, and the
protein synthesis inhibitor, cycloheximide, on eosinophil
apoptosis induced by gliotoxin, TNFa or on a combination of
these agents. Eosinophils were treated with the indicated reagents for 4
hours at 37°C before cytocentrifuge preparations were made and apoptosis
assessed morphologically. Concentrations are as follows; TNFa (lOng/ml),
gliotoxin (glio) (lOOng/ml), zVAD-fmk (100pM), and cycloheximide (CHX)
(5pM). The data are expressed as the mean ± SEM of 4 separate experiments
using eosinophils isolated from different donors. *Represents significance
differences (p<0.05) from control and # represents significance difference
from Glio/TNFa and t represents significance difference form CHX/TNFa.
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Figure 4-6-B; Effects of the caspase inhibitor, zVAD-
fmkapoptosis induced by Mgl32, TNFa or on a combination of
these agents. Eosinophils were treated with the indicated reagents for 48
hours at 37°C before cytocentrifuge preparations were made and apoptosis
assessed morphologically. Concentrations are as follows; TNFa (lOng/ml),
Mgl32 (lOOng/ml), zVAD-fmk (lOOpM). The data are expressed as the mean
± SEM of 2 separate experiments using eosinophils isolated from different
donors. *Represents significance differences (p<0.05) from control and #
represents significance difference from Mgl32/TNFa.
observe the synergistic effects of TNFa and gliotoxin. (Less than 4 hours, apoptosis
rate is not significant.)
Similarly, panel B shows the effect of Mgl32 on eosinophil apoptosis assessed
morphologically. To observe the effect of Mgl32 to induce TNFa-mediated
eosinophil apoptosis, a time point of 30 hours was chosen. However, as it is shown
in figure 4-5-B, apoptosis was significantly induced with co-culture ofMgl32 and
TNFa.
As an additional independent assessment of eosinophil apoptosis we performed
experiments where surface changes associated with the apoptotic program were also
assessed. For this we measured FITC labeled annexin V binding in the presence of
Ca2+ to phosphatidylserine molecules exposed on the outer membrane of apoptotic
cells where the annexin V 'low peak' represents non-apoptotic cells and the annexin
V 'high peak' represents apoptotic cells. In agreement with morphological
assessment of apoptosis, figure 4-5-C shows that although control and TNFa treated
eosinophils at 4 hours exhibit low rates of apoptosis, the small increase in annexin V
positive cells observed with gliotoxin alone is again dramatically augmented when
the cells are cultured in the presence of both reagents together.
Furthermore, the marked synergism that was displayed by gliotoxin and TNFa is
mediated by triggering of the caspase pathway since the broad-spectrum caspase
inhibitor, zVAD-fmk (100 pM) completely blocked the pro-apoptotic effects
induced by the combination of TNFa plus gliotoxin (figure 4-6). When eosinophils
were co-cultured with the protein synthesis inhibitor cycloheximide (5pM), at a
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concentration and time point that had almost no direct effect on eosinophil
apoptosis, a similar un-masking of the pro-apoptotic effect of TNFa was observed.
The pro-apoptotic effects of Mgl32 per se and the enhanced apoptosis observed
with a combination ofMgl32 and TNFa was also suppressed by zVAD-ffnk (figure
4-6-B).
We did not determine the possibility of other pathway such as PKC or cAMP, which
may influence apoptosis pathway.
79
4.6. Discussion
In eosinophils, Western blot analysis and immunofluorescence data demonstrate
that p65 translocates from the cytoplasm to the nucleus in response to TNFa. This
action was prevented by gliotoxin and Mgl32. Therefore, combining gliotoxin or
Mgl32 with TNFa enhances pro-apoptotic property of TNFa. Such conditions
result in dramatic synergistic induction of apoptosis.
NF-kB binds to DNA regulatory sites on the upstream promotor sequences of target
genes that control the rate of gene transcription for many pro-inflammatory
mediators, some of which can influence granulocyte function and apoptosis (e.g.,
TNFa and IL-8). Eosinophils exposed to TNFa (figure 4-2-4) and LPS (Takanashi
et al., 1994) are capable of releasing EL-8. IL-8 itself can cause recruitment of
inflammatory cells into sites of inflammation and can also prime and/or activate
granulocytes (Baggiolini et al., 1992, Harada et al., 1994). Thus activation of the
NF-kB pathway can augment the inflammatory response by generating further pro¬
inflammatory mediators. In our studies, synthesis of IL-8 is inhibited by gliotoxin
even at a time point (90 min) where there is no significant induction of apoptosis,
consistent with the observation that GM-CSF and TNFa activate NF-kB to induce
IL-8 production in human eosinophils (Yamashita et al., 1999).
The mechanism of inhibition ofNF-kB by gliotoxin is unknown. Although we have
shown previously that gliotoxin, but not its structurally similar analog,
methylthiogliotoxin, can directly induce neutrophil apoptosis and enhance apoptosis
in the presence of TNFa (Ward et al., 1999) by selectively inhibiting NF-kB
activation, the underlying mechanisms were not identified.
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However, as it has been shown in figure 3-10 (chapter 3) in neutrophils, gliotoxin
prevented TNFa- or LPS-induced IicBa degradation. The treatment with gliotoxin
does not change the formation of IicBa, such as phosphorylation or ubiquitination.
Gliotoxin may interrupt the phosphorylation pathway of IicBa, IKK complexes.
IKKs are known to dimerised by disulfide bonds in helix-loop-helix (HLH) motifs
(Mercurio et ai, 1997). Mutation in HLH motifs of IKK1 and IKK2 result in loss of
kinase activity (Zandi et al., 1998). Gliotoxin is known to disrupt the interaction of
disulfide bonds (Waring and Beaver, 1996). Therefore, gliotoxin might disrupt the
disulfide composition of IKKs resulting in no phosphorylation on IkBcx (This idea
was kindly provided by Dr James Matthews, University of Wales). This might
explain the gliotoxin induced inhbition ofNF-kB in various cell types and cause the
gliotoxin mediated immunosuppression and apoptosis in inflammatory cells. This
interesting possibility was not investigated further.
Interestingly, Mgl32, like gliotoxin, can also induce eosinophil apoptosis directly
and also renders eosinophils responsive to the pro-apoptotic effects of TNFa. It is
noteworthy that Mgl32 required a longer incubation period in comparison to
gliotoxin to unmask TNFa induced apoptosis. The precise reason for this is
unknown but may reflect a difference in the mechanism of action or in the rates of
cellular incorporation between the two inhibitors ofNF-kB activation.
TNFa triggers a number of signalling pathways following ligation of TNFa
receptors. We have previously shown that neutrophils undergo an early induction of
apoptosis (2-8 h) and a later (>18 h) inhibition of apoptosis when cultured in vitro in
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the presence of TNFa (Murray et al., 1997). The pro-apoptotic effect of TNFa is
thought to be mediated by ligation of the TNFR1 containing a death domain that
interacts with the TNFa-receptor-associated death domain protein (TRADD)
allowing recruitment of Fas-associated death domain (FADD) leading to activation
of the caspase enzyme pathway. This highly regulated sequence of events enables
apoptosis to be triggered. TNF receptor 2, often in co-operation with TNFR1, results
in the activation of many kinases including the p38-Jun N-terminal kinase (JNK)
pathway and IKK (Rath and Aggarwal, 1999). It remains possible that blockade of
NF-kB will prevent the synthesis of NF-kB regulated survival cytokines such as
GM-CSF, IL-5 and IL-3. Indeed, it has recently been published that TNFa via
ligation of both TNFR1 and TNFR2 subtypes mediated eosinophil survival (as
assessed by Trypan blue exclusion) and that this occurred through regulation of
GM-CSF but not IL-3 and IL-5 production (Temkin and Levi-Schaffer, 2001).
Furthermore, it was shown that GM-CSF is indeed synthesized when eosinophils
are challenged with TNFa and that TNFa enhanced eosinophil survival is
significantly inhibited by the proteasome inhibitor Mgl32 (Temkin and Levi-
Schaffer, 2001). It also remains likely that eosinophils like other cells can generate
protein(s) that directly influence the apoptotic program. However, the precise
identity of the potential survival protein(s) is unknown, however several likely
candidate proteins have been implicated including members of the oncogene Bcl2
family such as Al (Chuan et al., 1998, Hamasaki et al., 1998) and Mcl-1 (Moulding
et al., 1998) and others such as c-Myc (Evan et al., 1992), A20 (Sarma et al., 1995),
cIAP (Chu et al., 1997, Wang et al., 1998), XIAP, c-IAPl, c-IAP-2 (Stehlik et al.,
1998, Deveraux et al., 1997, Deveraux et al., 1998), and IEX-lL(Wu et al., 1998).
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Although it is abundantly clear that NF-kB activation can play an important role in
regulating the production of cytokines and adhesion molecules that are vital for
orchestrating the inflammatory response there is relatively little direct in vivo
evidence indicating that this transcription factor can influence eosinophilic
inflammation. Compelling evidence that NF-kB plays an essential role in the
induction of eosinophilia in allergic airway inflammation, was obtained using mice
deficient in p50, when compared with wild type mice (Yang et al., 1998). In
addition to being incapable of mounting eosinophilic airway inflammation, p50 -/-
mice had a dramatically reduced capacity for the production NF-kB regulated
inflammatory mediators such as the T helper 2 cytokine IL-5 and the chemokines
eotaxin and MIP-1.
In summary, these data strongly suggest an important role of NF-kB in controlling
eosinophils responsiveness and apoptosis.
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Chapter 5
Use of TAT-IkBcx for the inhibition ofNF-kB in
HeLa, A549 cells and eosinophils, and its effect on
eosinophil apoptosis
5.1. Introduction
5.1.1. TAT protein and its domains for transduction
The HIV-1-trans-activator gene product, TAT, has been shown to be critical for
transduction of virus into cells and could transfect the viral HIV-LTR (Long
Terminal Repeat) promotor to cause virus replication. This 86 amino acid protein
has been studied by several groups for transduction ability into the both the
cytoplasm and nucleus. In 1988, for the first time, Green et al. (1988) and Frankel et
al. (1988), independently showed that TAT (amino acid 37-72), could transduce
into the cells. After their discoveries other groups have demonstrated that various
different parts of TAT have ability to transduce (see table 5-1-1), for example, TAT
amino acid (a.a.) 38-58 (Mann et al., 1991), a.a. 1-72, 37-72 (Farwell et al., 1994),
a.a. 37-47 (Vives et al., 1997) and a.a.47-57 (Nagahara et al., 1998). Furthermore,
Dowdy and co-workers (Nagahara et al., 1998) have demonstrated that the arginine
rich motif (ARM), which corresponds to amino acids 47-57, has the most efficient
transduction ability. ARM contains nucleus localisation signals (NLS) and RNA
binding domains to allow virus to manipulate transcriptional activities when the rest
of the virus is presented (Friedler et al., 2000). Thus, ARM is the most important
part for HIV-1 for virus internalisation and to promote transcription activity for
virus replication.
Distinct from TAT, a similar transduction ability has been demonstrated by the
protein transduction domain (PDT) by VP22 from herpes simplex virus (Elliott and
O'Hare 1997), and the Drosophila Antennapedia homeotic protein (Joliot et al.,
1991), which also possesses a similar high arginine and lysine content. Both
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Figure 5-1-1; Summary of reported transduction domains in 86 a.a.
HIV-1 TAT. Various groups have demonstrated efficient transduction domains in
TAT. Arginine rich motif (ARM) has been identified as the most effective transduction
domain in TAT.
5.1.3.).
5.1.2. TAT as a molecular tool
Farwell et al., (1994) first demonstrated that TAT transduced not only HIV-1 virus
but also some other proteins linked with TAT through the cell membrane. P-
galactosidase linked with TAT (a.a. 1-72, 37-72) could be successfully transduced
into various tissues and organs in mice. Nagahara and Dowdy (Nagahara et al.,
1998) developed an 11 amino acid ARM TAT (GYGRKKRRQRRRG) as a 'tool' to
transduce proteins such as antibodies and enzymes, nucleic acids and beads into
cells in a receptor and transporter independent manner. Furthermore, Dowdy and
co-workers (1998, 1999, 2000a, 2000b) demonstrated that proteins linked to TAT
such as TAT-p27 (Nagahara et al., 1998), TAT-caspase3 (Vocero-Akbani et al.,
1999), TAT-GTPase (Vocerc-Akbani et al., 2000), TAT-P-galactosidase (Schwarze
et al., 2000), resulted in 100% efficiency transduction in 30 minutes into many cells
(e.g., lymphocytes, diploid human fibroblasts, keratinocytes, bone marrow stem
cells, osteoclasts, fibrosarcoma cells, osteosarcoma, glioma, hepatocellular
carcinoma, renal carcinoma, NIH 3T3). Similarly other groups have been
demonstrated TAT transduction into various cell types using different proteins
linked with TAT (for a summary see table 5-1-2). Farwell et al. (1994) and Pooga et
al. (1998) have shown that almost any type of tissue can be transfected by TAT,
including the blood-brain barrier. In granulocytes, Hall et al. (2000) and Alblas et
al., (2001) and Bruyninckx et al., (2001) have demonstrated that TAT fusion protein
is successfully transduced into eosinophils and neutrophils which are generally
extremely difficult to molecularly manipulate. For example, the efficiency of
transduction of TAT-H-Ras-FITC in eosinophils was almost 100% in 30 minutes
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Brachmann (pc) TAT-GFP Drosophilci eyes
Fawell (1994) TAT-P-gal
Limited but significant capacity to tissues in
mouse
Table 5-1-2; Summary of reported examples of TAT linked with
various proteins, which transduced into different cell types.
pc;personal communications to Schwarze and Dowdy (2000).
(Hall et al., 2000). This remarkable result should lead to further usage of the TAT
system to transduce protein into eosinophils in order to investigate specific
intracellular proteins and signalling pathways (see 5.1.4. for the usage of TAT in
eosinophils).
In summary the advantages of the usage of the TAT-transduction technique are
given as follows;
Direct transduction of peptide, protein, nucleic acid and small objects (e.g.
beads) into cells
Most cells can be transduced (specific receptor and transporter independent
mechanism)
Rapid transduction (TAT internalisation sometimes starts from 5 minutes.)
100% efficient (different from virus transfection)
Specific and direct approach to manipulate cell signalling pathways (different
from using pharmacological agents which might influence other pathways).
Thus, TAT fusion proteins can provide an huge potential in molecular and cellular
biology research, especially for cells which do not accept virus transfection
methods.
5.1.3. The mechanisms involved in TAT transduction
The precise mechanism of translocation of TAT peptide through the membrane is
not currently known. However, various groups have suggested possible
mechanisms, for example; a) an energy endocytosis pathway, b) via low density
lipoprotein receptor-related protein (LRP) and c) via a cell surface heparan sulfate
(HS).
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a) The energy endocytosis pathway; Recently Eguchi et al., (2001) have reported
that conserved domains of TAT is used by X phage for its transduction into cells via
caveolae on the cell surface. Caveolae are small flask-shaped invaginations of the
plasma membrane, rich in cholesterol and glycosphingolipids, which forms coated
buds for transportation. However, Suzuki et a/.,(2002) showed that Nystain, a
caveolae formation inhibitor did not suppress TAT (48-60), Rev (34-50;
TRQARRNRRRRWRERQRGC) and arginine rich peptides (Arg8) (RRRRRRRR-
GC) intake into cells. Also, other endocytosis inhibitors and metabolic inhibitors did
not show any suppression of TAT and other arginine rich peptide intake. Thus,
energy endocytosis may be involved but not crucial for TAT transduction system.
b) The low density lipoprotein receptor-related protein (LRP); Liu et al,, (2000)
have demonstrated that TAT segments (32-48), (48-57) are transduced into neurons
through lipoprotein receptor-related protein (LRP). However, LRP expression varies
in different cell types and organs and so it does not explain why TAT peptide
transduction is able to occur in almost all cell types as described previously
(Nagahara et al., 1998). However, Suzuki et al. (2002) claimed that intemalisation
of TAT domain (48-60), Rev (34-50) and arginine rich peptides (Arg8) were not
affected by disturbance of LRP. Thus, LRP may not play a major role in the
transduction of TAT peptide or arginine rich peptide.
c) Cell surface heparan sulfate (HS); heparan sulfate (HS) is strongly negatively
charged and expressed ubiquitously on the surface of animal cells. Negatively
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charged HS may cause electrostatic interaction with positively charged arginine rich
peptide ARM in TAT. So ARM may act as 'cargo' to flick over whatever the
proteins or objects are linked to TAT into the cells. Suzuki et al., (2002) has shown
that anti-HS antibody or blocking the function of sulfated polysaccharides
significantly inhibited internalisation of TAT (48-60), Rev (34-50) and arginine rich
peptides (Arg8). Thus, this strongly suggests that sulphated polysaccharides of HS
is a favourable explanation for TAT internalisation.
Although, as it has been reported by Suzuki et al, (2002) that the slight differences
in experimental methodologies (e.g. full length of TAT or TAT peptides) may give
contradictory explanations or that more than one mechanism is involved in TAT
internalisaion.
5.1.4. The possibility of TAT trasduction system in eosinophils
For the introduction of specific cellular proteins into cells, manipulation by viral
transfection and microinjection have been demonstrated to be useful techniques in
various cell types, often in stable cell lines. However, eosinophils are particularly
difficult cells in which to perform such experiments due to lack of virus receptors or
specific transporters and because of their life span. Thus, much eosinophil study is
dependent upon the usage of pharmacological reagents which may be limited by
their specificity. Therefore, we decided to explore the usage of TAT to introduce
cellular proteins into eosinophils for the first time as a direct approach to manipulate
intracellular signalling pathways.
During this project, Hall et al. (2001) have demonstrated transduction of TAT-p27
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into eosinophils. They showed that within 30 minutes, FITC-TAT-RAS and FITC-
TAT-GFP were transduced into 95% of the eosinophils. This remarkable result
shows that even eosinophils are capable of using this TAT transduction system, and
opens the opportunity for a direct approach to understand the mechanisms and
functions of specific cellular proteins in eosinophils.
5.1.5. TAT-IicBa
Various groups have reported that TAT can be linked with various proteins
including IkBol Abu-Amer et al., (2001) have used TAT-hcBa (mutated at tyrosine
42) to study the function of tyrosine cascades in osteoclastogenesis. In these
experiments bone marrow cells are also difficult to transfect, but were successfully
transduced by TAT-IicBa and the resulted in the arrest of osteoclastogenesis.
Recently, Kabouridis et al., (2002) have also demonstrated inhibition of IL-1- and
TNFa-induced-NF-icB by TAT-IkBo.32,36 in HeLa and Jurkat cells. These reports
suggest the possibility of the usage of TAT-IicBa as a tool to manipulate the NF-kB
signalling pathway in cell lines and bone marrow cells.
Once cells receive an extracellular stimuli, such as TNFa, IL-1, LPS, through the
IKK complex, ItcBa is phosphorylated on serines 32 and 36 in its N-terminus and is
ubiquitinated. This form of IkBo, is then recognised and degraded by the 26S
proteasome. When NF-kB is freed upon IkBcx degradation, NF-kB translocates into
the nucleus for the induction of transcription and protein synthesis. Prevention of
IkBcx degradation results in the inhibition of NF-kB. Therefore, mutation of the
phosphorylation sites at Ser 32 and Ser 36 prevents IkBo. degradation and over-
expression of IkBcx in cytoplasm results in prevention NF-kB translocation into the
nucleus. Mutation of these phorphylation sites has been a most favoured approach
for inhibition ofNF-kB by viral transfection or by microinjection methods.
When TAT-IkBoc is transduced into cells through the cell membrane, it should over-
express IkBoc and prevention of NF-kB into the nucleus for transcriptional
activities. This method may overcome some disadvantages of using
pharmacological reagents and viral transfection. Here, TAT-IkBoc both wild type
(WT), mutation of Ser 32 and Ser 36 (TAT-IkBcc32, 36) and GST-TAT as a control,
were generated to investigate NF-kB inhibition in four different types of cells,
namely HeLa, A549, Jurkat cell lines and eosinophils.
In our previous study (see chapter 4 and Fujihara et al., 2002) inhibition ofNF-kB
in eosinophils was demonstrated to be the one of the key elements regulating
apoptosis upon TNFa stimulation. Inhibition of NF-kB was dependent on
pharmacological reagents, such as Mgl32 or gliotoxin. Here, using the TAT system,
the mechanism of NF-kB pathway to induce apoptosis in eosinophils is further
investigated.
The aims of this chapter are;
. To introduce methodology of cloning of TAT-IkBcx.
To investigate the effect of TAT-bcBa in HeLa cells, A549 cell lines and
eosinophils.
. To investigate the effect of TAT-IkBoc on eosinophil apoptosis.
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5.2. - 5.5. Results
5.2. Cloning and purification methods for TAT-IkBoc
5.2.1. Cloning map
As shown in figure 5-2-1, GST-TAT-IkBcc gene was cloned for TAT-IkBcx wild
type (WT), TAT-IkBoc mutated at S32,36, and recombinant wild type of IkBcc
(rlicBa) and GST-TAT. (See Methods and Materials in chapter 2 for more detailed
methods.) GST-TAT, which had been obtained from the same plasmid has been
used in the following experiments as a control protein for TAT-IkBcc.
5.2.2. DNA Sequence
After the insertion of the TAT and IicBa gene into pGEX2T and transformed into
E.Coli DH5a cells, some colonies were selected for DNA sequencing, PCR (data
not shown) and mini protein purification (see figure 5-2-3) to determine the gene
which contains the TAT-IkBoc. Typical results of a successful DNA sequence of
GST-TAT-IkBoc gene is shown in figure 5-2-2. TAT sequence
(a.a.GYGRKKRRQRRRG) is highlighted in bold letters. Combining all the results
of DNA sequencing, PCR and mini protein purification, a successful gene (colony)
was chosen for protein purification as described in the method section.
Fieure 5-2-2; DNA sequence for TAT, reading bottom strand.










Figure 5-2-1;A. Plasmid map of pGEX-2T inserting TAT and IkBgc gene.
IkBo. and TAT were inserted into pGEX-2T at the GST site. B. DNA or protein for
protein purification; For protein purification, thrombin was used to cut offGST parts
and eluted through a column (see methods section, in chapter 2).
5.2.3. Protein purification
After protein purification (as described in the method section), the protein from the
peak fraction was run on a 10% acrylamide gel for determination of TAT-IkBcx by
molecular weight, compared to recombinant IicBa (37KDa). TAT-hcBa is 11 amino
acids heavier than recombinant hcBa, thus this difference is shown as a shifted band
on the gel compared with recombinant IkBcx. In figure 5-2-3 lane 1; recombinant
IkBoc, lane 2; TAT-IicBa are shown. 11 amino acids clearly show the band shifted
in lane 2 compared with lane 1 with recombinant IkBoc.
5.2.4. Mass Spectrometry
The purified TAT-hcBa protein in the peak fraction was also checked by mass
spectrometry using slow crystrallisation (Botting, 2000) by Dr Botting, University
of St Andrews, as shown in figure 5-2-4. In the figure 5-2-3 on the protein gel TAT-
IkBoc was shown to be the shifted band and was analysed by mass spectrometry as a
molecular weight of 37579Da, whereas recombinant IicBa is 35471 Da
5.3. Inhibition of NF-kB by TAT-IicBa (WT and 32,36) in HeLa cells
5.3.1. Controls; recombinant IkBoc and GST-TAT in HeLa cells
As described previously (Arenzana-Seisdedos et al., 1997) a cloned HeLa cell line
(57A), containing luciferase gene linked with NF-kB binding sites was used to
determine NF-kB activation. Briefly, these cells were transfected with luciferase





Figure 5-2-3; TAT-lKBa and recombinant IicBa
(rlKBa ). TAT-IkBcc and r iKBa were run on a 10%
polyacrylamide gel. TAT-IkBcx is shown to be heavier than
37KDa recombinant IkBcc (rlKBa ).
BSA
Figure 5-2-4; Analysis of TAT-IkBcc by mass spectrometry.
The molecular mass of TAT-IkBcx was measured by mass spectrometry
by slow crystallisation and calibrated with BSA by Dr Botting (University
of St Andrews).
correlated with the amount of luciferase synthesised. GST-TAT and recombinant
IkBcc were both made using the same methods as TAT-IkBoc and were used as
control proteins to determine NF-kB activation with or without TNFa. GST-TAT
(30pg/ml) and recombinant IkBoc (rlKBa) (30pg/ml) were pre-incubated with cells
for 30 minutes at 37°C before TNFa (5ng/ml) was added. After 6 hours of
incubation, cells were harvested for luciferase measurement (see chapter 2 for
further details in methods).
Figure 5-3-1-A shows the effect of luciferase activation in HeLa cells when
recombinant IicBa (rlKBa) is incubated with or without TNFa. There was no
significant effect on rlKBa both with or without TNFa compared to control
conditions without rIicBa. Recombinant IicBa did not induce any activation nor
inhibition on its own and did not inhibit TNFa -induced NF-kB activation.
GST-TAT was used as another control protein for TAT-IicBa. Figure 5-3-1-B
shows the effect of GST-TAT. There was slight activation (14-fold) observed when
GST-TAT was used. Similarly, stimulated with TNFa, GST-TAT induced
luciferase activation (164-fold). This effect was greater than TNFa on its own (137-
fold).
Summary
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Figure 5-3-1; Recombinant IicBa and GST-TAT do not inhibit
TNFa-induced NF-kB activation in HeLa cells. HeLa cells
containing NF-KB-dependent the luciferase reporter gene was incubated with
recombinant IkBoc (rlxBa ) (30pg/ml) (A) or GST-TAT (30pg/ml) (B) for 30
minutes at 37°C and treated with TNFa (5ng/ml). All the conditions were
incubated for a further 6 hours for luciferase expression. 'C' indicates the
control condition, which had no treatment. The activation of luciferease were
measured and was compared with untreated condition 'C' and expressed as fold
(Y-axis). A. recombinant IxBa does not induce NF-kB activation nor inhibit
TNFa-induced activation. B. GST-TAT itself induces NF-kB activation slightly
and further induction is seen when TNFa is added. This is a representative
result of triplicate experiments performed on at least two separate occasions.
GST-TAT does slightly increase luciferase activity in HeLa cells whether alone
or in the presence of TNTa.
5.3.2. TAT-lKBa (WT and 32,36) in HeLa cells
Purified TAT-hcBa32,36, and TAT-IicBaWT (wild type), were assessed for their
effects on NF-kB activation in HeLa cells. TAT-IicBa32,36 has serines 32 and 36
on N-terminus mutated with alanine, resulting in the prevention of phosphorylation
of IkBoc and over-expression of h<Ba in the cytoplasm. TAT-IkBo.32,36 and TAT-
IkBocWT were incubated with cells for 30 minutes at 37°C before adding TNFa.
Then the cells were measured for luciferase activity.
Figure 5-3-2-A demonstrates that TAT-IkBo.32,36 significantly inhibits TNFa-
induced NF-kB activation. TAT-IkBcx32,36 on its own from 0.03 pg/ml to 100
pg/ml, did not significantly affect luciferase activity compared with untreated
control cells (indicated as 'C'). In this experiment TNFa on its own induced
transcriptional activity and was about 81-fold compared with control (C). However,
this TNFa-induced-NF-icB-activation was inhibited by incubation with TAT-
IicBa32,36. There was a dose-dependent inhibition of TNFa-induced NF-kB
activation. For example, luciferase activity was about 5 fold at 100p.g/ml TAT-
lKBa32,36 with TNFa. This is about 93% inhibition compared with TNFa only
(81-fold). Similarly, 91% inhibition of TNFa-induced transcription was observed at
30pg/ml TAT-h<Ba32,36. Even at 0.03pg/ml TAT-hcBa32,36 reduced TNFa-
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Dose response of TAT-IkBcx32,36 (p g/ml)
Figure 5-3-2-A; TAT-lKBa 32,36 inhibits TNFa-induced NF-kB
activation in HeLa cells. HeLa cells containing NF-KB-dependent
luciferase reporter gene was incubated with TAT-IkBcc 32,36 for 30 minutes at
37°C and further treated with TNFa and then all the conditions were incubated
for 6 hours for luciferase expression. The activation of luciferease was measured
and was compared with untreated condition and expressed as fold (Y-axis).
Lane 1 from the left. TAT-IicBa 32,36 itself does not influence luciferase
activity, compared to no treated condition in lane 1 from the left. When TNFa is
added, TNFa-induced NF-kB activation was suppressed by TAT-IxBa 32,36 in
dose-dependent manner. The dose ofTAT-IxBa 32,36 correlates with the
inhibition of luciferase activity. This is a representative result of triplicate
experiments performed on at least two separate occasions.
TAT-IkBoc (pg/ml)
□;TAT-IkB(x WT, ■ ;TAT-IkBcx WT +TNF,
A; TAT-lKBa 32,36, A;TAT-IicBa 32,36 +TNF,
0;no treatment, #;TNF only
Figure 5-3-2-B; TAT-IkBcx 32,36 inhibits TNFa-induced NF-kB
greater than wild type (WT) TAT-IkBcx. HeLa cells containing NF-kB-
dependent luciferase reporter gene was incubated with TAT-IicBa 32,36 or TAT-IkBcx
wild type (WT) for 30 minutes at 37°C and further treated with TNFa for 6 hours for
luciferase expression. The activation of luciferease were measured and was compared
with untreated condition (O) and expressed as fold (Y-axis). on Y-axis indicates
the luciferase activity of TNF only. TAT-IkBcc 32,36 shows lower luciferase activity
than TAT-IkBcc WT. In other words, TNFa-induced NF-kB transcriptional activity
was more suppressed by TAT-IxBa 32,36, which is incapable of being
phosphorylated, compared with TAT-IxBa WT, which can still be degraded upon
TNFa stimulation. At the lower concentration TAT-IxBa WT reaches at the same
transcription level as TNFa only ('•' on Y axis). This is a representative result of
triplicate experiments performed on at least two separate occasions.
The different effects of inhibition of transcription activity of NF-kB by TAT-
hcBa32,36 and TAT-IkBocWT is demonstrated in figure 5-3-2-B. Dose-response
curves were performed in the presence of TAT-hcBa and TNFa. TNFa only (85-
fold) is shown as filled circle on Y axis in the graph. There is no induction of
luciferase activity seen by TAT-IkBcx32,36 and TAT-IkBocWT alone.
Both TAT-hcBa32,36 and TAT-IkBccWT inhibit TNFa-induced NF-kB activation
in a dose-dependent manner. There is a significantly different effect on the
inhibition of TNFa-induced NF-kB activation between the mutation and wild type.
Compared with TAT-hcBa32,36, TAT-hcBaWT is less effective at inhibiting
TNFa-induced NF-kB activation. For example, the lowest dose of TAT-hcBaWT
(0.013 pg/ml), had no effect on TNFa-induced transcription (83-fold). Wild type
can still inhibit TNFa-induced NF-kB activation but its effect is limited. Although
WT is over-expressed in the cells they are still capable of being degraded and as a
result in to free NF-kB for transcriptional activities. On the other hand, TAT-
hcBa32,36 is not able to be degraded, which therefore results in a strong inhibition.
Therefore, TAT-hcBa32,36 was chosen to be used for the rest of the following
experiments.
Summary
TAT-hcBa32,36 and TAT-IicBaWT have no effect on NF-kB activation alone.
TAT-hcBa32,36 inhibits TNFa-induced-NF-icB activation.
TAT-hcBaWT inhibits TNFa-induced-NF-KB activation.
100
TAT-IkBoc32,36 is a stronger inhibitor of TNFa-induced NF-kB activation
compared to TAT-IicBaWT.
5.3.3. Other experimental conditions
Because TAT-IicBa is a new technique, therefore, some experimental conditions
were therefore investigated to obtain optimal conditions for the following
experiments.
Denatured VS non-denatured
Nagahara et al. (1998) emphasised the importance of denaturing TAT proteins
before addition to cells. Therefore, TAT-IicBaWT was denatured with 8M urea and
dialysed against cell culture medium. Figure 5-3-3-A shows the effect of denatured
TAT-IicBaWT (30pg/ml) and non-denatured TAT-IkBocWT (30pg/ml) in HeLa
cells. Both denatured (D) and non-denatured (ND) TAT-hcBa suppresses TNFa-
induced luciferase activity, with the non-denatured protein showing the better
suppression. Denaturing proteins may be required for larger proteins. However, in
TAT-IicBa, because ND exerted better inhibition, the denaturing process was not
chosen for the following experiments.
Preincubation time
In order to investigate the consequence of preincubation time, TAT-IicBa was
incubated for 15 or 30 minutes before adding TNFa to the cells. According to
Nagahara et al., (1998), TAT enter T cells as early as 10 minutes. Using HeLa cells,
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Figure 5-3-3-A; Denatured or non denatured TAT-IkBcx WT
inhibits TNFa induced NF-kB luciferase activity in HeLa cells.
HeLa cells containing NF-icB-dependent luciferase reporter gene was incubated
with denatured (D) or non-denatured (ND) TAT-lKBa WT (30 pg/ml) for 30
minutes at 37°C and then treated with TNFa (5ng/ml) for 6 hours before
luciferase expression was measured. The activation of luciferease was measured
and was compared with untreated condition and expressed as fold (Y-axis).
TAT-IxBa WT was denatured by 8M Urea. However, there was no advantage
of denatured TAT-IxBa WT for NF-kB inhibition.
TNFa — + — +
TAT-IkB(x32,36 —j— —J"
Figure 5-3-3-B; TAT-lKBa 32,36 inhibits TNFa induced NF-kB
luciferase activity within 15 minutes of pre-incubation. HeLa cells
containing NF-KB-dependent luciferase reporter gene was incubated with 30
pg/ml TAT- IkBcx 32,36 (30pg/ml) for 15 minutes or 30 minutes at 37°C and
then treated with TNFa (5ng/ml) for 6 hours before luciferase expression was
measured. The activation of luciferease were measured and was compared with
untreated condition and expressed as fold (Y-axis). A 15 minutes incubation was
sufficient for inhibition of TNFa induced NF-kB luciferase activation.
(5ng/ml) was added. As shown in figure 5-3-3-B both preincubation times of 15 min
or 30 min significantly suppressed TNFa-induced NF-kB activation. Moreover, a
15-min preincubation time exerts a slightly better inhibition than 30 minutes.
Although 15 min pre-incubation period may be sufficient for suppressing NF-kB in
HeLa cells, all the following experiments were performed using 30 min pre¬
incubation time for convenience (see 5.6.4. in discussion).
Washed and non-washed medium
Due to the nature of the luciferase experiment, reagents (e.g. TNFa, TAT-IicBa
etc.) were left in the medium with the cells for 6 hours. To determine the effect of
those reagents in the medium, cells were washed with fresh medium after treatment
for 30 minutes with TAT-IicBa (30pg/ml) and 30 minutes with TNFa (5ng/ml) and
incubated in fresh medium. After 6 hours incubation, luciferase activity was
measured (data not shown). Generally washed cells exerted slightly lower luciferase
activity. Thus, in order to obtain better luciferase activity, cells were incubated with
the reagents for 6 hours rather than performing a washing step.
Serum Free Medium
Most experiments were performed with medium containing 10% FCS. However, in
order to examine the effects of TAT-IicBa in serum free medium TAT-IicBa (WT)
(30pg/ml) was co-incubated with TNFa (5ng/ml) in HeLa cells with the medium
containing no serum. In serum free conditions, a similar dose-dependent inhibition
of TNFa-induced-NF-icB was seen in serum containing medium (data not shown)
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suggesting that the effect of TAT-hcBa was not dependent on the presence of
serum. Following experiments were performed with medium containing 10% FCS.
Jurkat cells
Similarly to 57A HeLa cells, the Jurkat cell line, Jurkat a5.1 (Professor Hay,
University of St Andrews), which contains luciferase reporter gene was used to
examine the effect of TAT-IkBcx. TAT-hcBa also inhibited TNFa-induced NF-kB
activation in these cell lines (data not shown). However, the effect ofTNFa itself on
Jurkat a5.1 was limited compared to 57A HeLa cells (as shown previously). Jurkat
cells were therefore not used for the further experiments.
Summary
The following conditions were selected for the following experiments;
Non-denatured TAT-bcBa
A 30 minutes incubation time with TAT-IkBoc was used.
Reagents (TAT-IicBa and TNFa) were kept with the cells and not washed away
for luciferase expression
Medium containing 10% FCS
5.4. TAT-IicBa32,36 in A549 cells
5.4.1. Western blotting analysis for IicBa in A549 cells
To investigate the effect of TAT-ItcBa further, the epithelial cell line A549 was
used for Western blotting (WB) and immunofluorescent microscopic analysis. TAT-
hcBa32,36 (30 pg/ml) was incubated with A549 for 30 min at 37°C before TNFa
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Figure 5-4-1; iKBa expression in A549 cells. A549 cells were incubated
with TAT-IkBcc 32,36 (indicated as TAT-IkBoc) (30pg/ml), and GST-TAT
(30pg/ml) for 30 minutes at 37°C and then treated with TNFa (5ng/ml) for 30
minutes. Cytoplasmic extract was analysed by Western blotting with polyclonal
antibody specific for IxBa. Two forms of bands are seen. In the no TAT condition
endogenous IicBa band (lower) is seen and degraded upon TNFa stimulation.
Similar results are seen with GST-TAT. TAT-IicBa32,36 is seen as upper bands in
lane 3 and 4 due to extra 11 amino acid TAT (see figure 5-2-1-4). TNFa stimulation
degrades endogenous (lower) IxBa but keeps TAT-IxBa 32,36 (upper) remaining in
the cells. This is a representative experiment out of four different experiments
performed on the separate times.
(5ng/ml) was added and incubated for a further 30 min. Cells were lysed (see
material and methods) and WB was performed using an anti-lKBa antibody to
measure hcBa expression in the cytoplasm as an index of NF-kB activation. As
shown in figure 5-4-1, two forms of IkBcc are seen, a lower and an upper band. The
conditions without any TAT (the 1st and 2nd lane from the left) shows endogenous
IicBa (the 1st lane from the left) and its degradation by TNFa (the 2nd lane) as
expected. Thus, the lower band is the endogenous normal form of IkBoc. A similar
pattern of IkBoc degradation by TNFa is seen when GST-TAT (the 5th and 6th lane
from the left) is used. Again, the lower band of IicBa (endogenous) is degraded by
TNFa, when co-incubated with GST-TAT. Thus, in the presence of GST-TAT,
TNFa likely releases NF-kB for the following transcription activities. However,
with TAT-lKBa (lane 3 and 4), two forms of hcBa are seen. The lower band
indicates an endogenous IicBa (see lane 1 and 5) and the upper band is TAT-
hcBa32,36, which is 11 amino acids heavier than normal hcBa. Analysis by mass
spectrometry of TAT-IicBa32,36 determined its molecular weight as 37570Da (see
figure 5-2-4) whereas rlicBa is 35471Da. The upper band of IicBa indicated the
presence of TAT-MBa32,36, which transduced through the cell membrane into the
cytoplasm. In lane 3 two forms of IicBa retain NF-kB in the cytoplasm, resulting in
a strong inhibition ofNF-kB. In lane 4 it is shown that the endogenous hcBa (lower
band) is degraded, under TNFa stimulation, but clearly TAT-hcBa32,36 band
(upper) does not get degraded, due to the mutations of serines 32 and 36. Although
endogenous hcBa is degraded, over-expressed TAT-h<Ba32,36 in the cytoplasm
prevents NF-kB translocation and hence its transcriptional activity.
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Summary
Endogenous IkBoc can be degraded by TNFa.
TAT-IkB(x32,36 transduces into the cytoplasm ofA549 cells.
. TAT-IicBa32,36 is not degraded following TNFa stimulation.
• GST-TAT does not influence the degradation pattern of IicBa.
5.4.2. Immunofluorescence analysis of p65 in A549 cells
One of the common NF-kB dimers, p65 was examined in A549 cells and its
translocation into nucleus upon NF-kB activation was monitored. TAT-IicBa32,36
(30 pg/ml) was incubated with A549 for 30 minutes at 37°C before TNFa (5ng/ml)
was added and incubated for a further 30 minutes. Then cells were fixed and
permeabilised before immunofluorescence staining with anti-p65 antibody. In figure
5-4-2 p65 is clearly seen in the cytoplasm in the untreated condition (top left panel).
Upon TNFa stimulation, p65 is translocated into the nucleus as a result of the
activation ofNF-kB (top right panel). When using GST-TAT, the same pattern was
observed following TNFa stimulation. Thus, GST-TAT does not influence TNFa-
induced NF-kB activation. On the other hand, TAT-IicBa inhibits translocation of
p65 into the nucleus causing p65 to remain in the cytoplasm with or without TNFa
addition. Therefore, TNFa does not cause p65 translocation if TAT-lKBa32,36 is
present in the cytoplasm. These results correlate with the Western blotting analysis
of h<Ba expression as shown in figure 5-4-1. The results with A549 cells confirms







Figure 5-4-2; TAT-IkBoc 32,36 inhibits TNFa induced p65 translocation
in A549 cells. A549 cells were incubated with TAT-IkBo.32,36 (30pg/ml) or GST-
TAT (30pg/ml) for 30 minutes at 37°C and further treated with TNFa (5ng/ml) for 30
minutes. Cells were fixed and permeabilised for immunofluorescence staining with
polyclonal anti-p65 antibody. In untreated cells p65 stays in the cytoplasm but
translocates into the nucleus following TNFa stimulation. A similar pattern is observed in
GST-TAT treated cells. However, TAT-lKBa32,36 inhibits p65 translocation by TNFa
and retains p65 in the cytoplasm. This is a representative experiment out of three different
experiments performed at separate times.
Summary
• TAT-IkBoi prevents TNFa-induced-p65 translocation into the nucleus in A549
cells.
GST-TAT does not prevent p65 translocation into the nucleus in A549 cells.
5.5. TAT-IkBcx32,36 in eosinophils
5.5.1. TAT-IkBcx transduces into eosinophils
Unlike established cell lines, eosinophils have almost no ability to be virally
transfected. Thus, direct manipulation of intracellular proteins in eosinophils has
never been demonstrated in the past. Here, TAT-IicBa is added to eosinophils to
determine the possibility of transduction and inhibition ofNF-kB.
Eosinophils were isolated as described in chapter 2. TAT-IkBoc and recombinant
IkBcc (rhcBa) were conjugated with FITC for visualisation of internalisation of
TAT into the cells. TAT-lKBa32,36-FITC (30pg/ml) and rlKBa-FITC (30pg/ml)
were incubated with eosinophils for 30 minutes at 37°C in the dark. Cells were
washed with PBS twice (5 minutes each) and cytocentrifuge preparations were
obtained for observation under an immunofluorescent microscope as shown in
figure 5-5-1. The cells with FITC positive are indicated by arrows. These FITC
positive cells were observed in only TAT-IvcBa32,36-FITC but not in rlKBa-FITC.
These results suggest that TAT-lKBa32,36-FITC is transduced into eosinophils and




Figure 5-5-1; TAT-lKBa -FITC was transduced by eosinophil but
not recombinant IkBoc -FITC (rlicBa -FITC). FITC conjugated TAT-
iKBa or rlKBa (both at 30pg/ml) were incubated with eosinophils for 30 minutes
at 37°C in the dark. After incubation the cells were washed with PBS and cyto-
centrifugated for immunofluorescent-microscope observation. The small white
cells (arrows) are seen in panel A are FITC stained cells by TAT-IkBoi-FITC, but
not in panel B where rlicBa-FITC was not taken into the cells.
Summary
TAT-lKBa32,36-FITC is transduced into eosinophils.
rhcBa-FITC is not transduced into eosinophils.
5.5.2. IkBoc and p65 expression by Western blotting in eosinophils
TAT-lKBa32,36 (30pg/ml) or GST-TAT (30pg/ml) were incubated with
eosinophils for 30 minutes for 37°C then TNFa (lOng/ml) was added for a further
30 minutes before cells were lysed to obtain the cytoplasmic and nucleus extracts
for Western blot (WB) analysis. WB was performed with anti-IicBcc and -p65
antibody to examine the expression of IicBa in cytoplasm and p65 in nucleus as
shown in figure 5-5-2.
In the cytoplasmic extract two bands are observed, as it has been shown in A549
cells (see figure 5-4-1); an endogenous IkBoc (lower) and a TAT-IicBa (upper).
Lane 1 (from the left) is the untreated control, where an endogenous IicBa is seen,
while upon TNFa stimulation (lane 2) IicBa is degraded. A similar pattern was
observed when GST-TAT was used (lane 5 and 6). Endogenous IxBa (lane 5,
treated with GST-TAT) is seen as in the lane 1 for untreated control, but under
TNFa stimulation (lane 6, treated with GST-TAT) IicBa is degraded with only a
small amount of IxBa remaining in the cytoplasm. In lanes 3 and 4, when TAT-
IicBa32,36 is used, the upper band of IicBa, TAT-IicBa32,36, is seen. When TAT-
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Figure 5-5-2; IkBcx (cytoplasm) and p65 (nucleus) expression on
Western blotting in eosinophils. Eosinophils were incubated with TAT-
IkBcc32,36 (indicated as TAT-IkBcx) (30pg/ml) and GST-TAT (30pg/ml) for 30
minutes at 37°C and further treated with TNFa (5ng/ml) for 30 minutes. Cytoplasm
and nuclear extracts were analysed by Western blotting using polyclonal antibodies
specific for IicBa and p65. Cytoplasm; Two forms of bands are seen. In the no TAT
condition endogenous IicBa band (lower) is seen but degraded upon TNFa stimulation.
Same results are seen with GST-TAT pre-incubation. TAT-Ii<Ba32,36 is seen as an
upper band in lane 3 and 4 due to extra 11 amino acids TAT (see figure 5-2-3-1 for
IxBa expression in A549 cells). TNFa stimulation degrades endogenous (lower) IxBa
but keeps TAT-Ii<Ba32,36 (upper) remaining in the cytoplasm. Nucleus; Clear p65
translocation is seen after TNFa stimulation in lane 2, compared with the untreated
condition (lane 1). 3x10 cells were used per condition.
IkBcx32,36 is used, the presence of two forms of IkBcx, TAT-IkBcc32,36 are seen;
an upper band (TAT-hcBa32,36) and an endogenous hcBa as lower band, in the
cytoplasm indicating a strong inhibition of NF-kB. When stimulated with TNFa
(lane 4), the endogenous IkBoc (lower) is degraded. However, TAT-IicBa32,36
(upper) is resistant to degradation upon TNFa stimulation. These results are very
similar to the results obtained using A549 cells (figure 5-4-1).
On the other hand, nuclear extract was examined with an anti-p65 antibody. Lane 2
shows TNFa induction of p65 in the nucleus is clearly seen compared to lane 1
without TNFa. With TAT-hcBa32,36 incubation (lane 3), no p65 appears
indicating a strong NF-kB inhibition. In lane 4 a small amount of p65 is seen under
TNFa stimulation when TAT-lKBa32,36 was incubated together. This is a smaller
amount of p65 compared with TNFa only (lane 2). Thus, TAT-lKBa32,36 is indeed
inhibiting TNFa-induced NF-kB activation in eosinophils. In lane 6 GST-TAT and
TNFa showed slight p65 translocation. However, this is not as substantial as TNFa-
induced p65 translocation as shown in lane 2.
Summary
Endogenous iKBa is degraded when cells were stimulated by TNFa.
TAT-lKBa32,36 transduced into the cytoplasm of eosinophils.
TAT-hcBa32,36 is not degraded following TNFa stimulation.
p65 is translocated into nucleus following TNFa stimulation in eosinophils.
Translocation of p65 is prevented by TAT-hcBa32,36.
108
5.5.3. Eosinophil apoptosis
Inhibition of NF-kB induces apoptosis in many cells, especially when other death
pathways, such as the caspases cascades are stimulated. In our previous study (see
chapter 4, and Fujihara et al, 2002), when NF-kB inhibitors were used with TNFa
in eosinophils, it is demonstrated that eosinophils undergo apoptosis.
Here, TAT-IkBo32,36 was used as a tool to investigate eosinophil apoptosis. Figure
5-5-3 shows eosinophil apoptosis (%), assessed by morphologically, when using
TAT-hcBa32,36 (30pg/ml) and GST-TAT (30pg/ml) for 24 hours. In these
experiments, untreated control and TNFa (lOng/ml) alone do not show significant
differences-between them. However, incubating eosinophils with TAT-hcBa32,36
dramatically induced apoptosis (>80%) with or without TNFa. This is a significant
induction of apoptosis compared with the condition with no TAT-hcBa32,36 and
GST-TAT. GST-TAT itself does not significantly induce apoptosis. There was a
small induction of apoptosis when GST-TAT and TNFa were co-incubated. In
conclusion, TAT-IicBa32,36 itself significantly induced eosinophil apoptosis. This
effect appears to be further enhanced when TNFa was added. These results suggest
that inhibition of NF-kB plays an important role in inducing eosinophil apoptosis.
These results confirm the previous results shown in chapter 4.
However, it was notable that the induction of apoptosis was donor dependent. Some
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Figure 5-5-3; Eosinophil apoptosis induced by TAT-IicBa32,36.
Human eosinophils (3 x 106/ml) cultured in Iscove's DMEM containing 10%
autologous serum with TAT-IkBoc32,36 (30pg/ml) and GST-TAT (30pg/ml) for 30
minutes at 37°C and further treated with TNFa (5ng/ml) in the indicated
conditions. At 24 hours, cells were cytocentrifugated for microscopic observation
and apoptotic cells were assessed by %. TAT-lKBa32,36 induced eosinophil
apoptosis significantly. All values represent mean ± S. E. of n = 3 experiments. *
represents significant difference from appropriate controls (p<0.05).
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Figure 5-5-3-b; Eosinophil apoptosis induced by TAT-IkBcx32,36 in
two types of groups; responded- and non-responded.
Human eosinophils (3 x 106/ml) cultured in Iscove's DMEM containing 10%
autologous serum with TAT-IkBcc32,36 (30pg/ml) and GST-TAT (30pg/ml) for 30
minutes at 37°C and further treated with TNFa (5ng/ml) in the indicated
conditions. At 24 hours, cells were cytocentrifugated for microscopic observation
and apoptotic cells were assessed by %. TAT-IkBcx.32,36 induced eosinophil
apoptosis significantly. All values represent mean ± S. E. of n = 3 experiments. *
represents significant difference from appropriate controls (p<0.05). There are two
types of group of subjects; responded (filled bar) and non-responded (open bar) to
TAT-IicBa32,36-induced apoptosis.
figure 5-5-3, while some populations did not (Figure 5-5-3-B). The difference
between those populations in terms of induction of apoptosis is not known.
However, it is likely that eosinophils from those donors may have activated
pathways, such as NF-kB or tyrosine cascades, that may also interfere with the
apoptotic pathway.
Summary
TAT-IkBcx32,36 itself induces eosinophil apoptosis.
These results suggest the importance of inhibition ofNF-kB.
GST-TAT and TNFa induce eosinophil apoptosis to a small extent.
Eosinophils from some donors did not respond to TAT-bcBa32,36.
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5.6. Discussion
5.6.1. TAT as a tool for internalisation.
Direct internalisation of a target peptide, protein, enzyme, etc. using TAT into
various types of cells has widened the potential of a direct approach to manipulate
target intracellular proteins. Here, it has been shown that TAT-hcBa is successfully
transduced into HeLa cells, A549 cells and eosinophils. Although not shown here,
TAT-lKBa-FITC also confirmed successful internalisation into neutrophils.
Granulocytes are thought to be extremely difficult cells to use any direct approaches
to manipulate intracellular pathways, such as viral transfections due to lack of
specific receptors and their short lives. However, this TAT peptide is a promising
method to transduce protein into granulocytes.
5.6.2. TAT-IKBoc
It has recently been shown that internalisation of TAT-IkBoc in different cell types
inhibits activation of NF-kB (Kabouridis et al., 2002). In HeLa cells luciferase
activity clearly demonstrated that the inhibition of NF-kB, especially TNFa-
induced NF-kB activation (figure 5-3-2) by TAT-hcBa. In A549 cells,
internalisation of TAT-bcBa in the cytoplasm was shown by Western blotting
(figure 5-4-1). Over-expressed hcBa in the cytoplasm prevents translocation of p65
into nucleus. Furthermore, p65 translocation was examined by immunofluorescence
(figure 5-4-2). It has been demonstrated that TAT-IkBoc indeed prevents the
translocation of p65 into the nucleus despite stimulation of TNFa at the same time.
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These data obtained from HeLa and A549 cells strongly suggest that TAT-IicBa
inhibits NF-kB.
5.6.3. Optimal conditions for the usage of TAT-IkBo.
Because the usage of TAT was a new technique in not only eosinophils but also cell
lines, optimal conditions had to be investigated for our experiments. Various
conditions were tested in HeLa cells then those conditions were applied to
eosinophils and A549 cells.
In this study, as the control protein for TAT-IicBa, GST-TAT was chosen. This is
due to the process of cloning (see figure 5-2-1), GST-TAT was thought to be the
optimal control for this study. Similarly, other groups such as Kaburidis et al.,
(2002) have also used GST-TAT as a control for TAT-IkBcx. Ideally, TAT-IicBa
which is functionally unable to inhibit NF-kB would be the best control. For
instance, TAT-IkBo, which is mutated at NF-kB binding sites and therefore
incapable of holding NF-kB in the cytoplasm would be the best control protein.
This study should be performed for the next step.
Previously, TAT-p27 (Nagahara et al., 1998) and TAT-H-Ras (Hall et al, 2001)
were shown to start internalising into cells as early as 5 minutes. In HeLa cells as it
has been shown in figure 5-3-3-B, a pre-incubation time of 15 min with TAT-IkBoc
was sufficient. However, in this study 30 min incubation time was used. In our
previous study in chapter 4, gliotoxin and Mgl32 were pre-incubated for 30 min
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before TNFa was added. In order to have consistent experiments from the previous
studies, 30 min pre-incubation ofTAT-IicBa was chosen.
After the internalisation of TAT, its actual movement within the cells is not known.
It is a possibility that TAT-IkBoc may not only go through cell membrane but also
may enter the nucleus. It has been demonstrated that endogenous hcBa goes
through the nuclear membrane (Arenzana-Seisdedos et al., 1995) and transports NF-
kB back to the cytoplasm. Therefore, it is possible for TAT-frcBa to go into the
nucleus and export NF-kB from the nucleus back into the cytoplasm. Unfortunately,
this point was not investigated during this project. However, it would be interesting
to examine; 1. IicBa expression in nucleus extracts by Western blotting 2.
IkBoc expression by Immunofluorescence or confocal microscope study. In addition,
the function of TAT-hcBa can be investigated with immunoprecipitation to
demonstrate if p65 or p50 is actually held by TAT-IkBcc. These experiments would
answer the more specific questions of the function of TAT-hcBa in cells.
5.6.4. Denatured and non-denatured TAT-IkBo,
Although Nagahara et al., (1998) emphasised the importance of denaturing proteins,
most of the reported papers had used denatured TAT-protein. However, it appeared
that this process is not necessary for TAT-IkBcx. The requirement for denaturing
process can be dependent upon the shape and size of the protein, where some
proteins were easy to get into cells whereas some were not. For some reason
IkBcc may have the shape or other natures that make TAT-IicBa transduce easily
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into cells. However, in the same Dowdy's group, it is mentioned that 40nm super
paramagnetic beads were successfully transduced into T cells, which is no bigger
than 4 pm (Schwarze et al., 2000). This evidence raises the question for the
requirement of denaturing process if such a size of the beads can enter cells. It may
be due to the smooth surface of the beads that helped them into cells easily.
Therefore, odd shaped proteins might need the denaturing process although their
actual size is smaller than 40nm beads. These studies to investigate the shape and
composition of the protein may help understanding the mechanism of the TAT
internalisation into cells. Furthermore, it could be possible in the future to design
the protein linked with TAT that selectively target internalisation into specific cell
types for the therapeutic purposes.
5.6.5. Apoptosis in eosinophils
From studies of HeLa and A549 cells, there is strong evidence showing that TAT-
IkBoc inhibits NF-kB activation. In eosinophils, Western blotting analysis (figure 5-
5-2) demonstrates that over-expression of IkBcx in the cytoplasm results in the
inhibition of translocation of p65 into the nucleus. This is the first demonstration
that TAT-hcBa has been successfully transduced into eosinophils and shown to
functionally inhibit NF-kB both with or without TNFa stimulation.
As it has been shown in figure 5-5-3, TAT-IicBa induces eosinophils apoptosis.
Interestingly, this implicates that TAT-IicBa does not require TNFa cytotoxity but
can induce eosinophil apoptosis by itself. This outcome is more dramatic than our
previous results shown in chapter 4 using gliotoxin and Mgl32. It may be that TAT-
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IkBoc itselfwas toxic to the cells. The concentration might not be optimal. However,
as has mentioned in 5.5.3., this effect was donor dependent, in other words, in some
donors TAT-IkBoc did not exert its effect to induce apoptosis at all. Therefore,
concentration may not be the issue for the cytotoxity to eosinophils.
TAT-IkBoc32,36 blocks signal induced activation of NF-kB dependent reporter
gene activation in HeLa cells. In A549 cells TAT-hcBa32,36 does not block TNFa
induced degradation of endogenous IkBoc but appears to bind the released NF-kB
and retain it in the cytoplasm. This is consistent with recently demonstrated works
in HeLa cells. Uptake of TAT-hcBa 32,36 into eosinophils induces apoptosis in the
presence or absence of TNFa. This indicates that a basal level ofNF-kB is essential
for eosinophil survival in culture, presumably to content a constitutively activated
pathway. The ability of h<Ba to translocate to the cell nucleus and export NF-kB
complexes back to the cytoplasm would suggest that TAT-lKBa32,36 could inhibit
basal NF-kB dependent transcription activities, which influence apoptosis.
Although the basics for the heterogeneity of this response is unknown, it is likely to
be related to the extent of eosinophil activation and consequent NF-kB translocation
in these proteins.
Indeed, there could be two distinct populations that TAT-lKBa exert high sensitivity
or no effect at all especially for inducing apoptosis. To investigate this point,
ideally, dose response of TAT-IicBa may be required for each donor. However, to
perform this kind of experiment, large number of eosinophils are required.
Therefore, this would be very difficult series of experiments to be performed. In
addition, other methods (e.g., FACS analisys of Annexin V or DNA ladder etc.)
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should be employed to confirm apoptosis rather than morphologically. Since this
result which is donor dependent was totally unexpected outcome. Therefore, we did
not have any symptoms scores etc. to correlate. However, this is the next project to
determine the correlation between response to TAT-IicBa and other factors, as such,
allergic symptoms scores, if asthmatics FEV1, PC20, skin prick tests, peripheral
eosinophil counts, peripheral level of IgE.
There is no clear evidence or reason for the outcome of two different populations in
terms of the apoptosis assay. However, in my opinion, the difference may be based
on the state of the activation of eosinophils. Towards the end of this project, my
guess was that donors who did not respond to TAT-IicBa tended to be the 'high
eosinophil donors' who may likely to have allergic diseases, such as eczema and
asthma. In these donors, eosinophils are likely to be 'activated' when they were
isolated from peripheral blood. Unfortunately, there is no direct evidence to support
this hypothesis. Therefore, for the next step, it would be very interesting to
investigate this possibility, which can be examined by eosinophil counts in
peripheral blood, eosinophil activation by flow cytometry, activation level of other
signalling pathways and the production of pro-inflammatory cytokines.
There could be a few reasons why TAT-IkBoi does not induce apoptosis in some
populations. In eosinophils IL-5 triggers Jak-STAT 1 (Paxdrak et al., 1995), Lyn,
Syk (Yousefi et al., 1996) Jak 2 (Paxdrak et al., 1998) pathways, which have been
shown to be the crucial eosinophil survival pathways. Thus, in some donors,
tyrosine kinase cascades might be more important for eosinophil survival than NF-
kB dependent pathways. This could be investigated by blocking those tyrosine
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pathways in the same time using TAT-IicBa. In this project, the study of tyrosine
pathways was not included since NF-kB was the primary aim. However, to gain a
clear answer, to examination of tyrosine pathways should be included in eosinophils
apoptosis study. Because intracellular pathways are complex involving many
pathways, proteins, organelles etc. many as yet unknown pathways may exist to
control eosinophil apoptosis. The answer to their interesting questions will have to
await for future studies.
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Chapter 6
Hodgkin's Disease and eosinophilia
6.1. Introduction
6.1.1. Hodgkin's disease
The first description of Hodgkin's Disease (HD) made by Thomas Hodgkin in 1832
at Medical School in Edinburgh University was 'some morbid appearances of the
absorbant glands and spleen in lymph nodes' (Hodgkin, 1832). Almost 60 years
after Hodgkin's observations further characterisation of the disease was made by
Dorothy Reed and Carl Sternberg. They described the manifestation of unusual
large mononuclear cells which were named as Hodgkin (H) cells making up less
than 1% of the total tumour together with Reed-Sternberg (RS) cells which in
contrast are multinucleated (Reed, 1902, Sternberg, 1898, reviewed by Kiippers and
Rajewsky, 1998).
Hodgkin's disease (HD) of Hodgkin's lymphoma is the most common lymphoid
malignancy in the western world, affecting mainly young adults and people older
than the age of 55 years of age. The main symptoms of Hodgkin's disease are
painless swelling of the lymph nodes in the neck, underarm, or groin, fever, night
sweats, tiredness, weight loss, itchy skin, and there may be increased susceptibility
to infection due to an imbalance of the immune system. Accurate determination of
the progress and categorisation of Hodgkin's disease is by microscopic observation
of biopsy samples following surgery (see figure 6-1-1 for biopsy sample). Further
diagnosis is then determined with appropriate treatment.
The most standard treatment for HD is the combination chemotherapy MOPP
(Mechlorethamine, Vincristine, Procarbazine, Prednisone) and ABVD
(Doxorubicin, Blemycin, Vinblastine, Dacarbazine), which both demonstrate the
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superior effects. In addition to the chemotherapy, patients may receive radiotherapy
for advanced tumour.
HD can be categorised into four subgroups according the composition of the cells,
for example, Lymphocyte predominant (LP), lymphocyte-depleted (LD), nodular
sclerosis (NS) and mixed cellularity (MC) (reviewed by Burke et al., 1992).
6.1.2. HRS cells and inflammatory cells
Although being defined by the presence of cancerous Hodgkin Reed-Sternberg
(HRS) cells, more than 98% of the tumour in Hodgkin's disease is composed of
non-cancerous cells. The accumulated inflammatory infiltrate consists
predominantly of eosinophils and T cells, with less notable abundance of
neutrophils, basophils, macrophages and B cells. As shown in figure 6-1-1-A and B
eosinophils are commonly observed in the biopsy samples of HD. These features of
HD therefore share some similarities to the sites of inflammation.
Although the notable number of eosinophils and other inflammatory cells at HRS
cells has been known for many years, the function and mechanism of the
accumulation of inflammatory cells, are not fully understood. Previously
eosinophils were thought to be a 'bystander' and 'innocent' cells occurring during the
disease process. However, recently the role of the eosinophil has come into question
in light of clinical reports suggesting that the eosinophilia at HRS cells correlates to
the poor prognosis in patients (Enbald et al., 1993, von Wasieleski et al., 2000).
Enbald et al. (1993) and von Waseileski et al. (2000) have reported that patients
with eosinophilia at the tumour in comparison with ones with non-eosinophilia had
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Figure 6-1-2; Isolated HRS cells from biopsy samples. HRS cells were
purified and isolated from biopsy materials. These photos were kindly provided by
Professor R Jarrett, University of Glasgow.(Magnification x 100)
significantly poor prognosis for survival. Recently, von Wasielewski et al. (2000)
have suggested a possible negative influence of eosinophils in Hodgkin's disease,
which may be regulated by constitutive activation ofNF-kB. (Also see introduction
of chapter 1, 4 and 5 for a description of NF-kB activation as pro-inflammatory in
eosinophils.) It appears that eosinophilia may potentially exert a deleterious effect to
the host, but, currently the reasons and role of eosinophils in HD are not known.
T cells are another cell type commonly observed in HRS tumour. It has been
demonstrated that T cells rosette spontaneously to HRS cells assessed both in vitro
and in vivo (Sanders et al., 1988). There is some evidence suggesting that T cells at
HRS cells express CD4+ (Poppema et al., 1998), CD30L and CD40L (Pinto et al.,
1997) and that T cell activation may lead to tumour progression, rather than
cytotoxic anti-tumour properties (Poppema et al., 2000). Recent reports have
suggested that the interaction between T cells, eosinophils and HRS cells may
contribute to cellular activation ofHRS cells. Expression of CD30L, CD40L, CD40,
CD95/Fas and CD95/FasL on eosinophil surface appears to be higher in
hypereeosinophilic syndrome (HES) patients in HD than in normal healthy donors
(Pinto et al., 1996 and 1997). CD30 was originally identified as a surface antigen on
Reed-Stenberg cells and found to be preferentially expressed on activated CD4+ T
cells (Del Prete et al., 1995, Manetti et al., 1994). Interestingly, CD30 ligand binds
to CD30 on HRS cells and promotes cell proliferation, cell survival and production
of IL-3, IL-5 and GM-CSF (Elliss et al., 1993, Alzona et al., 1994, Del Prete et
al., 1995, Mosmann et al., 1996). These products also suppress eosinophil apoptosis.
Therefore, interaction between T cells and HRS cells may promote activation of not
only HRS cells but also other inflammatory cells, especially eosinophils.
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Other types of cells may also contribute directly or indirectly to the progress ofHD.
For example, in the surrounding tissue, release of eotaxin from fibroblasts may
contribute to the infiltration of eosinophils (Jundt et al., 1999). Furthermore
neutrophils may also have a part to play in tumour formation.
It appears to be that the host immune mechanism by some unknown reason is
triggered by FIRS cells resulting in the infiltration of normal inflammatory cells at
the site of FIRS cells. Accumulation of inflammatory cells may directly contribute
to the formation of the tumour. A greater understanding of the nature ofHD may be
obtained by gaining further insight into the mechanisms underlying the
accumulation of inflammatory cells in HD.
6.1.3. Activation of HRS ceils
Similarly to other cancerous cells, HRS cells posses distinct features; such as high
cellular activation and enhanced survival, possibly due to disruption of normal cell
activities, often caused by the abnormal action of cellular signalling pathways.
There is significant evidence that the cause of high cellular activation in HRS cells
may be due to the constitutive high activation of NF-kB (Cabanne et al., 1999 and
Krappmann et al., 1999), the absence of caspase-3 expression (Izban et al., 1999),
deficiency of CD95-induced apoptosis (Re et al. 2000, Muschen et al. 2000) and
infection with Epstein-Barr Virus (EBV). For example, Cabanne et al. (1999) and
Krappmann et al. (1999) have shown that the mutated deletion and abnormal
function of IkBcx in the cytoplasm in HRS cells leads to abnormally high activation
of NF-kB, which act in an anti-apoptotic manner and may be involved in the
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production of cytokines and chemokines, promoting the recruitment of
inflammatory cells. For example, the IL-8 gene is often upregulated by NF-kB
activation. (See chapter 4.) Thus, abnormal NF-kB activation in HRS cells can
cause infiltration of inflammatory cells and result in progression of disease.
EBV can infect human B cells and be commonly involved in various
haematological diseases (e.g. African Burkitt's lymphoma, post-transplantation B
cell lymphomas and certain T cell lymphoma) including HD (Weiss et al., 1996).
The role of EBV in the pathogenesis ofHD is not fully understood. However, recent
investigations suggest that EBV may be one of the causes for the mutations within
the cells to result in the formation ofHRS malignant cells from normal haemopoetic
cells (Kiippers and Rajewsky, 1998). Furthermore, EBV positive HRS cells have
higher cellular metabolism and activation, including NF-kB activation, resulting in
an increased production of various cytokines such as IL-10, (Vockerodt et al., 2001)
and elevated expression of surface receptors such as CD25 (Kube et al., 1999).
Thus, EBV may play an important role in the progress ofHD. In the HRS cell lines,
L428, L540, KMH2 (Vockerodt et al., 2001) are positively infected with EBV.
6.1.4. Origin of HRS cells
From microscopic observation, it appears that the morphology of HRS cells is quite
unique, containing 'ovoid' nuclei, and differs from the characteristic identifying
nature of other haematopeotic cells. Figure 6-1-1-B shows typical HRS cells
containing ovoid nuclei. Figure 6-1-2 shows the isolated HRS cells from biopsy
samples containing one to three nuclei per cell. There have been numerous studies
investigating the origin of HRS cells. However, often technical difficulties prevent
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Age/ Sex 20/F 37/F 31/F 37/M 74/M 29
Clinical stage IV-B IV-B IV-B IV IV
Cell kinetics Lymphoid
(L)


















Chromosome no. 66-71 48-50 66-71 >44 36
NBT reduction
phagocytosis
















Table 6-1-4; Summary of HRS cell lines establishment.
(Modified from Drexler 1993, HDMYZ data from Bourour et al, 1993)
The nature, origin and the original patients' information of six different
well established cell lines are shown. Typically, most of the cell lines
have been established from patients, younger than 40 years at the end-
stage of disease. The 'origin' of the most cell lines are lymphoid, T cells
or B cells, except HDMYZ. T cell rosettes have been reported in L540,
L428 and L591, but eosinophil rosettes have never been reported in any
cell lines, 'incl' indicates inconclusive. NBT is nitroblue tetrazodium
used to indicate uptake in a phagocytosis assay. * IkBcc study by
Cabanne et al., 1999.
accurate determination of the nature and origin of HRS cells. The problems of
purification of HRS cells are due to the large number of contaminating
inflammatory cells and small number of HRS cells obtained following purification.
Furthermore, often HRS cells do not survive long enough for establishing cell line
cultures.
However, despite the technical difficulties, successful study ofHRS cells by surface
marker expression by PCR and DNA analysis (e.g. southern blotting) have
demonstrated their origin as T cells (TCR expression, CD2, CD3, CD4 etc.) or B
cells (Ig heavy and light chains, CD20, CD75 etc.). Table 6-1-4 summarises the
origin of HRS cell lines, for example, gene rearrangement studies demonstrate that
L540 and HDLM2 have TCR gene arrangement, whereas L591 and KMH2 have Ig
gene rearrangement and L428 has both. In clinical samples, about 80% of HRS cells
are B cell in origin from LP and about 30% of them are T cell positive in LD, NS
and MC. Furthermore a recent study demonstrated that HRS cells share a similar
phenotype and function as dendritic cells (Kadin, 1994). In normal situations B
cells, T cells and dendritic cells have diverse functions from each other yet as a
consequence of becoming HRS cells, they all exert similar functions, for example
infiltration of inflammatory cells. The ability of diverse cell types to perform similar
function upon becoming HRS cells requires further investigation.
6.1.5. Establishment of HRS cell lines
There are relatively few HRS cell lines in comparison with other cancer cell lines
due to difficulty in establishing HRS cell lines. Table 6-1-4 summarises the origin
of the cells from patients. For example, Diehl and co-workers have established
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L428, L591 and KMH2 cell lines from bone marrow or pleural fluids taken from
patients with end-stage of HD (Diehl et al, 1981). For unknown reasons, there is a
better chance of establishing cell lines from patients with progressed malignancy
(Professor R Jarrett, University of Glasgow, personal communication). Thus, HRS
cells from the more aggressive tumours may be an essential factor for establishing
successful cell lines.
6.1.6. Substance x; chemoattractant and survival factors for eosinophils
The mechanism of infiltration and accumulation of inflammatory cells at HRS cells
may be due to release of various chemoattractants from HRS cells, surrounding
cells in the tissue, such as fibroblasts, and inflammatory cells themselves once at the
site of HRS cells (see figure 6-1-6 for a diagram). Furthermore, following the
recruitment of those inflammatory cells, there may be some substances released
resulting in high cellular activation and enhanced survival of inflammatory cells. As
a consequence activated inflammatory cells are able to successfully escape from the
normal induction of apoptosis which results in clearance of dying cells by
macrophage phagocytes. In this thesis, this substance(s) is called substance x, which
causes eosinophil chemoattraction, activation and survival.
The possibility exists that substance x can be either a known or unknown peptide,
protein or lipid or a cocktail of these substances. The list of candidate substances
seems endless and may even vary in different cell lines and biopsy materials.
However, in this thesis, in an attempt to understand the mechanisms responsible for
eosinophil accumulation at HRS cells, the survival effect of eosinophils by soluble
factors in the supernatant from HRS cells lines were investigated.
124
Figure 6-1-6; The diagram summarises possible causes of
eosinophilia at HRS cell tumours. Eosinophil chemoattractants
(indicated as X), activators or survival factors (Y) may be released by HRS
cells, T cells and surrounding tissue, such as fibroblasts. Also, activators and
survival factors (Z) may be released from the eosinophils themselves resulting
in positive feedback activation and survival.
6.1.7. Possible candidates for substance x
HRS cell lines and biopsy samples have been studied by gene expression and by
measuring the generation of substances, for example cytokines, chemokines and
adhesion receptors all of which may influence inflammatory cells recruitment,
activation and survival. Despite these previous studies, there has been no clear
answers explaining the accumulation of inflammatory cells in HRS tumours. An
investigation of the causes and mechanism of the infiltration of inflammatory cells,
especially of eosinophil is investigated in this thesis. It is already known that some
cytokines and chemokines are known to cause eosinophilia. Table 6-1-7-A
summarise the candidates cytokines and chemokines for substance x and are listed
according to their molecular weight. They are therefore possible candidates for
eosinophil accumulation at HRS cells. A literature summary of eosinophilic
cytokines and chemokines possibly present arid produced by HRS cell lines and
biopsy samples are shown in table 6-1-7-B. Cytokines and chemokines are
measured by various methods (e.g. protein level, mRNA, microarray, southern
blotting etc.) in various HRS cell lines and clinical samples.
Among various cytokines and chemokines as shown in table 6-1-7-B, some
chemokines, such as eotaxin, IL-8, TRAC, RANTES, and cytokines, such as TNFa,
TGFp, IL-2, IL-3, IL-5, GM-CSF and IL-13 modulate various aspects of eosinophil
function. Among them are eosinophil chemoattractants such as IL-2, RANTES, IL-
8 and eotaxin. Eosinophil activators are most of the chemokines and cytokines such
as IL-3, IL-5, GM-CSF, IL-13, TNFa, TGFp. In addition, cytokines which are
known to influence eosinophil survival include IL-3, IL-5, GM-CSF, IL-13, TNFa.











MIP la X X
10-30KDa IL-1 X
IL-2 X






GM-CSF low X X
IFN-y X
PDGF X
30-50KDa IL-5 low X X
IL-12 X
VEGF X
Table 6-1-7-A; Summary of roles of various cytokines and
chemokines which may act as eosinophil chemoattractants,
activators and survival factors, classified by molecular mass
(modified from Giembycz and Lindsay, 1999). These cytokines and
chemokines may be released from HRS cells resulting in eosinophil
infiltration, accumulation, activation and survival contributing to the tumour
progression in Hodgkin's disease.
Table 6-1 -7-B; Summary of reported expression of gene,
mRNA and protein secretion of various cytokines and
chemokines from clinical biopsy materials and HRS cell
lines, (figure legend continue to the next page)
clinical L428 L540 KMH2 HDLM2 L591 HDMYZ
IL-la R/P(l, 17) R (14) R/M (14,9) R/M (14,9) R (24)
IL-13 P (1» 8) R (24)
IL-2 P (8, 2)
[L-3 P (8) M (9) M (9)
1L-4 P (4)
IL-5 R (23) R (13) R/M (13) M (13,9) R (24)
1L-6 R7P
(7,8,11)
R/P (7,11) P (11) R/P/M
(7,9)
P/M (11,9) R (24)
[L-7 R (24)









1L-13 ~ R/P(13) R (13) R/P (3, 13) R (13)
1L-14
TL-15 R (13) R (13)
[L-16
GM-CSF P (8) R (13) R/M (13,9) M (9,13)
G-CSF P (8)
VI-CSF M (9) M (9)
TNFa R/P (1,8) R/P (7,9) R (7) R/P/M (9) P/M (9) R (7)
LT R (7) R/P (7) R/P (7) R/P/M
(7,9)
P/M (9) R (7)












LIF M (9) M (9)
S-ECP P (22)
(continued)
Table 6-1-7-B; Summary of reported expression of gene, mRNA
and protein secretion of various cytokines and chemokines from
clinical biopsy materials and HRS cell lines. Various cytokines and
chemokines are measured by the following methods, P; protein measurement by
ELISA or immunoblotting, R; mRNA expression by PCR, M; gene expression
measured by microarray. * indicates CD40L induced expression. Numbers
indicate the reference numbers as follows; 1. Benharrock et al. (1996), 2. Dukers
et al. (2000), 3. Fiumara et a/.(2001), 4. Ford et al. (1984), 5. Foss et al. (1996), 6
Hedvat et al. (2001), 7. Foss et al. (1993), 8. Gause et al. (1992), 9. Gruss et al.
(1992), 10.Gruss et al. (1994), 11. Hsu et al. (1992), 12. Hsu et al. (1993), 13.
Kapp et al. (1999), 14. McKenzie et al. (1992), 15. Mukopadhyaya et al. (1987),
16. Newcom and Gu (1995), 17. Perfetti et al. (1992), 18. Teruya-Feldstein et al.
(1999), 19. van den Berg et al. (1999), 20. Schwaller et al. (1995), 21. Jundt et al.
(1999), 22. Molin et al. (2001), 23. Samoszuk and Nansen (1990), 24. Bargou et
al, (1993)
behaviour may have important consequences for the function of eosinophils during
HD. In the following paragraphs, those eosinophil influencing factors in HD are
discussed.
6.1.8. Chemokines
Chemokines are 7 to lOKDa of molecular mass and contain four distinct cysteine
residues that provide the classical subfamily of chemokines. Most of the known
chemokines can induce eosinophil migration, activation and recruitment.
Eotaxin
Eotaxin is a strong chemoattractant and promotes tissue eosinophilia in the early
Stages of. inflammation. Interestingly, in HD, eotaxin has been reported
controversially from two groups. Jundt et al. (1999) examined several biopsy
samples and concluded that eotaxin is secreted by fibroblasts in surrounding tissue,
but not from HRS cells. On the other hand, Teruya-Feldstein et al. (1999 and 2000)
have reported HRS cells are indeed capable of producing eotaxin. Another potential
source of eotaxin are eosinophils themselves, which they have been shown to be
capable of secreting (Nakajima et al., 1998). Despite these contradictory results, it is
highly likely in vivo that eotaxin may be released from, surrounding tissue, HRS
cells or eosinophils to cause the infiltration of eosinophils.
IL-8
As it has been shown in chapter 4, eosinophils produce IL-8 which is controlled by
NF-kB pathway. Some HRS cells are also capable of producing IL-8. For example,
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in tissue specimen from NS, IL-8 positive cells are commonly found (Gruss et al.,
1992). Interestingly in some cases neutrophil infiltration has been observed and
correlated weakly between IL-8 production and neutrophil numbers in the tissue
(Foss et al., 1996). Unfortunately in the paper by Foss et al. (1996) there has been
no investigation of whether IL-8 is responsible for eosinophil migration. In the cell
lines, HDLM2 and KMH2 express IL-8 gene expression has been reported (Gruss et
al., 1992) and CD40L induced IL-8 production has been observed (Gmss et al.,
1994).
IL-8 is a pro-inflammatory cytokines and neutrophilic chemoattractant. In vitro, IL-
8 may have the limited effect as an eosinophil chemoattractant under primed
condition (Schweizwe 1994, Sehmi 1993). Eosinophils primed with IL-5 migrate
more recruiting towards IL-8 than non primed eosinophils (Schweizwe 1994). But
eosinophils from subjects with an eosinophilia migrate to IL-8 without priming with
IL-5, but not those from normal subjects (Sehmi 1993). Therefore, IL-8 may not be
the direct chemoattractant for eosinophil migration, however, under certain
condtions, it enhances the effect of other chemoattractants.
On the other hand, in vivo, IL-8 may exert its effect to activate other types of cells
which may secret chemoattractant or activator factors to enhance eosinophil
recruitment. Therefore, it is possible that IL-8 may not be the direct candidate factor
in the recruitment of eosinophils in HD in vitro, but may be so in vivo. There is no
direct evidence suggesting that eosinophils from HRS tumour sites produce IL-8,
but if they do, positive feedback production of IL-8 would occur. In other words,
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the more eosinophils present at HRS cells, the more IL-8 secretion may occur
resulting in more infiltration of eosinophils.
TRAC
The CCR4 receptor binding CC chemokine, TRAC (Thymus and Activation
Regulated Chemokine) is known to be a strong activator of T cells. In L428 HRS
cell lines and some biopsy material that spontaneous expression of TRAC has been
shown (van den Berg et al., 1999 ). This in turn may recruit Th2 cells and
consequently possibly cause the recruitment of eosinophils.
6.1.9. TNFa
The pro-inflammatory cytokine TNFa is commonly expressed in HRS cell lines and
can be detected at the mRNA (Foss et al., 1996) and protein level (Xerri et al.,
1992, Kretshmer et al., 1990, Hsu et al., 1989). Also in clinical samples, Foss et al.
(1996) have reported that upon examination of 26 different tissue specimens all
were detected as being TNFa positive. TNFa is a powerful eosinophil activator via
the NF-kB pathway as it has been shown in chapter 3, 4 and 5. Secretion of TNFa
by HRS cells may activate and influence of eosinophils and other cells at tumour
sites. In this context TNFa at HRS cells may mimic the situation observed at the
inflammatory sites.
6.1.10. Lymphotoxin (TNFP)
Lymphotoxin (LT) or TNFP is another cytokine produced by HRS cells. The exact
function of LT in HRS cells is still under investigation, however, it may be involved
in collagen synthesis in fibroblasts (Semenzato et al., 1990) resulting in
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morphogensis of HRS cells. Also LT is a B-cell growth factor (Kehrl et al., 1987)
and so may be influential in the development of B-cell origin HRS cells and may be
important as a T-cell activator. The direct effect of LT on eosinophils has not been
reported. Therefore, the effect of LT on the survival of eosinophils is examined (see
results chapter).
6.1.11. IL-5, GM-CSF and IL-3
Both IL-3, IL-5 and GM-CSF are important eosinophil activators. IL-5 and GM-
CSF were detected by ELISA in supernatants from L428 and KMH2 but not from
HDLM2 (Kapp et al., 1999). On the other hand, controversially, gene expression of
IL-5 and GM-CSF has been detected by Northern blotting in HDLM2 and KMH2
by Gruss et al. (1992). There have also been reports showing that serum from some
patients with HD has the significantly higher levels of circulation of IL-3, GM-CSF
and other cytokines (Gause et al., 1992). Further studies are required to ascertain the
secretion of these cytokines from HRS cells.
IL-3, IL-5 and GM-CSF have been shown to be weak chemoattractants for
eosinophils in vitro (Yamaguchi 1988, Hori 1993). In Vivo, although there has been
shown the correlation between existence IL-5 level and eosinophlia in BAL from
asthmatics, it is likely that those cytokines are responsible for eosinophil priming
and activation and activation of other inflammatory and surrounding cells.
6.1.12. IL-13
IL-13 is a Th2 cytokine that binds to the alpha chain of the IL-4 receptor. IL-13 has
also been reported to be an important chemoattractant for eosinophils (Horie et al..
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1997). Fiumara et al. (2001) showed RANK (Receptor Activator of NF-kB) ligand
(RANKL) upregulates mRNA expression of IL-13, IL-13 receptors, IL-15 and IL-9
in HDLM2, HDMYZ, L428, and KMH2. It has been reported recently that IL-13
and IL-13 receptors prolong HRS cell survival (Kapp et al., 1999, Skinnider et al.,
2001), which may contribute to pathogenesis ofHD.
Although there have been numerous investigations, the list (table 6-1-7-B) is still far
from complete. Also, methods may be various and to see the completed list of the
study on major cytokines and chemokines expression from HRS cells will await
future studies.
6.1.13. Eosinophils and other cancers
The involvement of eosinophils in other cancers has been observed in both
haematological diseases, such as non-HD leukemia, and in non-haemotological
tissues, such as colon, lung and cervix. It is not yet established whether tissue
eosinophilia is a contributing factor to the tumour development or beneficial to the
host (Reviewed by Samoszuk, 1997). For example, Bethwait et al. (1993) showed
that patients with eosinophilia in carcinoma of the cervix in stage IB significantly
survived on average 5 years longer compared with the patients with less eosinophil
influx in the carcinoma. Also Dalai et al. (1992) have reported a better radiation
response in eosinophilia patients in cervical carcinoma. Thus, in cervix carcinoma
eosinophilia may be a beneficial response.
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In most endometrial cancer, degranulating eosinophils have been reported
(Blumenthal et al., 2000). This suggests that some eosinophil activation occurs in
endometrial cancer but whether this action is beneficial or deleterious to the patient
is currently unknown.
To investigate the effect of eosinophilia caused by IL-5, in vivo, an adenocarcinoma
cell line, TSA was transfected with IL5 and IL4 genes and injected in syngenic mice
(Di Carlo et al., 1998). TSA-IL5 tumour grew progressively in the presence of a
large number of eosinophils, suggesting that eosinophilia is contributing to the
progress of the disease. On the other hand, TSA-IL4 tumour was rejected in the
presence of activated neutrophils, basophils, mast cells, and macrophages.
Interestingly, some HRS cell lines inhibit neutrophil migration (Schell-Frederick et
al., 1998). If neutrophils have anti-tumour roles, in HD it could be one of the
reasons that HRS cells manage to escape the cytotoxic function of the immune
system.
In summary it appears that the beneficial effect of eosinophilia in cancer may be
dependent on the tumour type and the presence of cytokines and chemokines.
6.1.14. Interaction between HRS cells and eosinophils- phagocytosis by HRS
cells?
In vivo, there are numerous interactions between HRS cells and other cell types.
Possibly the most common interaction is the adherance of HRS cells with
accumulated inflammatory cells. This action may further influence activation status
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of the accumulated inflammatory cells. Another possibility of physical interaction is
phagocytosis or emperipolesis, in which there is passage of a cell into the cytoplasm
of another cell. In fact, in the 1970s and 80s some researchers had indeed reported
by microscopic observation that HRS cells are capable of phagocytosis or
emperipolesis of granulocytes and other cells. For example, Brooks et al. (1979)
reported that HRS cells engulfed some neutrophils but not eosinophils. Similarly,
Quaglino et al. (1977, 1979) demonstrated phagocytosis (or emperipolesis) of
erythrocytes, lymphocytes (also Kay et al., 1975) and granulocytes (unknown
whether they were neutrophils or eosinophils). Also, Poppema et al., (1978) and
Bernuau et al., (1977) showed the existence of Ig and human serum albumin within
HD cells, suggesting cell wall 'disruption'. Finally, in vitro, phagocytosis of
Candida albicans by HDLM-1 and KIM-H2 (Hsu et al., 1990), latex and ink
particles by SU/RH-HD-1 (Olsson et al., 1984) and HuTll (Roberts et al., 1987)
has been reported. The main purpose of these reports were to identify the origin of
the HRS cells by microscopic observation before all the new techniques, to identify
the phenotype and surface markers of HRS cells, were available. Therefore, seeing
phagocytosis or emperipolesis of HRS cells, in some reports, HRS cells were
determined as macrophage origin. However, except in the clinical biopsy samples,
in only established cell lines, HDMYZ has been suspected as macrophage origin
(Bargour et al., 1993).
The aims of this chapter are;
To investigate whether supernatants derived from HRS cells could influence
eosinophil and neutrophil survival.
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• To compare the effect of supernatants from HRS cells with IL-5 or GM-CSF on
the survival of eosinophils.
• To examine whether eosinophil survival effects are dependent on the NF-kB
pathway.
• To investigate the molecular mass of substance x by molecular mass separation
techniques.
• Observation ofphagocytosis of eosinophils by L540.
• However, in here, to identify the substance x is not our aim and intention.
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6.2. - 6.15. Results
6.2. Experimental methods
As it has been discussed in the introduction, the causes of eosinophilia at HRS cells
may be due to migration, activation and survival of eosinophils. Although there is
more than one cause of eosinophilia, our initial study was to investigate whether
HRS supernatants influence eosinophil survival and apoptosis.
To investigate the effect of eosinophil survival by HRS cells, freshly isolated
eosinophils were cultured with the supernatants of various HRS cell lines without
cells (experiments 6.2. to 6.12.) and co-incubation with HRS cells (experiments
6.13. to 6.15.). After the eosinophils were cultured for the time indicated in each
experiment, eosinophils survival was assessed by microscopic observation. The aim
of culturing eosinophils with supernatants of HRS cells is to understand the nature
of 'substance x' on eosinophil survival. In contrast, co-incubation with eosinophils
and HRS cells is to investigate the interaction between the two different types of
cells in vitro.
In the following sections, supernatants were harvested from various HRS cell lines,
L428, L540, L591, KMH2, HDLM2 and HDMYZ (see their origin and nature in
table 6-1-4). Each supernatant was incubated at 10% of the final volume with
eosinophils (3.0 xlO6 cells/ml) and neutrophils (5.0 xlO6 cells/ml). After the
indicated incubation times, eosinophils and neutrophils were harvested and
morphologically assessed for their survival rate. The reasons for assessing the
number of the cells surviving instead of undergoing apoptis is due to the long time
period of the culture, it was difficult to quantify apoptotic cells since they had
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Figure 6-2; Typical view of eosinophils treated with
supernatant L540. Eosinophils were cultured with 10% of final volume
of supernatant of L540 for 12 days. Survival rate was morphologically
assessed by percentage. Survived cells (S), ghost cells (G), apoptotic cells (A)
are indicated. Magnification x 63.
turned into 'ghost cells' or cell fragments. Thus, in this chapter, only healthy living
cells were morphologically counted in the cell population. For example, figure 6-2
shows a typical light microscopy view of healthy eosinophils treated with L540
supernatant at 12 days. The arrow indicates the dead 'ghost' cells (G), which are
difficult to determine whether it is apoptotic (A) or necrosis. Therefore, survival rate
was assessed instead of apoptosis. In addition, throughout the experiments, the
number of the cells/ml was counted to confirm the number of the cells in the
culture. In the following experiments, control condition indicates that it contains
10% of'blank' medium, in which all the HRS cell lines (except HDMYZ) are kept.
Only HDMYZ was kept at 20% of FCS in RPMI1640 instead of 10%.
Instead of using 10% of supernatant medium from HRS cell lines to treat
neutrophils, 5% or 20% of the supernatants were also tested (figure 6-4-b). There
was no great difference between 10% and 20% of supernatants on both eosinophils
and neutrophil survival. On the other hand, 5% of the supernatants had about half
effect on granulocyte survival that of 10%. In summary 10% was determined to be
the optimal percentage for this study.
In addition, supernatants were also taken from the different passages of HRS cell
lines on separate occasions and eosinophil survival was examined. Supernatants
obtained from different passages did not appear to make any difference (data not
shown).
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6.3. The effect of supernatants obtained from HRS cell lines on eosinophil
survival.
To examine the different effects of supernatants from various HRS cell lines on
eosinophil survival, eosinophils were cultured with 10% of total volume of
supernatants from various HRS cell lines. After 7 days, cells were harvested and the
survival of cells were morphologically assessed.
The results are shown in figure 6-3 and 6-3-B. In here, control is indicated as 'C' and
contains 10% of'blank' medium (10% FCS in RPMI1640) in which all the HRS cell
lines, except HDMYZ, are kept. The eosinophils treated with L428 and L540
showed significantly prolonged longevity, compared to other conditions and GM-
CSF. As it has been demonstrated previously the rate of constitutive eosinophil
apoptosis in vitro is normally about between 4 to 7 days. Thus, it is striking that
eosinophil survival was induced by the supernatants of L540 (about 7 fold
compared to C) (see figure 6-3-B) and L428 (about 5 fold compared to C) for 7
days. Furthermore, in some occasions, some eosinophils survived up to 28 days
when treated with L540 supernatant (data not shown).
On the other hand, supernatants from other cells lines, L591, KMH2, HDLM2 and
NDMYZ did not show any significant survival effect compared to control
conditions. The difference between the most and least effective supernatants is not
known. To examine the origin and nature of the cells (see table 6-1-4) and
generation of cytokines and chemokines (see table 6-1-7-B), there appears be no






























Figure 6-3; Effect of supernatants from HRS cell lines on eosinophil
survival. Purified eosinophils (3.0 x 106 cells/ml), cultured in Iscove's DMEM
containing 10% autologous serum, were treated with 10% of supernatants from
different types of HRS cell lines and GM-CSF (500ng/ml)and kept at 37°C for 7
days. 'C' indicates the control condition with 'blank' medium, containing 10% FCS
in RPMI1640, in which all the HRS cell lines were kept, except HDMYZ. After 7
days cell survival was morphologically assessed. All the values represent mean with
standard error from four different donors. Supernatant from L540 and L428 showed








Figure 6-3-B; L540 supernatant treated eosinophils. Eosinophils
were cultured with supernatant from L540 cell line for 7 days (panel below).
Panel above shows the control condition, without any treatment for 7 days.
(Magnification x 63).
generations/passage of the HRS cell culture. They all show a similar trend in that
L428 and L540 have a greater effect on eosinophil survival.
Since L540 and L428 showed the best eosinophil survival effects, both supernatants
were selected for further experiments.
Dose response curve shows (figure 6-4- B) shows the correlation between
eosinophil survival and dose of supernatant from different HD cell lines. However,
10 % of supernatant was chosen as the concentration for the following experiments.
Summary
• L428 and L540 supernatants showed significantly prolonged survival of
eosinophils assessed after 7 days culture.
L591, KMH2, HDLM2, HDMYZ supernatants did not show any significant
effect on eosinophil survival after 7 days culture.
• The reasons for the difference between the cell lines which had a 'survival effect'
(L428 and L540), and those that had 'no-survival effect' (L591, KMH2,
HDLM2, HDMYZ) are not known.
• Dose response curve shows (figure 6-4- B) shows the correlation between
neutrophil survival and dose of supernatant from different HD cell lines.
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6.4. The effect of supernatants obtained from HRS cell lines on neutrophil
survival.
In HD, neutrophils are also occasionally observed at the tumour, although the
number of neutrophils are less notable than eosinophils. Similarly to eosinophils,
the causes ofneutrophil accumulation at the tumour is unknown.
To investigate whether supernatants of HRS cell lines may also influence neutrophil
survival, the same type of experiments as outlined as above (6.3.) were performed
on neutrophils incubated for 24 hours culture, at the time approximately 60 - 90% of
the non-treated cells spontaneously become apoptotic. All the experimental methods
were the same as above.
The results are shown in figure 6-4 and 6-4-B. Similar to eosinophils, L428 and
L540 supematants exerted significant neutrophil survival. Compared to the control
condition, L428 supernatant induced about 6 fold and L540 was about 7 fold greater
percentage in survival. Remarkably, neutrophils treated with L540 supernatant
occasionally survived up to 7 days (data not shown). This is a phenomenal result, to
be able to keep neutrophils alive for 7 days in vitro.
Although, the effects are not as great as L428 and L540, L591 and KMH2
supernatants showed efficient neutrophils survival effects compared to the control
condition. Both HDLM2 and MDMYZ supematants had very little effect on
neutrophil survival compared to control condition.
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Figure 6-4; Effect of supernatants of HRS cell lines on neutrophil
survival. Purified neutrophils (5.0 x 106 cells/ml), cultured in Iscove's DMEM
containing 10% autologous serum, were treated with 10% of supernatants from
different types of HRS cell lines and kept at 37°C for 24 hours. 'C' indicates the
control condition with 'blank' medium, containing 10% FCS in RPMI1640, in which
all the HRS cell lines were kept, except HDMYZ. After 7 days cell survival was
morphologically assessed. All the values represent mean with standard error from
four different donors. Supernatant from L540 and L428 showed significant
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Figure 6-4-B; Effect of dose response on supernatants of HRS cell
lines on neutrophil survival. Purified neutrophils (5.0 x 106 cells/ml), cultured
in Iscove's DMEM containing 10% autologous serum, were treated with 2.5%, 5.0%,
10% and 20% of supernatants from different types of HRS cell lines and kept at 37°C
for 24 hours. 'C' indicates the control condition with 'blank' medium, containing
2.5%, 5.0%, 10% and 20% FCS in RPMI1640, in which all the HRS cell lines were
kept, except HDMYZ. After 7 days cell survival was morphologically assessed. All
the values represent mean with standard error from four different donors.
Although neutrophils and eosinophils are derived from a common myeloid
precursor, they do have a different cellular metabolism and are activated differently,
therefore, different stimuli would cause different effects on their survival or
apoptosis. The supematants of L591, KMH2, and HDMYZ may be more efficient at
inducing survival effect in neutrophils compared to eosinophils. Although the
incubation times were different in each cell type, therefore, it may not be a straight
comparative study, however, if each supematants are compared to the control
condition, the different effect is clearly significant. In those supematants, they may
contain a substance(s), which is specific to neutrophil survival but not eosinophils.
In contrast, since L428 and L540 exert their effects on neutrophils survival, they
may also contain substances that induce survival in both neutrophils and
eosinophils.
Dose response curve shows (figure 6-4- B) shows the correlation between
neutrophil survival and dose of supernatant from different HD cell lines.
Summary
L428 and L540 supematants exerted prolonged neutrophil survival.
L428 and L540 may contain common survival factors for both neutrophils and
eosinophils.
L591, KMH2, HDLM2 and HDMYZ supematants induce neutrophil survival
but could not cause eosinophil survival.
L591, ICMH2, HDLM2 and HDMYZ may produce neutrophil specific survival
factors.
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Dose response curve shows (figure 6-4- B) shows the correlation between
neutrophil survival and dose of supernatant from different HD cell lines.
6.5. Supernatant of L540 is more efficient at prolonging eosinophil survival
than IL-5 and GM-CSF.
To assess the effect of L540 supernatant on eosinophil survival compared to other
known eosinophil survival factors, IL-5 and GM-CSF were chosen for comparison.
Both IL-5 and GM-CSF share the P subunit of receptors and trigger tyrosine kinases
pathways to influence survival (Yousefi et al., 1996, Paxdrak et al., 1997) and delay
apoptosis (Tai etal., 1991, Stern et al., 1992, Yamaguchi et al., 1991)
Eosinophils were cultured with IL-5 (50ng/ml) and GM-CSF (500ng/ml) for 7 days
and the rate of survival was assessed morphologically. The results are shown in
figure 6-5. For 7 days culture, L540 showed on average a slightly better effect on
eosinophil survival than IL-5 and GM-CSF alone.
This result may suggest that supernatant from L540 contains a 'stronger' survival
factor than a single incubation of 50ng/ml IL-5 or 500ng/ml GM-CSF. Previously,
we had performed concentration-response experiments of IL-5 and GM-CSF on
eosinophil survival and concluded that these concentration used were optimal.
Regardless of the existence of IL-5 and GM-CSF in the supernatant of L540, there













Figure 6-5; Effect of GM-CSF, IL-5, anti-GM-CSF antibody, anti-
IL-5 antibody and supernatant from L540 HRS cell line on
eosinophil survival. Purified eosinophils (3.0 x 106 cells/ml) cultured in Iscove's
DMEM containing 10% autologous serum were treated with GM-CSF (500ng/ml),
IL-5 (50ng/ml) and 10% of supernatant from L540 HRS cell line and kept at 37°C for
7 days. 'C' indicates the control condition with 'blank' medium, containing 10%
FCS in RPMI1640, in which all the HRS cell lines were kept, except HDMYZ. After
7 days cell survival was morphologically assessed. All the values represent mean
with standard error from four different donors. Supernatant from L540 showed the
significant differences from control indicated as * where P<0.01.
Preliminary, using anti-IL-5 and GM-CSF antibodies, neutralising experiment were
performed. However, there was no effect on supernatant of L540 to inhibit its effect
(data not shown). Unfortunately, this experiment could not be continued. (See
discussion 6.16.1. for more details.)
Summary
Supernatant of L540 exerted a slightly better effect on eosinophil survival
assessed 7 days culture compared to IL-5 and GM-CSF.
6.6. Lymphotoxin on eosinophil survival
Lymphotoxin (LT) or TNFp is produced in abundance by almost all the HRS cell
lines (Foss et al., 1993, Gruss et al., 1992). In particular in the supernatant derived
from L540 LT is present. LT is involved in the activation of T cells and B cells and
possibly HRS cells themselves. Little is known of the effect of LT on eosinophil
function and there have been no prior reports on eosinophils survival or apoptosis
by LT. To investigate if LT is playing any roles on eosinophil survival, LT was
cultured with eosinophils and survival was assessed.
The results are shown in figure 6-6. For 7 days culture, at the different
concentrations of LT used no significant effect on eosinophil survival was observed.
Although HRS cells secrete substantial amounts of LT, it appears that there is no
effect of LT on eosinophils survival. In the supernatant of L540, other substances




















Figure 6-6; Effect of Lymphotoxin (LT) on eosinophil survival.
Purified eosinophils (3.0 x 106 cells/ml) cultured in Iscove's DMEM containing 10%
autologous serum were treated with LT for 7 days. On Y-axis, • indicates as a
control condition without any treatment. X indicates as a 10% L540 supernatant-
treated eosinophil survival. After 7 days cell survival was morphologically assessed.
This is a representative experiment.
some other inflammatory cells at tumour but not the direct cause of eosinophil
survival.
Summary
LT does not appear to have any effect on eosinophil survival.
6.7. LT on neutrophil survival
LT was previously shown to enhance neutrophil phagocytosis (Shalaby et al., 1985)
However, there are no reports on the effect of LT on neutrophil apoptosis or
survival. To investigate the effect of LT on neutrophil survival, LT was cultured
with neutrophils for 24 hours and 48 hours and survival assessed.
The results are as shown in figure 6-7. After 24 hours culture, there was a slight
effect of LT on neutrophil survival especially at the higher concentration. At 48
hours, although the survival rate was substantially lower, some surviving cells were
observed, while there was none in the control condition. Therefore, LT may also
have a slight effect on neuturophil survival at 48 hours. However, at both time
points, the survival rate was not as high as the supernatant of HRS cells (e.g., L540).
LT is unlikely to be the direct cause of neutrophil survival. Thus, in the supernatant
of L540, other factors may be responsible for neutrophil survival.
Summary
LT may have a slight effect on neutrophil survival.





















Figure 6-7; Effect of Lymphotoxin (LT) on neutrophils survival.
Purified neutrophils (5.0 x 106 cells/ml) cultured in Iscove's DMEM containing 10%
autologous serum were treated with LT for 24 and 48 hours. On Y-axis, □ indicates
the control condition without any treatment at 24 hours. X indicates as a 10% L540
supernatant-treated eosinophil survival. At 48 hours under control conditions without
any treatment (A), no cells survived. After 24 and 48 hours cell survival was
morphologically assessed. This is a representative experiment.
6.8. Abrogation of L540-supernatant-induced eosinophil survival by NF-kB
inhibitors.
As it has been shown in the previous chapters, the NF-kB pathway plays an
essential role in eosinophil survival. To investigate the involvement of NF-kB in
L540-supernatant-induced eosinophil survival, eosinophils were cultured with NF-
kB inhibitors in the presence of supernatants of L540. The NF-kB inhibitors used
were Mgl32 (20pM) and TAT-hcBa32,36 (30pg/ml) and as a control GST-TAT
(30pg/ml).
The results from two different donors (panel A and B) are shown in figure 6-8.
Firstly, freshly isolated eosinophils were treated with 10% of L540 supernatant for 5
days. Then, NF-kB inhibitors were added to the culture. In panel A in figure 6-8,
there is a clear inhibition of eosinophil survival by TAT-IkBcc32,36. As shown in
chapter 5, the efficiency of TAT-hcBa32,36 may be donor-dependent. However, in
these experiments, using three different donors, all showed inhibition of L540-
supernatant-induced eosinophil survival. Similarly, graph B in figure 6-8 shows that
L540-supernatant-induced eosinophil survival was inhibited by TAT-IkBoc32,36
and Mgl32 in 7 days of culture. Mgl32 induced a dramatic killing effect on
eosinophils. GST-TAT showed a small inhibition of the survival effect induced by
L540 supernatant.
By using different NF-kB inhibitors, these results show that L540-supernatant-














































Figure 6-8; The effect of incubation with various NF-kB inhibitors
on eosinophils which had been previously treated with the
supernatant of L540 HRS cell line. Purified eosinophils (3.0 x 106 cells/ml)
cultured in Iscove's DMEM containing 10% autologous serum, were treated with
10% of supernatants from L540 HRS cell lines for 5 days. Then various NF-kB
inhibitors were added. Eosinophils used in panel A and B are from different donors.
From day 5 cells survival was morphologically assessed. These are represent
experiments out of three different experiments performed on separate occasions.
pathway appears to play an important role in controlling L540-supernatant-induced
eosinophil survival.
Summary
• TAT-lKBa32,36 inhibits L540-induced eosinophil survival.
• Mgl32 inhibits L540-induced eosinophil survival.
• Inhibition ofNF-kB abrogates L540-induced eosinophil survival.
6.9. Abrogation of eosinophil survival by NF-kB inhibitors cannot be reversed
by supernatant from L540.
In the next series of experiments, NF-kB inhibitors were cultured with eosinophils
before the addition of L540 supernatant. The aim of these experiment was to
investigate whether the effect of L540 supernatant can 'rescue' eosinophils, which
had been previously treated with NF-kB inhibitors. TAT-IkB(x32,36 (30pg/ml),
GST-TAT (30|o.g/ml) and Mgl32 (20pM) were added to eosinophils culture for 24
hours and then supernatants from L540 was added.
Purified eosinophils were cultured with NF-kB inhibitors or un-treated (indicated as
'C'), for 24 hours, then, supernatant of L540 were added (filled circle) or none (open
triangle). In control condition 'C', addition of supernatant of L540 'rescued'
eosinophils from constitutive apoptosis. For example at day 4, the survival rate of
untreated eosinophils was about 15%, whereas L540 supernatant treated cells
showed a good survival rate (60%). This is significantly different from cells without


































Figure 6-9; The effect of incubation with various NF-kB inhibitors
on eosinophils for a day before treatment with the supernatant from
L540 HRS cell line. Purified eosinophils (3.0 x 106 cells/ ml) cultured in Iscove's
DMEM containing 10% autologous serum, were treated with various NF-kB
inhibitors for one day. Then 10% of supernatants from L540 HRS cell line were
added to those cultures. 'C' indicates the control condition without any inhibitors.
Eosinophil survival was morphologically assessed from day one. These are represent
experiments out of three different experiments performed on separate time.
TAT. GST-TAT+L540 treated cells also showed a better survival rate compared to
the GST-TAT only. These results indicate that L540 supernatant can prolong
eosinophils survival after one-day of eosinophil culture.
In contrast, incubation with NF-kB inhibitors for 24 hours, eosinophils underwent
apoptosis. For example, the survival rate treated with Mgl32 was about 15%, TAT-
IkBcx was about 40% in 24 hours culture. However, after the addition of L540
supernatant, in both conditions L540 supernatant could not 'rescue' the inhibition of
eosinophil survival. These results suggest that eosinophil survival may be regulated
by the NF-kB pathway. Once the NF-kB pathway is inhibited by Mgl32 and TAT-
IicBa32,36, L540 supernatant cannot reverse the fate of the cells.
Summary
• Supernatant from L540 exerts its effect on survival on one-day-old (untreated)
eosinophils.
• Supernatant from L540 exerts its effect on eosinophil survival which had been
previously treated with GST-TAT for 24 hours.
• Supernatant from L540 does not exert its effect on survival on eosinophils,
which had been previously cultured with TAT-h<Ba32,36 and Mgl32 for one
day.
• These data suggest the involvement of the NF-kB pathway in L540-supernatant-
induced eosinophil survival.
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6.10. Separation of supernatant of L540 by molecular mass and their survival
effect on eosinophils.
To identify substance x will require extensive investigation. (For further discussion
of screening process is discussed in the discussion 6.16.1.) However, to attempt to
determine the possible candidates for substance x, isolation of the supernatant
according to the molecular mass by centrifugation was performed (see methods
2.12.3.). The supernatants were isolated as; x<10KDa, 10KDa<x<30KDa,
30KDa<x<50KDa, 50KDa<x. Each fractions of supernatants were cultured with
eosinophils for up to 10 days and survival rate was assessed.
The results are shown in figure 6-10. 'L540' indicates the supernatant without
centrifugation. The fraction smaller than lOKDa (x<10KDa) showed very low
eosinophil survival in 5 days and none at 10 days. Although the precise content of
supernatant less than 1 OKDa is not known, it is likely to contain chemokines, lipids,
peptides etc. Interestingly, chemokines which are known eosinophils activators,
chemoattractants and survival factors are usually less than lOKDa (see table 6-1-7-
A for summary). Thus, it may be possible to eliminate these low molecular weight
produces from the list of candidates for substance x. Substances bigger than lOKDa
are the likely eosinophil survival factors.
The fraction between lOKDa and 30KDa (10KDa<x<30KDa) showed less survival
effect in both 5 and 10 days compared to the whole L540 supernatant. The fraction
between 30KDa and 50KDa (30KDa<x<50KDa) showed similar survival effect to





L540 x<10 10<x<30 30<x<50 x>50 (KDa)
Figure 6-10; The effect of the incubation with the supernatant of
L540 HRS cells, in which the contents of the supernatants had been
separated according to molecular mass. Purified eosinophils (3.0 x 106
cells/ml) cultured in Iscove's DMEM containing 10% autologous serum, were treated
with 10% of supernatants from L540 HRS cell line in which the contents of the
supernatant had been separated according to molecular mass by a series of
centrifugations. 'L540' indicates the control condition which has been treated with
whole L540 supernatant (10%). Then eosinophil survival after 5 days or 10 days
were assessed morphologically. All the values represent mean with standard error of
three different donors.
The fraction, which is bigger than 50KDa (x>50KDa) showed good survival effects,
similar to uncentrifuged supernatant of L540 after 5 and 10 days. Even, after 10
days culture, x>50KDa showed a better survival effect than the whole supernatant
of L540. This indicates the presence of powerful eosinophil survival factors in the
x>50KDa fraction.
Summary
• In L540 supernatant, the fraction, which is smaller than lOKDa does not contain
the eosinophil survival factor.
• In L540 supernatant, the fraction, which is bigger than 50KDa may contain the
strong eosinophil survival factor.
6.11. Separation of supernatant of L428 by molecular mass and their survival
effect on eosinophils.
The same experiment as above (6.10.) was performed using the supernatant derived
from L428. The results are shown in figure 6-11. Compared to whole L540, whole
L428 exerted less eosinophil survival after 10 days culture. With the exception of
this time point, a similar trend was seen with L428 culture compared to L540. The
fraction less than lOKDa (x<10KDa) has dramatically reduced survival effect
assessed after 5 days and none after 10 days. Again, the possibility of chemokines
as the eosinophil survival factors can be ruled out. On the other hand, fractions
bigger than 30KDa (30KDa<x<50KDa and x>50KDa) showed better eosinophil
survival especially after 5 and 10 days. Therefore, the fractions bigger than 30KDa
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L428 x<10 10<x<30 30<x<50 x>50 (KDa)
Figure 6-11; The effect of the incubation with the supernatant of
L428 HRS cells, in which the contents of the supernatants had been
separated according to molecular mass. Purified eosinophils (3.0 x 106
cells/ml) cultured in Iscove's DMEM containing 10% autologous serum, were treated
with 10% of supernatants from L428 HRS cell line in which the contents of the
supernatant had been separated according to molecular mass by a series of
centrifugations. 'L428' indicates the control condition which has been treated with
whole L428 supernatant (10%). Then eosinophil survival after 5 days or 10 days
were assessed morphologically. All the values represent mean with standard error of
three different donors.
contains the eosinophils survival factor in the supernatant of L428. The fraction
between 10 and 30KDa (10KDa<x<30KDa) showed very similar rates of eosinophil
survival compared to the whole L428.
Summary
In L428 supernatant, the fraction, which is smaller than lOKDa does not contain
the eosinophil survival factor.
In L428 supernatant, the fraction, which is bigger than 30KDa contains the
eosinophil survival factor.
6.12. Separation of supernatant of L540 by molecular mass and heat shocked
To investigate further the isolated fraction from supernatant of L540 (6.10.), the
fractions were examined to see whether they contained heat resistance substances or
not. Each fractions were heat shocked at 40°C, 60°C, 80°C and 100°C for 15 minutes
and cultured (10% of final volume) with eosinophils for up to 10 days and the
survival rate was assessed. The results are shown in figure 6-12.
In the whole supernatant, in 5 days culture, despite heat treatment for the different
temperatures, there was no significant differences on eosinophil survival. In
contrast, after 10 days culture, heat treated supernatants failed to prolong survival
compared to the non-heat-treated condition. This indicates that some survival
factors in the supernatant of L540 are heat unstable.
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Figure6-12;Theffectofincubationwithsupernata tL540,hichhadbe n separatedaccor ingtomolecularssndh thocke .Purifieeosinophils(3.0xlO6 cells/ml)ulturedinIscove'sDMEMontaining10%a tologouss r mwetreati hf supernatantsfromL540HRSc lllini whichtheont ntsfrnatanthadbesolat dccording
tomolecularassbyhseriefcentrifugations.Iadditi ,h seupernatanthe ttr at dfr m 40°Cto1 0°for5minutes.'NH'indicatasnon-heated.'L54hc roldi i nwhich iswholeL54010%supernatant.Th neosin philurvivaafterd ysr0morpho ogically assessed.Allthva u srepre ntm awithst ndarder orofdiff r ntonors
Fractions bigger than 30KDa (30KDa<x<50KDa and x>50KDa) showed a very
similar pattern to whole supernatant. Indeed, in 5 days culture, heat shock treatment
did not affect any survival rates. However, in 10 days heat shock treatment actually
reduced their survival effect. These indicate that the fractions in 30KDa<x<50KDa
and x>50KDa contain some heat unstable substances. They may be such as peptides
and proteins.
On the other hand in the fraction less than 30KDa (x<10KDa and
10KDa<x<30KDa) the pattern of the survival rate showed differently. In these
cases, heat shock treatment actually improved the survival rates. This indicates that
these fractions may contain heat stable survival factors, and heat unstable pro-
apoptotic factors. After heat treatment, heat stable substances, for example, lipid,
may be responsible for eosinophil survival. Oh the other hand, the heat unstable
substance, for example protein, may be acting as an inhibitor of survival. However,
it is likely that substances x is heat stable in this fraction.
Table 6-12 and figure 6-12-B summarise this experiment. It may be possible to
conclude that substance x in the fraction smaller than 30KDa is a heat stable
substance (e.g., lipid), but in fractions bigger than 30KDa is heat unstable substance
(e.g., protein).
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O heat unstable substance,e.g. protein
heat stable substance,e.g. lipid
survival inducer
|H survival inhibitor
Figure 6-12-B; Summary of the experiment (6-2-11) molecular weight
cut off and heat shock. Fractions bigger than 30KDa contain eosinophil survival
inducers, which are heat unstable, such as protein, but smaller than 30KDa contains
eosinophil survival inhibitor, which are heat stable, such as lipid.
days heat L540 x<10 10<x<30 30<x<50 x>50
5
stable ic survival survival ic ic
unstable ic inhibition inhibition ic ic
10
stable inhibition? survival ? ?
unstable survival inhibition survival? survival
Table 6-12; Summarised from the heat shock experiment (figure 6-
12, 6-12-B). 'survival' indicates that they contain eosinophils survival factors,
'inhibition' indicates inhibition of eosinophil survival, 'ic' indicates that the
results are inconclusive. Isolation ofmolecular mass is KDa.
Additionally, if chemokines exist in the supernatant of L540, they are in the fraction
less than lOKDa. Heat treatment should disturb the structures and function of
chemokines. In the fraction less than lOKDa, after the heat treatment, survival rate
was in fact improved. Therefore, it is unlikely that chemokines are the eosinophil
survival factors in the supernatant of L540.
Summary
• The fraction bigger than 30KDa may contain the eosinophil survival factors
which are heat unstable, such as proteins and peptides.
• The fraction smaller than 30KDa may contain the eosinophil survival factors
which are heat stable, such as lipids.
• The fraction smaller than 30KDa may contain the pro-apoptotic substances,
which are heat unstable, such as proteins and peptides.
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• It is unlikely that chemokines in the supernatant of L540 are the eosinophil
survival factors.
6.13. Co-culture with eosinophils and L540 cells, phagocytosis by L540 cells
Previous experiments were focused on eosinophil survival by supernatants derived
from HRS cell lines. This time to investigate the interaction between HRS cells and
eosinophils further, in the following experiments, eosinophils were cultured with
L540 cells.
When eosinophils and L540 cells were co-cultured together in vitro, there were
interesting phenomena observed. They were 1) eosinophils were phagocytosed by
L540 cells, 2) increased number of multinucleated L540 cells (see 6.14.), 3)
disappearance of eosinophils or L540 cells, depending on the ratio of the cells in the
culture (see 6.15.).
Phagocytosis activities by HRS cells have been occasionally reported (see
introduction 6.1.14.), however, there are no reports of phagocytosis by the T cell
derived L540 cells. During the co-culture with L540 and eosinophils, observed
frequent phagocytosis or phagocytosis-like activities by L540 are shown in figure 6-
13. Typically, L540 extended its 'hand' like structures to surround eosinophils for
possible engulffnent. This feature was more commonly observed when L540
became bigger and multinucleated (see 6.14., 6.15.).
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Figure 6-13; Phagocytosis of eosinophils by L540 cell. When eosinophils
and L540 cells were co-cultured together, phagocytosis or -like phenomena were
frequently observed, (magnification x 100)
This is the first report showing that L540 cells may have the ability to phagocytosis
other cells.
Ingested eosinophils by L540 cells were both apoptotic and viable. The precise
mechanism is unknown.
Summary
L540 cells may phagocytose eosinophils during co-culture.
. Engulfed eosinophils were both viable and apoptotic.
6.14. Multinucleated HRS cells
By definition, Hodgkin cells possess one nucleus per cell and Reed-Stemberg cells
possess more than two nuclei per cell. In addition, multinucleated Reed-Stemberg
cells are generally regarded as being a more aggressive and advanced form of
cancerous cells. As shown in figure 6-1-2, isolated HRS cells from biopsy samples
often are multinucleated with condensed chromatin like structures within the nuclei.
Usually in cell culture L540 are single nucleated cells, about 95% mono-nucleated,
5% multinucleated. As shown in figure 6-14-A, in non-stimulated L540 cells, most
of the cells are single nucleated cells. (L540 cells have a T cell morphological
phenotype.) When L540 cells were co-cultured with eosinophils, in 7-10 days
culture, the number of multinuclear L540 increased (see figure 6-14-B for the
graph). Those multinucleated cells possessed features similar to HRS cells obtained




Figure 6-14-A; The turn over
of HRS cells. HRS cells L540 were
cultured with eosinophils for the time
indicated. From single nucleated
L540 at the resting stage (day 0),
soon after co-cultured with
eosinophils, the number ofmulti¬
nucleated cells were increased (day 9
and 11). After 16 days, the majority
of HRS cells became the single
nucleus cells, again. (Magnification x
100)
Figure 6-14-B; The relationship between eosinophil number and
multi-nucleated L540 cells. Purified eosinophils (1.0 x 106 cells) were cultured
with L540 cells in RPMI1640 containing 10% FCS and kept at 37 0 C for 16 days.
The number of eosinophils (•) and multi-nuclei L540 cells (A)were counted. All the
values represent mean with standard error of three experiments performed on the
separate occasions. The number of multinucleated L540 cells increased between 8
and 10 days but decreases after the peak. In contrast eosinophils number kept
decreasing and no eosinophils after 11 days.
However, after a certain period of culture the number of multinucleated cells
decreased and eventually went back to the basal levels.
To investigate if there was any correlation between eosinophils and multinucleated
cells of L540, the number of both of them were counted and the results are shown in
figure 6-14-B. Eosinophil numbers steadily declined during co-culturing with L540.
In contrast the number ofmultinucleated L540 cells increased at between day 8 and
10 and then decreased after this peak.
The mechanism regulating the ability of those cells to become multinucleated cells,
which is believed to be the more aggressive form of cancerous cells, is currently
unknown. However, it may be that some stimuli liberated by eosinophils change the
appearance of L540 cells.
To further elucidate the causes of multinucleated cells by eosinophils, as the next
experiment investigated, eosinophils may be added constantly or after an interval of
certain periods to the L540 cell culture to observe the correlation between the
number of those cells in the cell culture.
The same experiment was also performed on eosinophils and Jurkat cells, which are
T cell leukaemia cells. No increase in the number of multinucleated cells were
observed (data not shown).
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Summary
Multinucleated L540 cell numbers increased about 8-10 days after co-culture
with eosinophils.
Once eosinophils disappear from the culture, the number of multinucleated
L540 cells declined.
6.15. Ratio study
As it has been shown in 6.14., the increase in multinucleated cell number may be
directly influenced by eosinophils. To investigate the relation between eosinophils
and L540 cells further, differing numbers and ratios of eosinophils and L540 cells
were co-cultured for up to 7 days. Eosinophils were added to L540 cells, the same
number (eosinophils: L540 cells = 1:1) or 10 times L540 cells (eosinophils: L540
cells = 10:1) were examined. The results are shawn in figure 6-15-A.
After 3 days incubation, one of the obvious features was that eosinophils and L540
cells attached to each other. After 7 days of incubation, the effects of the different
ratios of the cells was striking. The ratio of eosinophils: L540 cells =1:1 (figure 6-
15-A), after 7 days, eosinophils disappeared from the culture (figure 6-15-A shows
3, 6 and lOdays). In contrast, eosinophils: L540 cells =10:1 (figure 6-15-A-2)
culture showed no L540 cells but only eosinophils survived. The reasons for
disappearance of eosinophils or L540 cells are not clear. However, it may be due to
phagocytosis or 'uptake' of eosinophils into L540 cells. On the other hand,
eosinophils might exhibit on ability for killing as they do for parasitic invaders. This
will be discussed further in discussion 6.16.5.
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Figure 6-15-A-l; Co-culture of eosinophils and L540. Eosinophils and
L540 cells were co-cultured at a 1:1 ratio for the time indicated. Eosinophils were
gradually disappeared but L540 cells survived on day 10. Magnification x 63.
eosinophils: L540 cells = 10:1
Continued to the next page
eosinophils: L540 cells = 10:1
Figure 6-15-A-2; Co-culture of eosinophils and L540. Eosinophils and L540 cells
were co-cultured at a 10:1 ratio for the time indicated. L540 cells were gradually disappeared
but eosinophils survived on day 10. Magnification x 63.
Figure 6-15-B; Interaction between eosinophils and L540 ceils.
Eosinophils and L540 cells were co-cultured for 5 days. Eosinophil granules are
seen in the cytoplasm of L540 cells. (Magnification x 100)
Figure 6-15-C; Co-cultured L540 cells and eosinophils are positively
transfected by Ad-|3gal. L540 cells (indicated as black arrow) and eosinophils
(white arrow) were co-cultured together for 2 days and transfected with Adeno-Pgal for
6 hours. Eosinophils attached to L540 cells were successfully transfected and showed
Pgal stained. (Magnification x 32 panel above, x 63 panel below.)
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Figure 6-15-D; Effect of supernatant from L-540-supernatant-
treated eosinophil and supernatant from L540 HRS cell line (B) on
L540 survival. L540 (3.0 x 106 cells/ml) cultured in RPMI 1640 containing 10%
FCS serum were treated with 10% of supernatant from L-540-supernatant-treated
eosinophil (B) or without (A) and kept at 37°C for 5 days. After 5 days cell survival
was assessed by trypan blue.
To extend this point, experiments were performed to investigate whether the release
of granules contents from eosinophils may act to inhibit L540 cell survival (figure
6-15-D). Eosinophils were incubated with supernatants of L540 for 7 days. Then,
the supernatant of this L540-supernatant-treated eosinophils culture was taken and
put back into L540 culture, where the original supernatant from L540 came from.
After 5 days, all L540 cells died. These experiments indicate that some toxic or
apoptosis inducing substances from eosinophils may cause L540 cell death.
The contact between cells were so close that they appear to have fused into one cell
in some cases. Those cells are shown in figure 6-15-B. Strangely, in some cases,
eosinophils granules (stained in orange colour) were seen in the cytoplasm of L540
cells, indicated as black arrows. These cells were prepared by cytospin
centrifugation and may therefore be subject to artifactual interpretation.
Interestingly, when those 'fused' cells were transfected with Adeno virus-Pgal (Ad-
Pgal), eosinophils, which cannot be transfected by Adeno virus due to a lack of
receptors, were indeed successfully transfected. (This experiment was kindly done
by Dr Sallenave, CIR lab, University of Edinburgh.) These results are shown in
figure 6-15-C. The precise reason for Ad-Pgal transfection of those eosinophils is
not known. However, this may indicate that L540 cells and eosinophils may be
partially fused. Further studies are however required to investigate this intriguing
hypothesis.
The relation between eosinophils and L540 cells is very peculiar and to our
knowledge has never been reported before. There are some physical interactions
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between eosinophils, L540 cells and some substances released by eosinophils may
have an ability to kill L540 cells. These are very interesting observations and many
experiments have to be performed to investigate further.
Summary
. When the ratio of eosinophils: L540 cells =1:1, only L540 survived.
When the ratio of eosinophils: L540 cells =10:1, only eosinophils survived.
. Eosinophils and L540 cells may be fused and share the cellular features.




The studies herein have sought to elucidate the effects of eosinophilia and
neutrophilia by HRS cells. The results presented in this chapter are unique and may
be the first steps to understand eosinophil recruitment and survival at tumours of
HD.
6.16.1. The substance x in L540 make eosinophils prolong their longevity.
Supematants of L540 and L428 exerted for the first time a striking effect on both
eosinophil and neutrophil survival. It is clear that there are strong eosinophil and
neutrophil survival factors, substance x, in those supernatants. This substance x
could be a known or an unknown factor or a cocktail of different factors.
However, from the experiments where supernatant of L540 was separated by
molecular mass and exposed to different temperatures (6.10. to 6.12.), some
interesting findings were made. (See also figure 6-12-B for summary.) Substances
bigger than 30KDa and heat unstable, such as cytokines, proteins, etc., are likely to
be the eosinophil survival factors. In contrast, substances smaller than 30KDa and
heat stable, such as lipid and other low molecular weight substances may be the
survival factors. From these results, substance x may be a cocktail of different
substances of a various molecular masses and nature. Interestingly, substances less
than lOKDa and heat unstable, such as peptides and small proteins, may be
inhibitory factors for eosinophil survival. This might also include certain
chemokines. Chemokines are known as the powerful eosinophil chemoattractants
and survival factors, however, they can be ruled out from the list of candidates of
eosinophils survival factors in these studies. On the contrary cytokines with
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molecular mass bigger than 30KDa, may be candidates as survival factors. To
investigate what cytokines are in the supernatants of L540, a series of targeted
ELISA may be the direct way to determine. Although as shown in the table 6-1-7-B,
there have been reports showing the production of various cytokines and
chemokines from HRS cells and clinical samples. However, the list is still
incomplete due to the lack of consistency of the methodology used to determine
only selected cytokines in selected cell lines and clinical samples. A complete study,
has to be performed to measure the amounts of all the known cytokines from all
known or major HRS cell lines.
During this project, we chose not to directly investigate possible candidates for
substance x. Thus, ELISA or other methods to detect possible candidates for
substance x were purposely avoided due to the existence of too many different
cytokines likely present in the supernatants from HRS cell lines. However, if they
had performed, it would not even identify a whole substance x if substance x was
yet an unidentified factors. In addition, these experiments are time consuming and
expensive. Thus, our strategy was to leave screening programme, kindly offered by
Dr Stuart Farrow at Glaxo SmithKline for the further investigation. Currently, all
the supernatants from HRS cell lines are being investigated by screening of the
known cytokines and chemokines at the protein level. Purification would be the
next possibility to identity substance x. The challenge would be to ascertain the
identity of novel substances involved in eosinophil survival. Unfortunately, the
answers of those experiments have to be waiting for the future studies.
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IL-5 and GM-CSF are two of the strongest eosinophil activators and survival factors
known. In addition, in figure 6-5, L540 supernatant showed a slightly better effect at
causing eosinophil survival compared to IL-5 and GM-CSF. The question has arisen
whether supernatant of L540 may contain IL-5 and GM-CSF. To take this step
further, neutralising experiments using anti IL-5 and anti-GM-CSF antibodies were
performed to abrogate the survival effect of supernatant of L540. Anti-GM-CSF
antibody l.Opg/ml, which should be sufficient to neutralise 50% of the bioactivity
of 0.5ng/ml rhGM-CSF (according to the manufacture) was used. (Similar dose-
response to anti EL-5 antibody.) However, there was no effect on inhibition of
eosinophil survival (figure 6-5). These could be because 1) no IL-5 and GM-CSF
were present, 2) there was not enough antibody to neutralise. 3) There are other
substances which may have a profound eosinophil survival effect. For further
investigation, ELISA is required to measure accurately the amount of the IL-5 and
GM-CSF in the supernatant of L540. If detected, a suitable amount of antibody
should be determined for using in the neutralising experiments.
In addition, although IL-5 and GM-CSF are known as profound eosinophil survival
factors, however, in long term culture its effect may not be as strong as the
supernatant of L540. Eosinophils treated with L540 supernatant were occasionally
observed surviving up to about 30 days in the cell culture sometimes even without
changing the medium. IL-5 and GM-CSF are unlikely to produce such striking
results. This indicates that there may be other substances in the supernatant of L540
that mediate the powerful eosinophil survival effect observed in this study.
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6.16.2. The role ofNF-kB in mediating eosinophil survival by HRS cells
NF-kB is an important regulator of eosinophil fate. In this chapter it is shown that
various NF-kB inhibitors abrogated L540-supernatant-mediated eosinophil survival,
suggesting that NF-kB is indeed playing a role in L540-supernatant-mediated
eosinophil survival (figure 6-8 and 6-9). There may be some substances in the
supernatant of L540 that may be pro-apoptotic which may be enhanced by co-
incubation with NF-kB inhibitors. TNFa is a likely candidate since the presence of
TNFa has been previously detected in L540 (Foss et al., 1993).
To investigate the role ofNF-kB further, other studies to determine the level ofNF-
kB activation should be examined, for example, measuring the expression of hcBa
and p65 by Western blotting, p65 translocation by immunofluorescence studies etc.
Not only NF-kB but other pathways, such as JAK, STATS, MAPK etc., should also
be investigated in the next stage, especially, substance x might trigger various
signalling pathways in the cells.
NF-kB is a potential target transcription factor for cancer therapy. In HD tumours,
there may be excessive NF-kB activation occurring in various cells. For example
high constitutive activation of NF-kB in HRS cells (Cabanne et al., 1999 and
Krapmann et al., 1999) results in the high metabolic activities in those cells.
Similarly, as shown here, L540-supernatant-mediated eosinophil survival is
dependent on the NF-kB pathway. NF-kB activation not only regulates survival, but
also may be pro-inflammatory due to the production of pro-inflammatory cytokines.
Consequently production and release of cytokines may cause further progression of
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the tumour. The supernatant of L540 and other HRS cell lines do contain some
survival factors for eosinophils and neutrophils. Interestingly, Fabineen Allie at the
University of St Andrews has found that lymphotoxin in the supernatants of HRS
cell lines does activate NF-kB in HeLa cells. However, lymphotoxin did not directly
induce eosinophil survival, but may activate in other types of cells at the tumour
site.
In general, the most drugs used in chemotherapy inhibit NF-kB activation. For
example, corticosteroid Prednisone, is the standard drug used for the treatment of
HD. Steroids are believed to inhibit NF-kB transcription activities binding to DNA
(Adcock et al., 1999).
6.16.3. Neutrophils and T cells in HD
The number of neutrophils accumulated at tumours of HD is limited, thus, fewer
studies have been done on neutrophils. There are yet no conclusive reasons given as
to the mechanism and function of neutophil accumulation. Eosinophils and
neutrophils arise from a common precursor in bone marrow and share many
common signalling pathways, including NF-kB. Similar to eosinophils, it has been
shown in this chapter that supernatant from L540 exert its effect on neutrophil
survival. Therefore, it is reasonable to assume that in the supernatant of L540 there
are common survival factors, which may influence the NF-kB pathway. On the
contrary, there are some differences in activation pathways and their activator
ligands between neutrophils and eosinophils. It would be interesting to perform the
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comparison studies of molecular weight cut off and heat shock experiment in
neutrophils as has been done in eosinophils (figure 6-12).
Other types of cells, e.g. T cells, fibroblasts, macrophage, etc., should be considered
for the further investigation. For example, Th2 cells are highly expressed in HD and
may contribute to the recruitment of inflammatory cells (Poppema et al., 1998). In
addition, the involvement of surrounding tissue cells, such as fibroblasts, may be
one of the causes of recruitment of inflammatory cells. Especially since fibroblasts
have the capability to release eotaxin (Teruya-Feldstein et al., 1999) which is likely
one of the direct causes of eosinophil recruitment. To understand eosinophilia
further, other types of cells should be included for further studies in order to
elucidate the mechanism and function of eosinophilia at the HD tumour.
6.16.4. Further studies
To investigate the function and mechanism of eosinophilia and accumulation of
other inflammatory cells further, the following experiments should be considered.
Activation
Since eosinophil and neutrophil survival has been shown, it would be worth
performing, activation and migration studies. To investigate if HRS cells activate
eosinophils, extracellular release of granules products may be measured as an
indicator of activation. This could be measured by evaluation of eosinophil
peroxidase or MBP levels, which are typical markers of eosinophil degranuelation.
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In addition, preliminary experiments to determine the possibility of release of
cytotoxic granules contents of eosinophils was performed. (Data not shown, but also
see 6.15. for the ratio studies. Briefly, eosinophils were cultured with the 10%
supernatant of L540 for 7 days. The supernatant from which eosinophils were
cultured was taken and put back onto the L540 cell line culture for the total volume
of 10%. After 24 hours, all L540 cells were killed.) This experiment strongly
suggests the existence of cytotoxic substances in the supernatant of eosinophils
culture which had been treated with L540 supernatant. The precise identity of these
substances is unknown, but it is highly likely that they are the contents of cytotoxic
granules. To determine this possibility, extracellular release of granule products
should be measured.
In addition, as for eosinophil activation the influence of other inflammatory cells
such as T cells should be examined. Activated inflammatory cells are likely to
influence other inflammatory cells. Thus, activation studies are very important to
investigate the roles and mechanism of accumulation of inflammatory cells at the
site ofHD tumour.
Migration
Migration study would be important to investigate the mechanism of accumulation
of inflammatory cells at the HD tumour. In the study of asthma, eosinophil
migration studies have been investigated both in vivo and vitro. Therefore, the
knowledge from migration studies of eosinophils in the airways could be applied to
HD study. These can be done with eosinophils and HRS cell lines, but also, it would
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be interesting to see the influence of other types of cells such as fibroblasts to cause
eosinophil migration as it has been shown that eotaxin is released from fibroblasts
(Teruya-Feldstein et al., 1999).
An interesting study by Schell-Frederick et al., (1988) showed that a subfamily of
the L428 cell line, L428 KSA, inhibits neutrophil migration. However, this study
was limited since only this subgroup of cell line and neutrophils was examined. It
was concluded that this could be the reason for the immunodeficiency observed in
HD. However, the neutrophilia in the tumour ofHD was not discussed. Additionally
migration studies using eosinophils as well as neutrophils and T cells should be
performed using other HRS cell lines.
Ga!ectin-9
Human galectin-9 was first cloned from the cDNA library derived from HD (Tiireci
et al., 1997), and detected in the sera from 10 of 18 patients with HD (Sahin et al.,
1995). Galectin-9 is a family of thiol-dependent lectins with a conserved
carbohydrate recognition domain and high P-galactoside binding activity. It
regulates intra-cellular binding resulting in the promotion of cell proliferation or
apoptosis. Galectin-9 is highly expressed in HRS cells and Jurkat cells, but not
THP-1 and monocytes. Recently sequence studies revealed that galactin-9 was
identified as ecalectin (Matstumoto et al., 1998), which has high eosinophil
chemoattractant properties. Therefore, galectin-9 is good candidate for causing
eosinophil migration in the HD tumours. Eosinophil migration assays can be
performed to investigate the effect of galectin-9. (This experiment idea was kindly
suggested by ProfR Jarrett, University ofGlasgow.)
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6.16.5. Cell-cell interaction in HD
The direct relationship between HRS cells and eosinophils are currently unknown.
From the observation studies shown in this chapter, when eosinophils and L540
cells were co-cultured, the following observations were made; 1) L540 cells may
have the ability to phagocytose, 2) increased number of multinucleated cells 3)
L540 cells may be killed by eosinophils depending on the ratio of eosinophils and
L540 cells.
As previously reported, HRS cells are capable of emperipoiesis and phagocytosis
(see introduction 6.1.14. for summary). In addition, the observations from this thesis
reveal that there may be some phagocytosis or emperipoiesis activities by L540
cells. It is still unclear why L540 cells which are derived from a T cell origin are
capable of phagocytosis. When another T cell origin cell line, Jurkat cells were co-
cultured with eosinophils, there was no phagocytosis observed. Thus, phagocytosis
or emperipoiesis may be one of the features of HRS cells despite their origins.
Recently studies have revealed that not only monocytes, but also other types of cells
can indeed phagocytose other cells. For example, epithelial cells in the airways
engulf apoptotic eosinophils (Walsh et al., 1999). There might be some feature
changes in those cells allowing them to phagocytose.
Another interesting observation was that when L540 cells and eosinophils were co-
cultured, occasionally eosinophil granules-like structures, which are stained orange
by eosin, were observed in the cytoplasm of L540 cells. However, to provide
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definite proof for this phenomenon, electron microscopic observation is required..
However, if it is true that granules are indeed in the cytoplasm of L540 cells this
may be further evidence for the engulfment of eosinophils. However, whatever the
reasons, if granules are indeed in the cytoplasm of L540 cells, toxic proteases from
granules would be deleterious for L540 cells. This may be the explanation why
some L540 cells were killed by eosinophils, when the eosinophil ratio was high
against L540 cells. On the other hand, this might disturb the normal intracellular
activities of HRS cells, such as mitosis. This may be the reason why there was an
increased number of multinucleated cells when L540 cells were incubated with
eosinophils.
In normal circumstances, only apoptotic eosinophils are phagocytosed. In those
cases, once cells become apoptotic, granules are still present in the apoptotic body.
In case of L540, it was observed that they engulf any eosinophil, dead or alive. So it
could be possible that L540 may ' emperipoiesis ' live eosinophils rather than
phagocytose apoptotic eosinophils, and the results in the existence of granules from
eosinophils in the cytoplasm of L540 cells. Or it may be possible that eosinophils
are thought to be 'viable' might be at an early stage of apoptosis without obvious
morphological changes, such as chromatin condensation. To determine the
phagocytosis or emperipoiesis activities more specifically, other methods have to be
introduced, for example, electron microscopy, for the future studies.
When L540 cells and eosinophils were incubated together, the number of
multinucleated cells was increased (see figure 6-14-A and -B). Those
multinucleated cells are very like Reed-Sternberg cells in the biopsy samples (see
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figure 6-1-2). The observations made here suggesting that multinucleated cells were
indeed peculiar and abnormal looking. Nuclei are usually in two, four or five per
cell. Very often nuclei appear paired because they are symmetrical, which are
identical shapes and patterns of darkly stained areas. This may suggest that those
cells may have failed for the normal cell mitosis but fused into one cell after nuclei
are divided. Therefore, they do contain identical looking nuclei in the same cell. The
reasons for this observation are unknown. As it has been mentioned above, it is
possible that eosinophil granules may be disturbing some normal intracellular
functions to cause multinucleated cells. These interesting observations however
require further experiments.
Additionally, in figure 6-16-5, the biggest L540 cells observed during this project is
shown. Compared to surrounding eosinophils and the number of the nuclei present,
this phenomenal cell maybe the result of the failures of normal cellular activities.
6.16.6. Is eosinophilia beneficial or deleterious for the pathogenesis of HD?
These studies have showed that there may be a role for eosinophils in the
pathogenesis ofHD. What roles eosinophils may be playing in terms of the progress
of the disease seems unclear. Especially co-culture experiments raises the questions
of the functions of eosinophils. Incubation with eosinophils increased
multinucleated HRS cells, which are regarded in the clinical situation as a more
aggressive form of the tumour. On the other hand, excess amounts of eosinophils do
kill L540 cells. This might indicate that eosinophils could be beneficial for the
removal of HRS cells.
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Figure 6-16; Giant L540 cells. Eosinophils and L540 cells were co-cultured
for 5 days. Multi- nucleated giant cell is seen. (Magnification x 100)
This debate can be applied to other types of cancer studies and eosinophilia. As it
has been reported that in the pathogenesis of cancer, eosinophilia could be
beneficial or deleterious for the host (also see 6.1.13. for eosinophils and other
cancers). There have not yet been enough studies to determine the role of
eosinophils in cancer. Nevertheless, it may depend on the type of cancer. However,
it is likely that in HD, eosinophils are not favourable for prognosis. Therefore, the
removal of eosinophils from HRS cells may be still a favourable therapeutic target.
HD and inflammation are very different, yet, share some similarities in terms of
accumulation of inflammatory cells. If eosinophil accumulation in HD is
undesirable, inflammatory diseases such as asthma share a similar therapeutic target





Accumulation of eosinophils is one of the features of inflammation but eosinophilia
is also seen in other diseases (shown in table 7-1). As has been discussed in chapter
6, although HD and inflammation diseases are diverse and result in different





























Table 7-1; The diseases associated with eosinophilia (modified from Krogel et
aL, 1994)
Activated eosinophils are deleterious to host tissue due to the release of pro¬
inflammatory cytokines (e.g., IL-8) and histotoxic contents resulting in further
progress of the disease. Therefore, the removal of eosinophils is beneficial for
preventing tissue damage. For the 'silent' removal of eosinophils, eosinophil
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apoptosis is essential in order to inhibit their activities and being phagocytosed by
macrophages and other types of cells.
Eosinophil survival and apoptosis pathways are complex but at least NF-kB
pathway seems to play an important role. In this thesis, it has been shown that
inhibition of NF-kB is important for enhancing eosinophil apoptosis. Gliotoxin and
Mgl32 inhibit NF-kB and induced significant eosinophil apoptosis especially when
stimulated with TNFa. Although TAT-IkBcc showed a significant effect on
eosinophil apoptosis, this effect was however donor dependent. In those donors
whose eosinophils did not respond to TAT-hcBa, NF-kB activation may have
already occured. During the immunofluorescent staining of p65, it was notable that
eosinophils from a few donors had p65 translocation in the nucleus without any
stimuli, whereas normally "p65 was observed in the cytoplasm from other donors.
This suggests that in some donors, the NF-kB pathway is highly activated and may
result in the different levels of response towards NF-kB inhibitors. Secondly, the
mechanism of TAT-hcBa, gliotoxin and Mgl32 on inhibition ofNF-kB is different
which may have different influences in different donors. Some inhibitors may
disturb other signalling pathways but not necessary specifically only the NF-kB
pathway. However, although inhibition ofNF-kB is still one of the key issues in the
induction of eosinophil apoptosis future investigations should consider other
intracelluar pathways.
Table 7-2 shows the potential therapeutic anti-eosinophil drugs and reagents.
Mainly, their functions act to suppress eosinophil recruitment, activation and
survival. Some (e.g., corticosteroids) may work on inhibition of NF-kB pathway
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(Adcock et al., 1999), but others (e.g., IL-5, IL-3, GM-CSF antagonists) may do so
on tyrosine cascades.
Table 7-2; Potential anti-eosinophil reagents for the clearance
of accumulated eosinophils at inflammatory sites. (Modified from
Sampson, 2000.)
Corticosteroids
IL-10R agonists or IL-10
Leukotriene modifiers






For example, corticosteroids are known to induce eosinophil apoptosis both in vitro
and in vivo. As has been shown in asthma patients, corticosteroids enhance the
clearance of apoptotic eosinophils by macrophage phagocytosis in airways
(Woolley et al., 1996). However, eotaxin and RANTES antagonists may be
necessary to inhibit further eosinophil recruitment at inflammatory sites. IL-10
(Takanashi et al., 1994) has been shown to inhibit LPS induced eosinophil survival.
Woolley et al., (1994) has demonstrated that the inhibition of eosinophilia in
sensitised Brown Norway rats by administration of IL-10. BION-1 is a monoclonal
antibody against the beta(c) of IL-5, IL-3, GM-CSF receptor (Sun et al., 1999) and
has been shown to inhibit eosinophil survival. ICAM-1, VCAM-1, (32 integrin
(Chihara et al., 2000) expressed on epithelial cells, activates eosinophils, therefore,
VCAM antagonist acts to inhibit eosinophil activation and accumulation.
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These reagents may prevent eosinophil recruitment at inflammatory sites, therefore,
eosinophilia may be suppressed. However, to resolve inflammation, there are other
issues that have to be targeted, such as suppression of recruitment of inflammatory
cells, lower cellular activities of inflammatory cells and induction of apoptotic
inflammatory cells. For those reasons, generally at inflammatory sites, cellular
metabolisms have to be suppressed in various cells. NF-kB is one of the key
transcription factors responsible for pro-inflammatory consequences in various
types of cells. Therefore, NF-kB inhibitors are often used as anti-inflammatory
drugs, for example salicylates (Yin et al.t 1998) and Helenalin (Lyss et al, 1997).
Inhibition of NF-kB at the inflammatory sites exerts its effect not only by
suppressing transcritiptional activity but may also induce apoptosis in accumulated
inflammatory cells.
As previously introduced in this thesis, HIV-1 TAT may be a promising peptide for
future therapeutic purposes. TAT can be transduced into almost any type of cell,
resulting in the transduction in various types of cell at the same time. For example,
TAT-IkBcc may be useful in suppressing cellular activities in different cell types at
the inflammatory sites. This might prevent the pathogenesis of inflammation.
On the other hand, if TAT can be transduced into specific cell types, it would be a
strong advantage, too, especially in vivo. The mechanism of transduction system of
TAT is not fully elucidated. However, in the future, it may become possible to
'design' a TAT peptide for transduction into the selective cell types. This might
enhance the ability ofTAT and its therapeutic benefit in vivo.
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For therapeutic purposes, the mechanisms regulating inflammation have to be
understood in more detail.
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Inhibition of nuclear factor-icB activation un-masks
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Apoptosis renders eosinophils functionally effete and marks them for 'silent' removal from
inflamed sites by macrophages. We show, for the first time, that eosinophils exposed to
TNF-a rapidly lose their cytoplasmic levels of licBa, the inhibitory subunit of NF-kB. Conse¬
quently, TNF-a triggers NF-kB mobilization from the cytoplasm to the nucleus, as deter¬
mined by tracking the NF-kB subunit p65 by immunofluorescence and Western blot analy¬
sis. Inhibition of TNF-a-mediated iKBa degradation and NF-kB activation by gliotoxin or the
proteasome inhibitor MG-132 un-masks the caspase-dependent pro-apoptotic properties of
TNF-a. In addition, cycloheximide similarly renders TNF-a pro-apoptotic, suggesting that
NF-kB activation controls the production of a protein(s) that protects eosinophils from the
cytotoxic effects of TNF-a. Evidence is presented suggesting that TNF-a triggered
apoptosis is more susceptible to NF-kB inhibition than constitutive apoptosis, leading to the
possibility of the specific targeting of apoptosis in eosinophil sub-populations. Prior to mor¬
phological signs of apoptosis, TNF-a-induced IL-8 synthesis is abrogated by inhibition of
NF-kB. We propose that NF-kB activation plays a critical role in controlling eosinophil
responsiveness and apoptosis, and speculate that selective inhibitors of eosinophil NF-kB
activation may ultimately provide alternative therapeutic agents for the treatment of eosino¬
philic diseases, including asthma and allergic rhinitis. Received 18/6/01Revised 9/10/01
Accepted 27/11/01
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1 Introduction
Eosinophilic granulocytes are normally involved in
orchestrating the destruction and removal of invading
parasites. However, if these cells are inappropriately
recruited or activated at inflammatory sites they can
liberate excessive amounts of toxic products (e.g. free
02 radicals, major basic protein, etc.), which can cause
damage to the surrounding tissue. Thus, eosinophii-
mediated epithelial cell damage in the respiratory tract is
likely to contribute to the pathogenesis and propagation
of asthma and allergic rhinitis [1, 2]. Ligation of specific
cell surface receptors and the consequent triggering of
diverse signal transduction pathways control eosinophil
functional responsiveness [3] and physiological pro¬
grammed cell death (apoptosis) [4], During apoptosis
[I 22139]
granulocytes undergo a series of dramatic morphologi¬
cal transformations (e.g. shrinkage and chromatin con¬
densation) and surface molecule alterations (e.g. expres¬
sion of phosphatidylserine) [5-8]. Apoptosis also causes
a marked reduction in the cell's ability to respond to pro¬
inflammatory stimuli [5], and is critical for the efficient
non-inflammatory [5, 6] removal of effete granulocytes
from the inflammatory site by macrophages [7] and other
cells including epithelial cells [9].
Eosinophils have the capacity to release inflammatory
mediators derived from lipid metabolism and are capable
of synthesizing pro-inflammatory cytokines [e.g. IL-8,
TNF-a, granulocyte/macrophage-colony stimulating fac¬
tor (GM-CSF), IL-5, etc.] [3], many of which are regulated
by the transcription factor nuclear factor-kb (NF-kB)
[10-12]. Our recent demonstration that neutrophil apop¬
tosis is critically regulated by the synthesis of NF-kB
controlled survival protein(s) [13, 14] suggests that NF-
kB may control gene transcription of proteins that influ¬
ence granulocyte apoptosis as well the synthesis of pro-
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nflammatory agents. NF-kB1 (p50), NF-kB2 (p52), RelA
p65), relB and c-rel are a family of proteins which bind to
3ne another to form NF-kB dimers (often p50/p65), that
eside predominantly in the cytoplasm. NF-kB is held in
he cytoplasm in an inactive state by being bound to an
nhibitory protein from the IkB family in which the 37-kDa
kBcx is the major form. When cells are appropriately stim-
jlated, the IkBo subunit is rapidly phosphorylated and
jbiquinated before finally being degraded by the 26S pro-
:easome [10-12], Translocation of NF-kB subunits to the
nucleus, where they bind to regulatory DNA sequences in
:he upstream promoter region of target genes, controls
■ates of transcription [10,11]. Inflammatory cells have the
capacity to synthesize and respond to exogenous NF-kB
'egulated pro-inflammatory cytokines [15]. For example,
FNF-a is capable of priming neutrophils, rendering them
more susceptible to activation upon subsequent exposure
to other neutrophil secretagogues [16, 17], Furthermore,
FNF-a can influence apoptosis in many cells including
granulocytes [13, 18-20]; effects that may be controlled
by activation of NF-kB [13,18, 20], For example, apopto¬
sis is promoted when neutrophils are exposed to TNF-a
for short periods of culture (i.e. 2-8 h) in a concentration-
dependent manner. When apoptosis is assessed after
20 h of TNF-a exposure apoptosis is delayed [18]. Inter¬
estingly, TNF-a has the ability to induce apoptosis in
human neutrophils via a mechanism where TNF recep¬
tor 2 (TNFR2) facilitates the dominant TNF receptor 1
(TNFR1) death effect. In human eosinophils TNF-a has
been shown to exert an anti-apoptotic effect that signals
partly via the p38 MAP kinase pathway [19], and more
recently Temkin and Levi-Schaffer [20] have shown that
TNF-a-mediated eosinophil survival occurs via ligation of
both TNF receptor subtypes and through the generation
of the eosinophil survival factor GM-CSF; an effect that
seems to involve activation of NF-kB. Although we [13]
and others [20, 21, 22] have shown that NF-kB is present
in granulocytes, the role of NF-kB in the regulation of
eosinophil-derived chemokine production and apoptosis
remains poorly understood. We used two compounds that
inhibit NF-kB activation; MG-132, a widely used protea-
some inhibitor that prevents IkB degradation [23] and glio-
toxin [13, 24]. Gliotoxin is an epipolythiodioxoperazine
which exhibits immune suppressive activity both in vitro
and in vivo [24, 25] and selectively inhibits NF-kB activa¬
tion [24]. We demonstrate that both gliotoxin and MG-132
can un-mask the potential of TNF-a to induce eosinophil
apoptosis. At the same concentration that affects apopto¬
sis and inhibits TNF-a-induced IL-8 secretion, gliotoxin
inhibits the translocation of p65 to the nucleus from the
cytoplasm by inhibiting the degradation of IkBo. From our
data we therefore propose that the NF-kB pathway plays
a key role in regulation of eosinophil responsiveness and
apoptosis; a system that may be modulated for therapeu¬
tic gain.
2 Results
2.1 NF-kB regulates eosinophil apoptosis
We have shown that NF-kB plays a central role in eosino¬
phil apoptosis by demonstrating that blockade of NF-kB
activation by gliotoxin un-masks the ability of TNF-a to
dramatically induce eosinophil apoptosis. This is clearly
depicted in Fig. 1A, where TNF-a (10ng/ml) alone and
gliotoxin (100ng/ml) alone cultured with eosinophils
for 4 h caused little morphological apoptosis; however,
when eosinophils were cultured in the presence of TNF-a
plus gliotoxin there was a dramatic induction of charac¬
teristic pyknotic nuclei typical of eosinophil apoptosis.
Our preliminary data indicated that it requires a signifi¬
cant amount of time (>3 h) to observe significant apop¬
tosis and that the 4-h time point is optimal for observing
the synergistic effects of TNF-a and gliotoxin (data not
shown). As an additional independent assessment of
eosinophil apoptosis, we performed experiments in
which surface changes associated with the apoptotic
program were also assessed. For this we measured
FITC-labeled annexin V binding in the presence of Ca2+
to phosphatidylserine molecules exposed on the outer
membrane of apoptotic cells, where the annexin V 'low
peak' represents non-apoptotic cells and the annexin V
'high peak' represents apoptoric cells. In agreement with
morphological assessment of apoptosis, Fig. 1C shows
that, although control and TNF-a-treated eosinophils at
4 h exhibit low rates of apoptosis, the small increase in
annexin V+ cells observed with gliotoxin alone is again
dramatically augmented when the cells are cultured in
the presence of both reagents together. Furthermore, the
marked synergism that was displayed by gliotoxin and
TNF-a is mediated by triggering of the caspase pathway
since the broad-spectrum caspase inhibitor, zVAD-fmk
(100|.iM) completely blocked the pro-apoptotic effects
induced by the combination of TNF-a plus gliotoxin
(Fig. 2). When eosinophils were co-cultured with the pro¬
tein synthesis inhibitor cycloheximide (5 riM), at a con¬
centration and time point that had almost no direct effect
on eosinophil apoptosis, a similar un-masking of the pro-
apoptotic effect of TNF-a was observed; an effect that
was also suppressed by zVAD-fmk (Fig. 2).
In addition, when eosinophils were cultured with the pro-
teasome inhibitor MG-132 (20 fiM) a marked induction
of apoptosis was also observed, although the pro-
apoptotic effect required longer incubation times than
gliotoxin. For example, no significant induction of apop¬
tosis was observed above constitutive levels when
eosinophils were cultured for 8 h with MG-132 (data not
shown). Even with incubation periods of 30 h, MG-132
induced little apoptosis; however, in the presence of
TNF-u there was a dramatic synergistic induction of













































Fig. 7. The effect of gliotoxin, MG-132 and TNF-a on eosinophil apoptosis. (A) Cytocentrifuge preparations were made of human
eosinophils incubated for 4 h at 37°C in medium alone (control), 10 ng/ml TNF-a, 100 ng/ml gliotoxin, and combination of these
reagents. The rates of apoptosis in this experiment are control, 5%; TNF-a, 5%; gliotoxin, 26.5%; and gliotoxin/TNF-a, 47.5%.
(B) Cytocentrifuge preparations of human eosinophils incubated for 30 h at 37°C in medium alone (control), 10 ng/ml TNF-a, MG-
132 (20 nM), and combination of these reagents. The rates of apoptosis in this experiment are control, 14.6%; TNF-a, 23 3%;
MG-132, 11.4%; and MG-132/TNF-a, 75.7%. (C) Aliquots (20 pi) were taken from human eosinophils that had been incubated
for 4 h at 37°C in medium alone (control), 10 ng/ml TNF-a, 100 ng/ml gliotoxin, and a combination of these reagents and incu¬
bated with FITC-labeled recombinant human annexin V to determine the phosphatidylserine expression on the cell surface. Flow
cytometric traces from a typical experiment are depicted with the percentage of cells in the annexin-V high population being
7.0% in control, 9.8% in TNF-a, 28.5% in gliotoxin and 50.8% in TNF-a plus gliotoxin-treated samples.
apoptosis (Fig. 1B). When apoptosis was assessed after
40-h treatment with MG-132 there was a significant
induction of apoptosis (control, 24.8±8.7%; MG-132,
72.5±15.8% apoptosis; p<0.05, n=4). The pro-apoptotic
effects of MG-132 per se and the enhanced apoptosis
observed with a combination of MG-132 and TNF-a
were also suppressed by zVAD-fmk (data not shown).
Taken together the above results support the view that
TNF-a treatment results in the NF-kB controlled genera¬
tion of a survival protein(s) that protects eosinophils from
the TNF-a receptor- and caspase-dependent induction
of apoptosis. To substantiate this hypothesis we per¬
formed a detailed direct analysis of NF-kB activation.
2.2 TNF-a induced cytoplasmic IkBo degradation
and p65 disappearance in eosinophils
Upon appropriate cell stimulation, the inhibitory subunit
of NF-kB, iKBa, is rapidly phosphorylated and under¬
goes proteolytic breakdown by the proteasome, thereby
permitting NF-kB to translocate from the cytoplasm from
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the nucleus [10]. Since the phosphorylation and subse¬
quent degradation of IkBcx is a prerequisite for NF-kB
activation, the amount of IkBoi in cytosolic extracts of
eosinophils was examined by Western blotting to find
evidence for the activation of the NF-kB pathway. In qui¬
escent un-stimulated cells, IkBci appeared as a single
band of 37 kDa, which disappeared following TNF-a
stimulation, indicating degradation of InBa (Fig. 3A) and
translocation of NF-kB to the nucleus. Following TNF-a
stimulation the amount of p65 in the cytoplasm was
reduced (Fig. 3B), indicating that, following the degrada¬
tion of IkBo, p65 is released from IkBo in the cytoplasm
and translocated into the nucleus. As shown in Fig. 3A,
gliotoxin had no direct effect on IkBo levels but inhibited
TNF-a-induced disappearance of IkBo. The latter obser¬
vation is consistent with gliotoxin-mediated inhibition of
TNF-a-induced loss of cytoplasmic p65 (Fig. 3B). These
results therefore suggest that TNF-a stimulation results
in InBa degradation and translocation of NF-kB from the
cytoplasm to the nucleus.
2.3 Immunohistochemical analysis of NF-kB
translocation in eosinophils
To provide compelling evidence for subcellular move¬
ment of NF-kB in eosinophils we performed quantitative
immunohistochemical analysis of TNF-a-induced trans¬
location of p65. Immunofluorescent confocal images of
p65 (FITC: green) reveal translocation into the nucleus
(propidium iodide: red) by TNF-a stimulation (shown as
yellow as the result of overlapping green p65-FITC, and
red propidium iodide) (Fig. 4) that is effectively prevented
by gliotoxin. These results are consistent with the West¬
ern blot analysis shown in Fig. 3A and B, and therefore
provide evidence that gliotoxin acts by inhibition of NF-
kB activation. Quantification of translocation is depicted
in Fig. 5A-C where the immunofluorescent images are
analyzed on a Leica Q550IW image analyzer to detect
p65 amount in the cytoplasm and nucleus and the
results expressed as a ratio. Fig. 5A and B clearly show
the inhibition of TNF-a-induced NF-kB translocation into
the nucleus by gliotoxin and MG-132. In Fig. 5C the time
course of translocation of p65 stimulated with TNF-a
from a representative experiment is depicted. Maximum
induction of TNF-a-stimulated p65 translocation in
eosinophils isolated from this particular donor occurred
after 60-min exposure to TNF-a as assessed by immu¬
nofluorescence. Following this time point, NF-kB levels
in the nucleus rapidly decrease almost to basal levels,
perhaps reflecting rapid re-synthesis of iKBa and conse¬
quent removal of NF-kB from the nucleus. Although dif¬
ferent levels of basal and stimulated p65 distribution























Fig. 2. Effects of the caspase inhibitor, zVAD-fmk, and the
protein synthesis inhibitor, cycloheximide, on eosinophil
apoptosis induced by gliotoxin, TNF-a or on a combination
of these agents. Human eosinophils were treated with the
indicated reagents for 4 h at 37°C before cytocentrifuge
preparations were made and apoptosis assessed morpho¬
logically. Concentrations are: 10 ng/ml TNF-a, 100 ng/ml gli¬
otoxin, 100 nM zVAD-fmk, and 5 pM cycloheximide (CHX).
The data are expressed as the mean ± SEM of four separate
experiments using eosinophils isolated from different donors.
'Represents significance differences (p<0.05) from control,
and # represents significance difference from Glio/TNF-a and
t represents significance difference form CHX/TNF-a.
Fig. 3. Western blot analysis of cytoplasmic IkBo and p65.
Eosinophils were stimulated with 10 ng/ml TNF-a, 100 ng/
ml gliotoxin for 15 min in Iscove's DMEM at 37°C and cyto¬
plasmic extract prepared and analyzed by Western blotting
with anti-lKBa antibody, and anti-p65 antibody. (A) Cyto¬
plasmic IkBq expression. Upon TNF-a stimulation the InBa
band disappears, indicative of proteosomal degradation;
treatment of the cells with gliotoxin stabilizes licBa in the
cytoplasm both in the absence and presence of TNF-a. For
a control Jurkat cell cytoplasmic extracts were included
(lane 5). (B) The amount cytoplasmic p65. The loss of p65
expression in the cytoplasm with TNF-a stimulation corre¬
lated with InBa loss and suggests translocation of p65 into
the nucleus, a process blocked by gliotoxin. The blots are
representative of at least three separate experiments.
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Control Gliotoxin a 18
Fig. 4. Confocal microscope images of p65 expression in
human eosinophils stimulated with TNF-oc with and without
gliotoxin. Eosinophils were stimulated for 45 min in Iscove's
DMEM with 10 ng/ml TNF-a and 100 ng/mi gliotoxin. Anti-
p65 antibody was FITC labeled (shown as green) and the
nucleus was stained with propidium iodine (shown as red).
Upon TNF-a stimulation p65 migrates into the nucleus,
resulting in an enhanced yellow color. Gliotoxin, with or with¬
out TNF-a, dramatically inhibits p65 nuclear migration.
NF-kB activation by TNF-a stimulation was observed
(data not shown).
Fig. 5. Quantitative analysis of p65 translocation to the
nucleus. Computer analysis of p65 expression in the
nucleus was measured as the ratio of p65-FITC nuclear fluo¬
rescence versus cytoplasmic fluorescence in each cell. At
least 300 cells were counted per condition and the data are
represented as mean ± SEM determined for each experi¬
ment independently. Eosinophils were incubated in Iscove's
DMEM at 37°C with the indicated stimuli (A and B) for 45 min
and with TNF-a for the indicated times (C). (A) The effect of
100 ng/ml gliotoxin on activation by 10 ng/ml TNF-a. (B) The
effect of 20 (iM MG-132 on p65 translocation into the
nucleus. (C) Time course of the effect of 10 ng/ml TNF-a.
The data are representative of one experiment of at least
three similar experiments.
2.4 NF-kB activation mediates IL-8 production
by human eosinophils
Flaving clearly shown the presence and activation of the
NF-kB pathway in eosinophils and demonstrated that
this pathway regulates the eosinophil apoptotic program
in response to TNF-a, we next sought to investigate its
role in regulating eosinophil responsiveness. It is estab¬
lished in many cell types [11, 26] that IL-8 production is
tightly controlled by NF-kB, and eosinophils have the
capacity to synthesize this important pro-inflammatory
cytokine [3, 21]. TNF-a is a powerful stimulator of IL-8
production in eosinophils (Fig. 6) even at the early time
point of 90 min, a time point chosen since there is no
gliotoxin-induced apoptosis that could influence IL-8
production (data not shown). The production of IL-8 was
dramatically suppressed by gliotoxin at a concentration
that effectively inhibits NF-kB activation at this time point
where there is no significant apoptosis.
3 Discussion
We have clearly demonstrated that human eosinophils
possesses a fully functional NF-kB signaling system that
plays an important role in regulating cellular responsive¬
ness and apoptosis. Our data show that the eosinophil
contains p65 and that NF-kB is presumably maintained
in the cytoplasm by the inhibitor protein IkBo. Upon
exposure to the pro-inflammatory agent TNF-a, IkBq is
rapidly lost from the cytoplasm by a process that
involves phosphorylation and ubiquitination, followed by
subsequent degradation by the proteasome. In eosino¬
phils, Western blot analysis and immunofluorescence
data demonstrate that p65 translocates from the cyto¬
plasm to the nucleus in response to TNF-a. One likely
partner for p65 in eosinophils is p50, as identified by
Western blot analysis ([21] and data not shown). Glio¬
toxin and MG-132 effectively prevents p65 translocation
to the nucleus, which we suggest is important for the
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Fig. 6. Effect of gliotoxin on TNF-a-induced IL-8 release
from human eosinophils. Eosinophils were stimulated with
10 ng/ml TNF-a for 90 min in the absence and presence of
100 ng/ml gliotoxin and the IL-8 concentrations in the cell
supernatants determined by specific ELISA. The data are
expressed as the mean ± SEM of four separate experiments
using eosinophils isolated from different donors. Significant
increase (p<0.05) from the control is indicated by *.
direct effect of these compounds on apoptosis. TNF-a is
a powerful activator of NF-kB and gliotoxin and MG-132
inhibit NF-kB activation upon TNF-a stimulation result¬
ing in a dramatic synergistic induction of apoptosis.
Interestingly, the following observations suggest that
TNF-a-triggered apoDtosis is more susceptible to NF-kB
inhibition than constitutive apoptosis; firstly, higher con¬
centrations of gliotoxin are required to directly induce
apoptosis than required to render the cells responsive to
the pro-apoptotic effects of TNF-a [13] and secondly
MG-132 augments TNF-a-induced apoptosis at earlier
time points than are required to induce apoptosis
directly. These findings clearly require further investiga¬
tion but provide the intriguing possibility of selectively
targeting the removal of potentially histotoxic eosinophils
from inflammatory sites by manipulating apoptosis of
such eosinophil sub-populations without influencing
constitutive tissue eosinophils.
The NF-kB complex binds to DNA regulatory sites on the
upstream (5') promotor sequences of target genes that
control the rate of gene transcription for many pro¬
inflammatory mediators, some of which can influence
granulocyte function and apoptosis (e.g. TNF-a and
IL-8). Eosinophils exposed to TNF-a (Fig. 6) and lipo-
polysaccharide [27] are capable of releasing IL-8. IL-8
itself can cause recruitment of inflammatory cells into
sites of inflammation and can also prime and/or activate
granulocytes [28, 29]. Thus activation of the NF-kB path¬
way can augment the inflammatory response by gener¬
ating further pro-inflammatory mediators. In our studies,
synthesis of IL-8 is inhibited by relatively low concentra¬
tions of gliotoxin even at a time point (90 min) at which
there is no significant induction of apoptosis, consistent
with the observation that TNF-a activates NF-kB to
induce IL-8 production in human eosinophils (Fig. 6;
[21]). Although we have shown previously that gliotoxin,
but not its structurally similar analog, methylthioglio-
toxin, can directly induce neutrophil apoptosis and
enhance apoptosis in the presence of TNF-a [13] by
selectively inhibiting NF-kB activation, the underlying
mechanisms were not identified. We show here that glio¬
toxin not only prevents translocation of p65 from the
cytoplasm to the nucleus but also prevents IkBo degra¬
dation. Interestingly, MG-132, like gliotoxin, can also
induce eosinophil apoptosis directly and also renders
eosinophils responsive to the pro-apoptotic effects of
TNF-a. It is noteworthy that MG-132 required a longer
incubation period in comparison to gliotoxin to un-mask
TNF-a-induced apoptosis. The precise reason for this is
unknown but may reflect a difference in the mechanism
of action or in the rates of cellular incorporation between
the two inhibitors of NF-kB activation. We do, however,
propose that NF-kB activation is a critical regulator of
granulocyte apoptotic programs. Studies using cyclo-
heximide suggests that granulocytes synthesize a sur¬
vival protein(s) that inhibits apoptosis [30]. Our results
showing that cycloheximide dramatically un-masks the
pro-apoptotic effect of TNF-a in eosinophils are entirely
consistent with our hypothesis that NF-kB activation
leads to the synthesis of a survival protein that limits the
ability of the cell to undergo apoptosis. Thus, TNF-a trig¬
gers a number of signaling pathways following ligation of
TNF-a receptors. We have previously shown that neutro¬
phils undergo an early induction of apoptosis (2-8 h) and
a later (>18 h) inhibition of apoptosis when cultured in
vitro in the presence of TNF-a [18]. The pro-apoptotic
effect of TNF-a is thought to be mediated by ligation of
the TNFR1 containing a death domain that interacts with
the TNF-receptor-associated death domain protein
(TRADD) allowing recruitment of Fas-associated death
domain (FADD), leading to activation of the caspase
enzyme pathway. This highly regulated sequence of
events enables apoptosis to be triggered. TNFR 2, often
in co-operation with TNFR1, results in the activation of
many kinases including the p38-Jun N-terminal kinase
(JNK) pathway and IKK [31]. Prevention of the survival
pathway by blocking the generation of NF-kb-mediated
protein synthesis allows the death pathway to predomi¬
nate and a massive induction of apoptosis is observed. It
remains possible that blockade of NF-kB will prevent the
synthesis of powerful NF-kb-regulated survival cyto¬
kines such as GM-CSF, IL-5 and IL-3. Indeed, it has very
recently been published that TNF-a via ligation of both
TNFRI and TNFR2 subtypes mediated eosinophil sur¬
vival (as assessed by Trypan blue exclusion), and that
this occurred through regulation of GM-CSF but not IL-3
and IL-5 production [20]. Furthermore, it was shown that
GM-CSF is indeed synthesized when eosinophils are
challenged with TNF-a and that TNF-a enhanced eosin-
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ophil survival is significantly inhibited by the proteasome
inhibitor MG-132 [20]. It also remains likely that eosino¬
phils like other cells can generate protein(s) that directly
influence the apoptotic program. However, the precise
identity of the potential survival protein(s) is unknown
(see [14] for a review); however, several likely candidate
-proteins have been implicated including members of the
oncogene Bcl2 family (e.g. A1 [32, 33] and Mcl-1 [34])
and others such as c-Myc [35], A20 [36], clAP [37, 38],
and IEX-1L [39].
Although it is abundantly clear that NF-kB activation can
play an important role in regulating the production of
cytokines and adhesion molecules that are vital for
orchestrating the inflammatory response, there is rela¬
tively little direct in vivo evidence indicating that this tran¬
scription factor can influence eosinophilic inflammation.
Compelling evidence that NF-kB plays an essential role
in the induction of eosinophilia in allergic airway inflam¬
mation, was obtained using mice deficient in p50, when
compared with wild-type mice [40], In addition to being
incapable of mounting eosinophilic airway inflammation,
p50-/- mice had a dramatically reduced capacity for
the production NF-kB regulated inflammatory mediators
such as the T helper 2 cytokine IL-5 and the chemokines
eotaxin and macrophage inflammatory protein (MIP)-1a
and MIP-1(3. We believe that NF-kB plays a prominent
role in controlling eosinophil responsiveness and longev¬
ity, and therefore could have far reaching implications for
understanding not only the generation and propagation,
but also the resolution, of eosinophilic inflammation. Fur¬
ther investigations may lead to the development of novel
compounds that interfere with the NF-kB signaling path¬
way which may be applied to clinically relevant eosino¬
philic diseases such as asthma and allergic rhinitis.
4 Materials and methods
4.1 Eosinophil isolation and culture
Granulocytes were isolated from the peripheral blood of
normal or mildly atopic donors by dextran sedimentation
followed by centrifugation through discontinuous Percoll
(Amersham/Pharmacia, Little Chalfont, GB) gradients [13,
41]. Eosinophils were separated from contaminating neutro¬
phils by negative selection using an immunomagnetic sepa¬
ration step with sheep anti-mouse IgG-Dynabeads (Dyna-
beads M-450, Dynal, Merseyside, GB) coated with the
murine anti-neutrophil antibody 3G8 (anti-CD16; a gift from
Dr. J. Unkeless, Mount Sinai Medical School, New York) as
described [42], Eosinophils were routinely >98% pure and
>99% viable. After purification, eosinophils were washed
twice in PBS without Ca2* and Mg2* and resuspended as
indicated below. Eosinophils in Iscove's Dulbecco's modi¬
fied Eagle's medium (DMEM) (Life Technologies, Paisley,
GB) supplemented with 10% autologous serum were cul¬
tured in Falcon flat-bottom flexible 96-well plates (Becton
Dickinson, Oxford, GB) at 37°C in a 5% C02 atmosphere at
2x106/ml. Cells were cultured in the absence or presence of
test agents as described in the figure legends.
4.2 Assessment of eosinophil apoptosis
4.2.1 Morphology
Cells (120 pit of 2x106/ml) were cyto-centrifuged, fixed in
methanol, stained with Diff-Ouik™ (Gamidor Ltd., Abingdon,
GB) and counted using oil immersion microscopy (x100
objective) to determine the proportion of cells with distinc¬
tive apoptotic morphology [4, 7, 13]. At least 500 cells were
counted per slide. Ail experiments were performed at least
three times and each treatment done in duplicate and the
results are expressed as the mean % apoptosis ± SEM.
4.2.2 Annexin V binding
A separate and independent assessment of apoptosis was
performed by flow cytometry using FITC-labeled recombi¬
nant human annexin V that binds to phosphatidylserine
exposed on the surface of apoptotic cells. Stock annexin V
(Bender MedSystems, Vienna, Austria) was diluted 1:200
with binding buffer and then added (20 pi) to 120 pi of the
recovered cell samples. Following a 10-min incubation at
4°C, these samples were fixed by the addition of 100 pi of
3% paraformaldehyde in PBS before analysis using an
EPICS Profile II (Coulter Electronics, Luton, GB) [13].
4.3 Preparation of cell cytoplasmic extracts
Following incubation at 37°C with the indicated reagents
(see figure legends for concentrations and times) eosino¬
phils were washed with ice-cold PBS and the cells lysed at
4°C for 15 min with Nonidet P-40 lysis buffer as described
[43] (50 mM NaF, 5 mM Na^O?, 1 mM Na3V04, 10 mM
[5-glyceropyrophosphate, 0.5 % (v/v) Nonidet P-40, 2 mM
EDTA, 16.8mM Na2HP04, 3.2 mM NaH2P04) containing
complete protease inhibitor cocktail EDTA free (Roche Diag¬
nostics, Mannheim, Germany). The cell fragments were then
centrifuged (13,000xg, 10 min, 4°C) and the supernatants
containing the cytoplasmic extracts collected.
4.4 Western blot analysis
The cell extracts were diluted with 3x sample buffer [5.7%
(wt/v) SDS, 14% mercaptoethanol, 150 mM Tris-HCI, pH
6.7; 30% (v/v) glycerol] and heated at 95°C for 3 min before
running on 10% (wt/v) SDS-polyacrylamide gel. Electopho-
retically separated proteins were transferred on PVDF micro-
porous membranes (Millipore Corporation). Non-specific
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binding was blocked with PBS containing 5% non-fat dry
milk and 0.1 % Tween 20 (Sigma Co., Poole, GB) and probed
with the indicated antibodies (anti-lKBa from New England
Biolab Ltd., Hertfordshire, GB; anti-p65 and -p50 antibodies
from Santa Cruz Biotechnology, CA). As a positive control
10 ng of protein extracted from un-treated Jurkat cell [main¬
tained in RPMI 1640 (Life Technologies), 10% FCS (Life
Technologies)] extract was also run on the gels. Immunode-
tected proteins were visualized by ECL™ detection reagents
(Amersham/Pharmacia).
4.5 Immunohistochemistry
Eosinophils (2.5x106/ml) were incubated in Iscove's DMEM
containing 5% FCS for 2 h at 37°C before treatment with the
indicated agents and time (see figure legends for details).
The cells were cyto-centrifuged, air dried for 10 min and
then fixed with 4% (w/v) p-formaldehyde/PBS for 10 min
and washed three times with PBS. The cells were permeabil-
ized and nonspecific binding was blocked in buffer contain¬
ing 0.2% (w/v) Triton X-100 protein block serum-free buffer
(DAKO Corp., Glostrup, Denmark) at room temperature for
30 min. The cells were incubated with rabbit polyclonal p65
antibody (Santa Cruz Biotechnology; 1:100 dilution) in anti¬
body diluent (DAKO) with 0.2% Triton X-100 for 1 h. The
cells were washed three times in antibody diluent with 0.2%
Triton X-100 and then incubated (1:100 dilution) with Alexa™
488 (goat anti-rabbit) IgG antibody (Molecular Probes,
Eugene, OR) for 1 h in antibody diluent with 0.2% Triton X-
100 then washed three times in the same buffer. The nucleus
was stained with 0.1% (v/v) propidium iodide (Sigma) with
2% (w/v) RNase in PBS at 37°C for 30 min followed by
washing (x3) with PBS before applying a glass coverslip.
4.6 Confocal microscopy and image analysis
Images are from single confocal sections, 0.3 urn thick,
taken through the center of the nucleus, on a Leica TSC 4D
confocal microscope using a 63x objective lens. NF-kB
nuclear translocation was determined with a Leica DMRB
microscope using a 40x NA 0.7 objective lens and Kappa
integrating monochrome CCD camera. Image analysis was
integrated with image capture as described before [44], The
image analyzer captures an image of the green NF-kB fluo¬
rescence and using an automated macro-program devel¬
oped for this application on a Leica Q550IW image analyzer
and uses the binary images of the propidium iodide staining
as a mask to measure only the NF-kB fluorescence of the
nuclei. The image analyzer then detects the green fluores¬
cence (488 nm excitation, 530 nm emission) and subtracts
the binary image of the red fluorescence (570 nm excitation,
620 nm emission) to give a binary mask for the cytoplasm.
At least 300 cells were counted per condition and the data
accumulated. Means ± SEM are determined for each experi¬
ment independently.
4.7 IL-8 measurement
The ELISA was performed using IL-8 recombinant protein as
a standard and IgG anti-human IL-8 according to the manu¬
facture's instructions (R&D systems, Abingdon, GB).
4.8 Materials
Further specific materials were obtained as follows: recom¬
binant human TNF-a (R&D Systems), MG-132 (N-cbz-Leu-
Leu-leucinal) (Biomol, Affinity Research Products, Mam-
head, GB) and zVAD-fmk (benzylocarbonyi-Val-Ala-Asp-
fluoromethylketone) (Bachem Ltd., Saffron Walden, GB).
4.9 Statistical analysis
The results are expressed as the mean ± SEM of the number
(n) of independent experiments each using cells isolated
from different donors with each treatment performed in
duplicate or triplicate. Statistical analysis was performed by
ANOVA with comparisons between groups made using the
Newmans-Kuels procedure. Where appropriate, analysis
was performed using the paired Student's f-test. Differences
were considered significant when p<0.05, and are repre¬
sented by the indicated symbol.
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NF-kB Activation Is a Critical Regulator of Human Granulocyte
Apoptosis in Vitro*
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During beneficial inflammation, potentially tissue-
damaging granulocytes undergo apoptosis before being
cleared by phagocytes in a non-phlogistic manner. Here
we show that the rate of constitutive apoptosis in hu¬
man neutrophils and eosinophils is greatly accelerated
in both a rapid and concentration-dependentmanner by
the fungal metabolite gliotoxin, but not by its inactive
analog methylthiogliotoxin. This induction of apoptosis
was abolished by the caspase inhibitor zVAD-fmk, cor¬
related with the inhibition of nuclear factor-kappa B
(NF-kB), and was mimicked by a cell permeable inhibi¬
tory peptide of NF-kB, SN-50; other NF-kB inhibitors,
curcumin and pyrrolidine dithiocarbamate; and the pro-
teasome inhibitor, MG-132. Gliotoxin also augmented
dramatically the early (2-6 h) pro-apoptotic effects of
tumor necrosis factor-a (TNF-n) in neutrophils and un¬
masked the ability of TNF-a to induce eosinophil apo¬
ptosis. In neutrophils, TNF-a caused a gliotoxin-inhibit-
able activation of an inducible form ofNF-kB, a response
that may underlie the ability of TNF-a to delay apoptosis
at later times (12-24 h) and limit its early killing effect.
Furthermore, cycloheximide displayed a similar capac¬
ity to enhance TNF-a induced neutrophil apoptosis even
at time points when cycloheximide alone had no pro-
apoptotic effect, suggesting that NF-kB may regulate the
production of protein!s) which protect neutrophils from
the cytotoxic effects of TNF-a. These data shed light on
the biochemical and molecular mechanisms regulating
human granulocyte apoptosis and, in particular, indi¬
cate that the transcription factor NF-kB plays a crucial
role in regulating the physiological cell death pathway
in granulocytes.
Neutrophilic and eosinophilic granulocytes originate from a
common myeloid precursor; neutrophils are particularly active
in the defense against invading micro-organisms whereas eo¬
sinophils serve in anti-parasitic defenses and play a role in
allergic inflammation. The normally beneficial acute inflam¬
matory response can become dysregulated and result in chronic
inflammatory conditions where tissue damage arises in part
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due to the inappropriate liberation of inflammatory cell-de-
rived histotoxic products. We have previously described a gran¬
ulocyte clearance mechanism likely to be important, in the
normal control and resolution processes of inflammation
whereby granulocytes must first, undergo apoptosis (pro¬
grammed cell death) before being phagocytosed and cleared by
macrophages in situ (1, 2). Apoptosis also causes functional
down-regulation of granulocytes and the retention of proteo¬
lytic granule contents to further limit the potential for granu-
locyte-mecliated tissue damage (3, 4). While little is known
about the physiological mechanisms involved in controlling
granulocyte apoptosis, many in vitro studies have now shown
that an array of pro-inflammatory cytokines and inflammatory
mediators known to be present at. inflamed sites inhibit the
process of apoptosis in granulocytes (2—9). This has led to the
suggestion that such agents act both to attract and activate
inflammatory cells and also delay their removal. A notable
exception to this rule, however, is TNF-a,1 which, at early time
points in neutrophil culture, causes acceleration of the consti¬
tutive rate of apoptosis (10).
Many inflammatory mediators regulate gene expression in
target cells by influencing the activities of transcription factors
such as nuclear factor-xB (NF-kB). NF-kB is composed of horno-
or heterodimers of the Rel family proteins (p-50/NFkBI, p52/
NF/<B2, p65/RelA. and cRel) which are sequestered in the cy¬
toplasm by physical association with inhibitor proteins referred
to as IkB (11). Upon activation, the IkB subunit is rapidly
phosphorylated leading to its proteolytic breakdown permitting
NF-kB to translocate to the nucleus (12. 13) where it regulates
the activity of many genes involved in the inflammatory re¬
sponse. including those for pro-inflammatory cytokines. In a
number of cell systems TNF-a has been shown to induce rapid
activation of NF-kB, a response known to mediate a number of
TNF-a induced cellular responses (reviewed in Refs. 14-16).
However, whether the activation of NF-kB is involved in either
the pro- or anti-apoptotic effects of TNF-« in granulocytes is
currently unknown.
Whereas the inhibition of NF-kB has been shown to induce
apoptosis in murine B cells (17), a completely opposite effect
has been observed in other cell types where apoptosis is asso¬
ciated with activation of NF-kB (18). In addition, several
groups have reported that inactivation of NF-kB increases the
cytotoxic effects of TNF-a (19- 21). In granulocytes, it remains
uncertain whether NF-kB can be activated by inflammatory
mediators, or is indeed present, in human neutrophils. For
! The abbreviations used are: TNF-u. t lienor necrosis factor-n; IIMSA.
electrophorelic mobility shift assay; LPS, tipopoiysacctiaride: NF kR.
nuc lear factor-evil; i'UTC, pyrrolidine dilliiorarbamate; xYA! t fcnk, ben
/.vloxyearboiiyl-Val-Ala-Asp-lluoroiiiethylkelone: DM KM, I tulbeeco's
modified Ragle's medium.
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example, while MacDonald et al., (22) reported that lipopo-
lysaccharide (LPS). TNF-«, and the chemotactic peptide N-
formyl-metliionyl-leucyl-phenylalanine all cause a marked ac¬
tivation of NF-kB, Browning et a/., (23) found no such activity
in these cells despite obvious NF-kB activation in peripheral
blood mononuclear cells.
Gliotoxin, a member of the epipolythiodioxoperazine family
of compounds (24), exhibits immunosuppressive activity both
in vivo and in vitro. For example, gliotoxin has been shown to
inhibit mitogen-induced proliferation of both T and B cells,
induce macrophage and osteoclast apoptosis in vitro (25, 26),
and cause thymocyte and spleen cell apoptosis in vivo (27).
However, the biochemical and molecular mechanisms underly¬
ing these effects remain uncertain. Gliotoxin has, however,
recently been shown to be a potent and specific inhibitor of
NF-kB (28). We therefore used gliotoxin as a pharmacological
tool to investigate the involvement of NF-kB in the regulation
ofgranulocyte apoptosis. We demonstrate that gliotoxin causes
a rapid and major induction of apoptosis in human peripheral
blood granulocytes in vitro and up-regulates TNF-or-induced
apoptosis in both neutrophils and eosinophils. In addition, we
present evidence that these effects occur via a specific, non¬
toxic and caspase-controlled mechanism that is mediated by
the ability of gliotoxin to inhibit an inducible form of NF-kB.
The ability of other NF-kB inhibitors to cause a similar induc¬
tion of apoptosis provides further evidence supporting the in¬
volvement of NF-kB in granulocyte apoptosis. Interestingly,
the pro-apoptotic effect of TNF-« is enhanced by protein syn¬
thesis blockade suggesting that NF-kB activation results in the
generation of an unidentified survival protein. These data
therefore strongly suggest that NF-kB plays a key role in
regulating both constitutive and TNF-a stimulated human
granulocyte apoptosis.
kxi>k iii micntal, proof,dures
Neutrophil and Eosinophil Isolation and Culture
Neutrophils and eosinophils were isolated from the peripheral blood
of normal donors by dextran sedimentation followed l>v centrifugatiori
through discontinuous plasma-Por<x>ll gradients (2, 29). Only neutro¬
phil preparations with a neutrophil purity of >98% were used. Eosin¬
ophils were separated from contaminating neutrophils using an iminu-
nomagnetic separation step with sheep anti-mouse IgG-Dynabeads
(l)ynabeads M-450, Dynal, Merseyside. United Kingdom) coated with
the murine anti-neutroph.il antibody 3G8 (anti-0I)16; a gift from Dr. J.
Unkeless, Mount. Sinai Medical School, New York). Cells were mixed
with washed 3G8-coaled Dynabeads at a beaduieutrophil ratio of 3:1 on
a rotary mixer at '1 "0 for 20 min, and the beads removed magnetically
by two 3-min stationary magnetic contacts (Dynal Magnetic Particle
Concentrator. MPC-l) to yield an a eosinophil population of >98#
purity. After purification, cells were washed twice in phosphate-buff¬
ered saline without calcium and magnesium and once in phosphate-
buffered saline before resuspending in Iseove's DM EM (Life Technolo¬
gies, Paisley. UK) with 10% autologous serum. Roth cell types were
cultured in flat-bottomed f alcon flexible wells (Becton Dickinson, Ox¬
ford. UK) at 37 "C in a 5# C()2 atmosphere; neutrophils at a concen¬
tration off) x ]0r7ml and eosinophils at 2 x l()°/ml. Cells were cultured
in the absence or presence of test agents as described in the figure
legends. All experiments were performed at least 3 times and each
treatment done in triplicate.
Assessment of Granulocyte Apoptosis
Mm■phnlogy Cells were cyto-ccntrifuged, fixed in methanol, stained
with Diff-C^uik IM. and counted using oil immersion microscopy (xlOO
objective) to determine the proportion ofCells with highly distinctive
apoptolic morphology l T>. 7. 10). At least hot) cells were counted fx-r slide
with the observer blinded to the experiment conditions. The results
were expressed as the mean apoptosis • S.E.
Anne Yin \' I'mding A separate and independent assessment ofapn
ptosis was performed by flow cytometry using fluorescein isolhiocva
nate labeled recombinant human aniiexin V that hinds to phosphate
dylserine exposed on the surface of apoplotic cells. Stock anuexin V
(Bender MedSvstems. Vienna. Austria) was diluted 1:200 with binding
buffer and then added (25 pi) to 75 pi of the recovered cell samples.
Following a 10-min incubation at 4 °C, these samples were fixed by the
addition of 100 pi of 3% paraformaldehyde in phosphate-buffered saline
before analysis using an EPICS Profile II (Coulter Electronics, Luton,
UK).
DNA Fragmentation Assay DNA was extracted as described previ¬
ously (10). Briefly, 2 x 10° neutrophils were taken after the indicated
treatment and lysed in 500 pi of lysis buffer (6 M guanidine hydrochlo¬
ride, 50 uim Tris-HCl, pH 8.0, and 0.1% AMauroyl sarcosine) at 4 °C and
the nucleic acids extracted by t he addition of an equal volume of 10 inM
Tris-HCl, pH 8.0-saturated phenokchloroforin mixture (50:50, v/v). The
resulting emulsion was centrifuged at 12,000 x gav for 10 min at room
temperature and the aqueous phase removed and precipitated with 0.6
volumes of isopropvl alcohol at room temperature. The precipitated
nucleic acids were then pelleted by centrifugation at 10,000 x gav for 5
min and re-clissolved in 50 pi of TE buffer (10 niM Tris-Cl, 1 mM EI)TA,
pll 8.0) containing 50 p.g/ml RNase A. The fragmented DNA was sep¬
arated by agarose gel electrophoresis on a 1.4% (w/v) agarose (Flowgen,
UK) 0.5 x TBE (10 him Trizma (Tris base), 10 mM boric acid, arid l mM
EDTA, pll 8.3) gel. The gel was run for 2 h at. 75 V and stained using
ethidium bromide (0.5 pg/ml). The UV transilliuninated image was
printed by digital thermal printing using a GS7600 gel documentation
system (UVP Products, UK).
Assessment of Cell Membrane Integrity
Since apoptotic neutrophils and eosinophils maintain the integrity of
their plasma membrane, assessment of granulocyte necrosis can be
determined by the ability of cells to exclude the vital dye trypan blue
and also by flow cytometry using propidiurn iodide staining. Samples
(150 pi of cells at 2 x 10°/rnl) were centrifuged and rcsuspended in 150
pi of propidium iodide solution (33 pg/ml propidium iodide in phos¬
phate-buffered saline containing 1.67 mg/ml RNase). The profiles of
heat-treated (necrotic cells) from the same samples were used as
controls.
Electrophoretic Mobility Shift Assay (EMSA)
EMSAs were carried out as described by the manufacturer (Promega
Corp, Southampton, UK). Nuclear extracts were prepared from 5 x 10''
cells using a modification of the method of Dignam et al. (30). Briefly,
pelleted cells were resuspended in 200 pi of hypotonic buffer (buffer A:
10 mM Tris-HCl, pll 7.8. 1.5 mM EDTA, 10 m.M KCl. 0.5 mM dithiothre¬
itol. 1 pg/ml aprotinin, leupeptin, and popstatin A. 1 p.M 4-(2-aminoeth-
yUbenz.enesulfonyl fluoride, 1 mM sodium ortliovanadate, 0.5 mM ben-
zamidine. and 2 m.M levamisole) and placed on ice for 10 min. Following
the addition of 0.1 volumes of 10% Nonidet P-40 (W/v) the cells were
vortexed briefly and centrifuged at 12,000 x »IIV for 2 min at. 4 °C. The
supernat ant was discarded and the pellet washed in 100 pi of buffer A
minus Nonidet P-40 and re-cent rifuged. The pelleted nuclei were then
resuspended in 50 pi ofhypertonic buffer (buffer B: 20 mM Tris-HCl, pH
7.8, 150 mM NaCl, 50 mM KCl, 1.5 mM EDTA, 5 mM dithiothreitol. 1
pg/ml aprotinin, leupeptin, and pepstatin A, 1 pM 4-(2-aminoet.hyl)ben-
zenesulfonvl fluoride, 1 mM sodium orthovanadate, 0.5 mM benzami-
dine. and 2 mM levamisole) and stored at 80 "C until use.
Nuclear extracts (approximately 2 /»g of protein, 7 x 1 05 cell equiv-
alent, in 7 pi) were incubated in binding buffer (4% glycerol. 1 mm
MgCl2. 0.5 ium EDTA. 0.5 him dithiothreitol. 50 niM NaCl. 10 mM
Tris-HCl, j)ll 7.5, with 50 pg/ml polyUlI-dC)-poly(dl-dC) (Phannacia
Biotech, UK) with 17 fmol of y^P-labeled double stranded oligonucleo¬
tide containing the decameric xB-binding site (3000 Ci/mmol; Promega
Con)., Southampton, UK) at 22 "C for 20 min prior to addition of 5 pi of
loading buffer (0.01% (\vA-) bromphenol blue, 20% (w/v) Eicoll 400™,
and 1 mM EDTA). Samples were loaded onto an 8% (w/v) native acryl-
amidegel (Protean llxi, Bio-Rad, Heniel Hempstead, UK) in 0.5 x TBE
buffer and run at 250 V for 2 h. The gel was then dried onto 3MM paper
(Whatman UK, Maidstone, UK) and BioMax MS-1 x-ray film (Kodak,
Anachem, Luton, UK) was exposed to the gel. Processed films were
analyzed using the (habit and Gel Plate software (UVP, Orme Technol¬
ogies. UK) and the data expressed as a percent of the control value for
each experiment.
Materials
Further specific materials were obtained as follows: ruivumin. glio
toxin. LPS [Escherichia <nh 0127:B8). melhvllhiogliotoxin. and l'DTC
(Sigma Co., Poole. UK); recombinant human TNF-o (R & D Systems,
Abingdon, Oxon. UK); /.VAD-fmk (Bachem (UK) Ltd., Saffron Walden.
UK). The proteasome inhibitor MU 132 (N-rbz-Loii Leu leurinal). and
the NF-kB inhibitory peptides SN50 and SN50M (Biomol, Affinity Re
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Fig. I. Time course and concentration-response curve for the
effect of gliotoxin on human neutrophil apoptosis. Human neu¬
trophils (5 x 10°/ml) were cultured at 37 °C in Iscove's DMEM contain¬
ing 10% autologous serum and treated with the indicated concentra¬
tions of gliotoxin. At the time periods indicated, the cells were
resuspended and cytocentrifuge preparations made. These were fixed
and stained, and apoptosis was assessed morphologically. A, represents
the effect of gliotoxin (0.001-30 pg/ml) on neutrophil apoptosis after '2,
6, or 20 h of culture. B, represents the effect, ofmethylthiogliotoxin (30
/.ig/ml) or gliotoxin (30 pg/ml) on neutrophil apoptosis after 2, 6, or 20 h
culture. All values represent mean ' S.E. of n ~ 3 experiments, each
performed in triplicate. Where not shown, S.E. values are less than 2%
of the mean.
search Products. Mamhead. UK). All other reagents were obtained from
Sigma, UK, and were of the highest purity.
Statistical Analysis
The results are expressed as mean ' S.E. of the number (a) of
inde|xmdent experiments each using cells from separate donors with
each treatment performed in triplicate. Statistical analysis was per¬
formed by ANOVA with comparisons between groups made using the
Newiuan-Kuel.s procedure. Differences were considered significant
when p < O.Ofi.
RESULTS
Effect ofGliotoxin on Neutrophil Apoptosis—As shown in Fig.
1 gliotoxin caused a rapid and profound induction of neutrophil
apoptosis in vitro which was both concentration ic.g at G h
EC,,,, - 76.1 ± 22.1 ng/tnl, Fig. 1A), and time-dependent (Fig. 1.
A and B\. Hence using a maximally effective gliotoxin concen¬
tration of 1 pg/ml. apoptosis was readily apparent within 2 h
and reached lOO'.v by 0 h. At 20 h, when the rate of constitutive
neutrophil apoptosis was 58.7 2: 2.9%, gliotoxin caused 100%
apoptosis at all concentrations greater than 0.1 pg/ml. The
inactive analogue of gliotoxin, methylthiogliotoxin, did not af¬
fect the constitutive rate of neutrophil apoptosis at any of the
time points studied (Fig. IB). Neither gliotoxin nor its inactive
analogue, methylthiogliotoxin, caused cell necrosis since less
than 1% of the cells were permeable to the vital dye trypan
blue.
Gliotoxin Acts Syncrgistically with TNF-a to Stimulate Neu¬
trophil Apoptosis—In contrast, to many other hematopoetic
cells, human neutrophils appear highly resistant to the induc¬
tion of apoptosis induced by certain agents, for example, incu¬
bation with Ca" ionophores (31, 32), cAMP elevating agents
(33), corticosteroids (9), and LPS (7) causes inhibition of apo¬
ptosis as does hypoxia (34). Furthermore, while TNF-a and
Fas-L can induce neutrophil apoptosis, this effect is modest and
transient, and in the case of TNF-a abolished if the cells are
initially primed with platelet-activating factor or LPS (10, 35).
We therefore sought to determine the effect of gliotoxin on
TNF-a-induced apoptosis in neutrophils. These experiments
were performed deliberately at a very early time point (2 h)
when the independent pro-apoptotic effects of even a maxi¬
mally effective concentration of TNF-« (10 ng/ml) (10) and
gliotoxin (1 p,g/ml; Fig. LA) are only just apparent. As shown in
Fig. 2A. a major synergy- was observed between these agents for
the induction of apoptosis which was apparent, even at gliotoxin
concentrations as low as 3 ng/ml. Hence, a concentration of 0.1
pg/ml gliotoxin in combination with TNF-a (10 ng/ml) caused
almost 100% apoptosis at 2 h. With gliotoxin alone, only 6%
apoptosis was noted at 2 h, with just over 65% at 6 h (Fig. 1A).
Again, methylthiogliotoxm had no effect on constitutive apo¬
ptosis or TNF-«-induced apoptosis at 2 h (Fig. 2B). The level of
necrosis in cells from each treatment was assessed by trypan
blue exclusion; all values were <1% (data not shown).
The genuine nature of both the intrinsic pro-apoptotic effect
of gliotoxin and the dramatic synergywith TNF-a was assessed
by comparing the quantitative morphological effects of these
agents with their effects on annexin V binding and DNA frag¬
mentation. The changes from normal cell morphology to apo-
ptotic morphology are clearly seen in Fig. 3A; where non-apo-
ptotic neutrophils contain a multilobed nucleus and the
apoptotic cells have a shrunken appearance with pyknotic nu¬
clei. These data can be compared with Fig. SB, where the
annexin V "low peak" represents non-apoptotic cells and the
annexin V "high peak" represents apoptotic cells since the
fluorescein isothiocyanate-labeled annexin V binds in the pres¬
ence of Ca2 ' to phosphatidylserine exposed on the outer mem¬
brane of apoptotic cells. Although control cells at 2 h exhibit, low
rates of apoptosis, the small increase in annexin V positive cells
observed with TNF-n and gliotoxin alone is again dramatically
augmented when the cells are cultured in the presence of both
reagents together. Analysis by DNA fragmentation also dem¬
onstrates that cells cultured alone or in combination with the
above reagents exhibit the classical "ladder" of DNA fragmen¬
tation associated with apoptosis (Fig. 3C).
Combined Gliotoxin and TNF-a Treatment Does Not Cause
Necrosis—Although our initial studies using trypan blue as a
marker of plasma membrane integrity indicated that gliotoxin,
both in the presence and absence of TNF-a, induced a purely
apoptotic form of cell death, we felt it was important to validate
this further by assessing necrosis in an independent manner
using propidium iodide staining detected by flow cytometry.
Fig. 3D shows the profile of neutrophils 4 h following treatment
with gliotoxin (0.1 /ig/ml) and TNF-a (10 ng/ml) where, despite
apoptotic rates of 100%, almost all cells showed low fluores¬
cence indicating that the ceil membrane had remained intact.
As a positive control, cells cultured initially with TNF-a and
gliotoxin were then heat-treated (60 °C, 5 min) to ensure 100%
necrosis. This resulted in a uniform and major increase in
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100 n
Fig. 2. The effect of gliotoxin, meth-
ylthiog'liotoxin, and TNF-a: on human
neutrophil apoptosis. Human neutro-
phils (5 x 106/ml) were cultured at 37 °C
in lscove's DM EM containing 10% autol¬
ogous serum and treated with the indi¬
cated concentrations of gliotoxin, plus or
minus TNF-a. After 2 h of culture, the
cells were resuspended and cytocentri-
fuge preparations made. These were fixed
and stained, and apoptosis was assessed
morphologically. A, represents the effect
of gliotoxin (0.001-30 /.ig/ml) on TNF-a
(10 ng/inl)-induced neutrophil apoptosis.
tt, represents the effect of methylthioglio-
toxin (30 /.ig/ml) or gliotoxin (30 /xg/ml),
plus or minus TNF-« (10 ng/ml). All val¬
ues represent mean ± S.E. of ;i =3 ex-
periments, each perfonned in triplicate.
Where not shown, S.E. values are less
than 2% of the mean.
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propidium iodide staining (Fig. 3Z5). These data coincide com¬
pletely with the results obtained with trypan blue staining and
confirm that these cells had undergone apoptotic cell death and
were not necrotic.
Gliotoxin Inhibits the Survival Effect ofLPS—To investigate
whether gliotoxin could modulate the effects of LPS on the rate
of neutrophil apoptosis we performed a series of experiments
where neutrophils were cultured for 2. 3, 4, and 20 h in the
presence of LPS. gliotoxin. and a combination of LPS plus
gliotoxin and apoptosis assessed morphologically (Fig. 4). As
reported previously (7) LPS caused an inhibition of neutrophil
apoptosis at 20 h when compared with control cells. Interest¬
ingly, the suppressive effect of LPS was prevented by the
strong pro-apoptotic effect of gliotoxin. In addition; unlike co-
culture of gliotoxin plus TNF-«. no synergistic induction of
apoptosis was observed when LPS was cultured in the presence
of gliotoxin (Fig. 4).
Gliotoxin Unmasks theAbility of TNF-a to Induce Eosinophil
Apoptosis- -To explore whether the pro-apoptotic effect of glio¬
toxin was restricted to neut rophils, a similar set of experiments
were performed using human peripheral blood eosinophils iso¬
lated from mildly atopic individuals. While these cells display a
similar capacity to undergo constitutive apoptosis when aged in
vitro, tins process is much slower than that observed for the
neutrophil and is differentially regulated being, for example,
stimulated rather than inhibited by corticosteroids (9), We
therefore investigated the effect of gliotoxin on eosinophil apo¬
ptosis at 4 h in the presence and absence of TNF-a. The results,
shown in Fig. 5, A and B, demonstrated that gliotoxin caused a
similar induction of apoptosis in eosinophils (EC-0 = 0.37 ±
0.22 /xg/inl) and caused a synergistic increase in the rate of
apoptosis when the cells were co-cultured with TNF-a. This
latter observation was all the more striking since in eosino¬
phils. TNF-« treatment alone had no effect on the rate of
apoptosis (Fig. 5B and data not shown). Hence, almost 100%
apoptosis was observed using a gliotoxin concentration of 0.1
pg/ml plus TNF-o at a time point of 4 h. In comparison, eosin¬
ophils cultured in the absence ofgliotoxin would normally show
only 40% apoptosis at a 40-h time point (2. 36). Necrosis in
these cells was <2% and the inactive analogue of gliotoxin had
no effect on either the constitutive rate of apoptosis alone or in
conjunction with TNF-a (data not shown). As with the neutro¬
phils, eosinophils demonstrated classic apoptotic morphology
when treated with these agents.
Gliotoxin Causes Inhibition of an Inducible Isofonn of NF-
kB—Recent studies have indicated that NF-kB may play on
important role in regulating the rate of apoptosis in certain
transformed cells i 17, 18). Hence, because gliotoxin has been
reported to act as a specific inhibitor ofNF-kB (28) experiments
were designed to identify and characterize the expression of
this transcription factor in human neutrophils and determine if
gliotoxin could inhibit such activity. Preliminary time course
data established 90 mill as the optimal time to examine basal,
gliotoxin. and TNF-a regulated NF-kB activity in these cells
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Fig. 3. The effect of gliotoxin and
TNF-rv 011 neutrophil morphology,
phosphatidylserine expression, and
cell membrane integrity. A, eytocentri-
fuge. preparations of human neutrophils
incubated for 2 h in Iscove's DMEM at
37 "C containing 10% autologous serum
alone (control.), plus TNF-o, plus glio¬
toxin. or with both TNF-q and gliotoxin at
the concentrations shown. Neutrophils
treated with both reagents all clearly
show apoplot.ic morphology. B, after 2 h in
culture at 37 "C, cells treated with
1.stoves DMEM, TNF-a (10 ng/ml), glio¬
toxin (0.1 /.ig/rnl), or with both TNF-a plus
gliotoxin were resuspended and incu¬
bated with fluorescein isothioeyanate-la-
beled recombinant human annexin V to
determine phosphatidylsorine expression.
The cells were then fixed and analyzed
using an 10 PICS Profile 11. Mean fluores¬
cence values are shown for a minimum of
5,000 cells for each condition. C. I.)NA
fragmentation in human neutrophils
treated with TNF-.t 110 ng/ml), gliotoxin
(0.1 /.tg/rnl). or both reagents together for
2 h. 1)NA was prepared as detailed under
"Experimental Procedures"; lane /, DNA
marker (1 -kilobase ladder); lane 2, freshly
isolated neutrophils: lane 3, control; lane
■I, TNF-a; lane 5, gliotoxin. 2 h; lane (>.
co-culture with gliotoxin and TNF-o; lane.
7, DNA marker (l-kilobase ladder). I), to
assess cell membrane integrity, cells
treated with both TNF-o (10 ng/ml) and
gliotoxin (0.1 /ig/ml) for -I h, which in¬
duced 100% apoptosis even b.v 2 h. were
resusponded and incubated with pro-
pidium iodide, fixed, and analyzed using
an EPICS Profile II (solid line). An aliquot
of cells from this preparation was heated
as indicated under "Experimental Proce¬
dures*' to produce 100% necrosis (dotted,
line). Mean fluorescence values are shown
for a minimum of 5,000 cells for each
rondit ion.
Ulinluxin (0.1 PG'nil) 2 h Apoptmi* (1 U%) TNI--a < 10 +Glkiln\m (0.1 pp/ml) \popt«rm < IUW%»
(data not shown). Of note, this time point also coincided with
the onset of the biologically observable effect of gliotoxin. As
shown in Fig. G, A-C, NF-kB EMSAs performed on neutrophil
unclear extracts indicated the presence of 3 discrete bands in
these gels. To ascertain which of these bands were specifically
NF-kB, an excess of unlabeled probe was included in the label¬
ing reaction to displace specific binding; as shown in Fig. SC.
two NF-kB bands were identified and designated A and B.
In bot-hTNF-d (10 ng/ml, 0-90 mini and LPS 11 jug/ml, 0-120
mm) treated cells. 110 change in the intensity of band B was
observed (Fig. 5, A and B. and data not. shown). This, together
with its strong expression in freshly prepared untreated neu-
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Fig. 4. The effect of g'liotoxin alone and in the presence of LPS
on human neutrophil apoptosis. Human neutrophils (5 x 10°/inl)
were cultured in Iscove's DMEM at 37 °C containing 10% autologous
serum alone and treated with gliotoxin (0.1 pg/ml), with orwithout LPS
(1 pg/ml). At the time periods indicated, the cells were resuspended and
cytocentrifuge preparation made. These were fixed and stained, and
apoptosis was assessed morphologically. All values represent mean ±
S.E. of /! = 3 -5 experiments, each performed in triplicate. Where not
shown, S.E. values are less than 2% of the mean.
tropliils suggests that this band represents a form of constitu-
tively active NF-kB. However, band A was markedly up-regu¬
lated by TNF-o (Fig. 6, A and C), and as shown in Fig. 6A.
gliotoxin caused both a concentration-dependent inhibition of
this NF-kB activity and abolished the TNF-« stimulated in¬
crease in this band. As shown in Fig. 61), densiometric analysis
of these data confirmed that co-treatment of neutrophils with
TNF-« and gliotoxin at a maximal effective functional concen¬
tration of 0.1 pg/ml (Fig. 2A) inhibited this band more than
treatment with gliotoxin alone. The results in Fig. 6, A and D,
confirm that the basal level of NF-kB activity in control sam¬
ples at 90 inin was inhibited by gliotoxin treatment; a finding
that was observed at all other time points tested.
Further evidence that strongly supports the suggestion that
NF-kB inhibition is linked to the induction of neutrophil apop¬
tosis is provided by the fact that the cell permeable NF-kB
inhibitory peptide. SN50 (37). also increased the rate of consti¬
tutive neutrophil apoptosis despite the fact that less than o'/r of
the peptide reportedly enters the cell (37). Hence at 6 h, the
SN50 peptide increased neutrophil apoptosis from 4.7 ± 1.2 to
15.0 t 3.26! in = 3; p < 0.05), whereas the less active peptide
SN50M only increased apoptosis from 4.7 - 1.2 to 5.6 * 0.8'.»
in ■--- 3). Similar effects on neutrophil apoptosis were seen at
20 h and eosinophil apoptosis at '20 and 40 h (Table 1 and data
not shown). Other agents known to inhibit NF-kB similarly
Fig. 5. The effect of gliotoxin alone and in the presence of
TNF-n on human eosinophil apoptosis. Human eosinophils (2 x
10°/ml) were cultured in Iscove's DMEM at 37 °C containing 10% au¬
tologous serum alone and treated with the indicated concentrations of
gliotoxin with or without TNF-a. At the time periods indicated, the cells
were resuspended and cytocentrifuge preparation made. These were
fixed and stained, and apoptosis was assessed morphologically. A, rep¬
resents the effects ofgliotoxin (0-3 pg/inl) on eosinophil apoptosis after
4 h of culture. B, represents the effects gliotoxin (0-0.3 pg/ml) with or
without TNF-« (10 ng/ml) on eosinophil apoptosis after a 4-h culture. All
values represent mean ~ S.E. of n = 3 experiments, each performed in
triplicate. Where not shown, S.E. values are less than 2% of the mean.
induced neutrophil apoptosis. The proteasome inhibitor, MG-
132 (38) and the NF-kB inhibitor curcumin (39) caused a time-
dependent induction of neutrophil apoptosis (Fig. 7A). PDTC,
that acts as both a radical scavenger and inhibitor of NF-kB
activation (40), also caused a significant, induction of apoptosis
when cultured with neutrophils for 20 h (Fig. IB). Further¬
more, treating neutrophils with LPS (100 ng/ml. 20 mill) which
we have previously reported to induce a profound inhibition of
neutrophil apoptosis (7) was found to cause the appearance of
this inducible isoform of NF-kB (Fig. 6B): and this induction
could be inhibited by gliotoxin (0.1 pg/rni).
Induction ofApoptosis by Gliotoxin Is Dependent on Activa¬
tion of the Caspase-cascade Pathway—We have recently dem¬
onstrated that the early pro-apoptotic effects of TNF-rv in hu¬
man neutrophils requires activation of both TNF-55 and
TNF-75 receptor subtypes and thereby differs significantly
from the priming effect of TNF-o which is signaled via the
TNF-poo receptor alone (10). To determine whether the pro-
apoptotic effects of giiotoxin and the marked synergism dis¬
played by TNF-a and gliotoxin were mediated via activation of
the caspase pathway, we co-incubated neutrophils with TNF-o,
gliotoxin, and zVAD-fmk. At 2 h. zVAD-fmk completely inhib¬
ited the increase in apoptosis induced by gliotoxin. TNF-a and
by both factors together (Fig. 8A). This demonstrates that
apoptosis induced by both factors alone, or together, is depend¬
ent on caspase activation.
Gliotoxin May Enhance TNF-n-induced Apoptosis by Inhib¬
iting Production of a Survival Factor—Taken together, the
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Tin• effect ofNP-tB inhibitory peptides on human neutrophil
apoptosis
Human neutrophils (5 x l()e'/ml) were resuspended in lseove's DMEM
without autologous serum and treated with control buffer, SN50 (100
jxg/ml), and SN50M 1100 pg/ml). After 15 min at 37 °C, 1071' autologous
serum (final concentration) was added, and after 6 and 20 h of culture,
the cells were resuspended and cytocentrifugo preparations made.
These were fixed and stained, and apoptosis was assessed morpholog¬
ically. All values are from n = three separate experiments, each per¬
formed in triplicate.
12 3 4
Treatment Time Mean S.E.
% apoptosis
Control (buffer) (ill 4.7 1.2
SN50 (active) (ill 15.0" 3.3
SN50M (less-active) (ih 6.8 5.6
Control (buffer) 201i 58.9 7.7
SN50 (active) 20k 81.4" 2.7
SN50M (less-active) 20h 70.3 8.2
4—A
4—B























Fl(J. (». Effect of g'liotoxin and TNF-u on NF-kB mobilization. A.
EMSA of nuclear extracts from neut rophils treated with control buffer.
lane I. TN F-r* (10 ng/inl); lane 2. gliotoxin (I /tg/ml); lane 3, gliotoxin
(0.1 /<g/ml); lane I. and TNF-n < 10 iig/mb |>l«s gliotoxin (0.1 ,ug/ml); lane
/>. for 00 min at '31 II, EMSA showing the np-regulation of the
inducible isoform {band A) by LPS (a known inhibitor of neutrophil
apoptosis! after 20 min culture: lane 1. control; lane 2, LPS (100 ng/ml);
and lane. 3, LPS <100 ng/ml) plus glio toxin (0.1 pg/mh. C, LMSA show¬
ing displacement of spei'ific NF-kB bands by excess cold oligonucleotide
probe; lane I. control; lane. 2, TNF-n (10 ng/nil): lane 3, INI*-o (10
ng/ml) phis HO-fold excess cold oligonucleotide; lane. 4. TNI--ft 110 ng/ml)
plus 1 Oil-fold excess cold oligonucleotide. Only the bands marked A and
B are specific. /), densioinetrv scanning of band A from the EMSA
shown in A. This shows the reduction of an inducible isoform of NF-kB
by glintnxin la 1 gg/iul; b 0.1 ug/ml), and further inhibition by
co-treatment with, TNF-.t plus gliotoxin (b).
above results suggest that activation of an inducible form of
NF-kB may inhibit or restrain the pro-apoptotic effects of
TNF-n* which are mediated by the parallel activation of the
MG-132 Curcumin
Fig. 7. Effect, of other NF-kB inhibitors on neutrophil apopto¬
sis. Human neutrophils (5 x 10°/inl) were cultured at 37 °C in Iscove's
DMEM containing 10% autologous serum and treated with the indi¬
cated reagent. A. neutrophils were treated with MCI 132 (20 fi\\) and
curcumin (20 pM) at the time periods indicated; H. neutrophils were
treated with MG-132 (100 pM), curcumin (20 pM), and PDTC (300 p.m)
for 20 h. After incubation, the cells were resuspended and cytocentri-
fuge preparations made. These were fixed and stained, and apoptosis
was assessed morphologically. All values represent mean ::: S.E. of n
three to six experiments, each performed in triplicate. Where not
shown, S.E. values are less than 2% of the mean.
caspase pathway. The possibility that this most likely reflects
the production of a protein or proteins which act to suppress
the activation of the caspase pathway and thus protect granu¬
locytes from the cytotoxic effects of this cytokine was investi¬
gated by incubating neutrophils with TNF-n- and cyclohexi-
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Fig. 8. Effect of the caspase inhibitor, zVAD-fmk, and the pro¬
tein synthesis inhibitor, cycloheximide, on gliotoxin, TNF-a, or
gliotoxin plus TNF-re-induced human neutrophil apoptosis. Hu¬
man neutrophils (5 x l()°/nil) were cultured in DMEM containing 10%
autologous serum and treated with the indicated reagents. After 2 h of
culture, the cells were resuspended and eytocentrifuge preparation
made. These were fixed and stained, and apoptosis was assessed mor¬
phologically. A, represents the effects of zVAD-fmk (100 uM) on glio¬
toxin (0.1 gg/ml)-, TNF-o (10 ng/ml)-, or gliotoxin plus TNF-o-induced
neutrophil apoptosis. B, represents the effects of cycloheximide (5 uM)
on gliotoxin (0.1 pg/ml)-, TNF-o (10 ng/ml)-, or gliotoxin plus TNF-o-
induced neutrophil apoptosis. All values represent mean * S.E. of n
three experiments, each performed in triplicate. Where not shown, S.E.
values are less than 2% of the mean.
raide. a protein synthesis inhibitor. As illustrated in Fig. SB,
cycloheximide used specifically at a concentration (5 p.v) that
alone had almost no effect on neutrophil apoptosis at 2 h,
caused a synergistic increase in the level of apoptosis when
neutrophils were co-cultured with TNF-n. This supports the
view that TNF-rv treatment indeed results in the generation of
a survival protein that protects these cells from the TNF re-
ceptor-caspase-dependent induction of apoptosis by TNF-o.
IIISCI.'SSION
We have demonstrated that gliotoxin. hut not its inactive
derivative methylthiogliotoxin, (a) induces a direct time- and
concentration-dependent increase in the rate of constitutive
apoptosis in both neutrophils and eosinophils. (6) enhances the
pro-apoptotic effect of TNF-o in neutrophils, and (c) reveals the
cytotoxic effects of TNF-o in eosinophils. In these studies ex¬
treme care was taken to ensure that gliotoxin, at all time points
and concentrations studied, was non-toxic and caused genuine
apoptosis that was indistinguishable from later constitutive
apoptosis. The similar effects of gliotoxin in both neutrophils
and eosinophils and the same concentration of gliotoxin (0.1
pg/ml) required for maximal enhancement of the pro-apoptotic
effects of TNF-«, suggests that an identical underlying mech¬
anism is regulating the induction of cell death in both these cell
types. However, although inhibition of basal NF-kB activity
may be involved in neutrophil apoptosis when induced by glio¬
toxin alone (Fig. 1) since gliotoxin appears to block basal levels
of NF-kB activity (Fig. 6, A and D), only the expression of the
inducible NF-kB isoforin is down-regulated before the onset of
cell death driven by the combined effects of TNF-a and glio¬
toxin (Fig. 6). Even in control neutrophils incubated for 20 h,
where the constitutive rate of apoptosis is approximately 70%,
the density of the constitutive NF-kB band was unaffected
(data not shown). These differences in the inducible and con¬
stitutive forms of NF-kB most likely reflects differential regu¬
lation ofactivation, for example, by the involvement of different
isoforins of the inhibitory IkB subunit, or that the constitu-
tively active NF-kB is formed from a different set of dimers
from the classical RelA/poO heterodimer. It has recently been
demonstrated that neutrophils contain c-Rel, p50, and plOo
(the p50 precursor protein) as well as Rel-A (22, 41). The
inducible band we observed has also been reported to be up-
regulated in neutrophils by phagocytosis of IgG opsonized yeast
particles (42), and has been shown to consist mainly of Rel-A/
poO heterodimers and possibly a small amount of c-Rel (42). In
that study, phagocytosis of these particles did not affect the
activity of the constitutive complex. In addition, it has recently
been reported that NF-kB becomes activated, via a mecha¬
nisms not involving oxidant generation, when neutrophils
phagocytose bacteria (43).
Because NF-kB is also activated by certain pro-apoptotic
stimuli such as TNF-«, this transcription factor has been con¬
sidered as a possible regulator of cell death. Hence, in some T
cell clones, activation of NF-kB appears to correlate with the
onset of apoptosis (18). However, NF-kB activation has clearly
been shown to be anti-apoptot.ic in HT 1080 fibrosarcoma cells
(21) and TNF-« induced NF-kB activation prevents cell death
in HeLa and MCF7 cells (44). Here we show for the first time
that in a non-transformed cell namely the neutrophil, inhibi¬
tion of an inducible form ofNF-kB is related to the induction of
apoptosis.
Several mechanisms, aside from NF-kB inhibition, have
been proposed for the pro-apoptotic actions of gliotoxin hi other
cells. Sutton et at. (45) have shown that although this fungal
metabolite did not affect intracellular calcium levels, there was
a correlation between increases in cAMP levels and apoptosis
in gliotoxin-treated splenocytes. However, we and others have
previously demonstrated that agents that elevate intracellular
cAMP inhibit apoptosis in both neutrophils and eosinophils (33,
46). It. has also been suggested that protein kinase A-dependent
phosphorylation of histone H3 correlates with gliotoxin-in-
duced apoptosis in thymocytes (47). but again in neutrophils,
activation of protein kinase A inhibits apoptosis (33). Although
gliotoxin has been reported to inhibit protein synthesis (48) it is
highly unlikely that this mechanism is directly responsible for
its pro-apoptotic effects: first, gliotoxni induces apoptosis in
thymocytes whereas inhibition of protein synthesis by cyclo¬
heximide inhibits thymocyte apoptosis. Second, since NF-kB
activation is involved in the control of multiple genes, many of
which encode for inflammatory mediator synthesis, inactiva-
tion of NF-kB would therefore be expected to inhibit protein
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synthesis. Third, while protein synthesis inhibitors do up-reg-
ulate the rate of constitutive cell death in granulocytes, the
kinetics of this response are very different to those observed
with gliotoxin. For example. Whyte et at. (49) have reported
that cycloheximide (50 nil) and actinomycin D (1 #im) induce
apoptosis in approximately 30% of neutrophils by 6 h. In our
experiments, gliotoxin (0.1 /rg/rnl), induces a rate of almost
twice this, whereas 1.0 pg/ml gliotoxin induced 100% neutro¬
phil apoptosis by this time point (see Fig. 1A). Likewise, our
own results with cycloheximide indicate that protein synthesis
inhibition alone does not affect the rate of neutrophil apoptosis
at 2 h whereas gliotoxin alone produced almost 15%' apoptosis
over this period (Figs. LA and 8B). While gliotoxin inhibits
NF-kB, cycloheximide and actinomycin D have been shown in
several systems to activate this transcription factor (50, 51).
Although both cycloheximide and gliotoxin give a similar syn¬
ergistic pro-apoptotic response with TNF-n, this suggests that
different mechanisms must be involved. However, while glio¬
toxin may prevent synthesis of a protective protein inducible by
NF-kB activation, cycloheximide would also preclude synthesis
of such a protein so that in both cases the cells would be
sensitive to the pro-apoptotic effects of TNF-n. It is of interest
to note that granulocytes do have the capacity to synthesize
proteins, albeit in a limited capacity (49). We believe that this
synthetic capacity will be directed toward resolution of the
inflammatory response with the generation of protein! s) that
affect the apoptotic program of inflammatory cells.
Our results indicate that the inducible isoform of NF -:B
disappears from the gliotoxin-treated granulocyte nucleus just
before the onset of stimulated apoptosis. The possibility that
these events are causally related is supported by the following
observations: (i) the synthetic cell-permeable peptide SN50
(37). a known inhibitor of NF-kB. also induces apoptosis in
neutrophils and eosinophils; (ii) other agents that inhibit
NF-kB activation, namely PDTC and curcumin as well as the
proteasome inhibitor MG-132 also cause an induction of gran¬
ulocyte apoptosis; (iii) the kinetics for gliotoxin-mediated inhi¬
bition of NF-kB match those for the onset, of induction of apo¬
ptosis; (iv) LPS which stimulates NF-kB activity prolongs
neutrophil and eosinophil survival; and (v) that gliotoxin sen¬
sitizes both neutrophils and eosinophils to the pro-apoptotic
effects of TNF-n:. Indeed, our studies provide the first plausible
explanation for the modest and temporally constrained apo¬
ptotic response of neutrophils to TNF-n and the observation
that pretreatment with LPS. PAF or granulocyte/macrophage-
colony stimulating factor, abolishes the cytotoxic effect of this
cytokine (10). Indeed, this latter point is of particular relevance
when investigating the pro-apoptotic effect of TNF-o in neutro¬
phils since pre-treatment of these cells causes a rapid decrease
of both TNF-o' receptors subtypes from the surface membrane
(10). This phenomenon, together with the fact that the effects of
SN50 are, at best, modest due to limited access of the peptide to
its intracellular target (37) and the requirement for pretreat¬
ment with the peptide, precluded accurate assessment of SN50
on TNF-o induced apoptosis in neutrophils.
When neutrophils were co-cultured with LPS and gliotoxin.
gliotoxin failed to render LPS pro-apoptotic despite the fact
that LPS induced survival was inhibited by gliotoxin (Fig. 4).
These results suggest that LPS does not trigger a death path¬
way in neutrophils but stimulates a NF-kp.-mediated survival
pathway i.e. when NF-kB activation is blocked, LPS is no
longer capable of delaying apoptosis. The precise intracellular
mechanisms by which the NF-kB inhibitors used in this study
induce apoptosis are unknown and is the subject of further
investigation. For example, it would be of interest to perform
an in-depth analyses of the effect of gliotoxin and the other
agents on the degradation of the inhibitory submiit IkB, espe¬
cially since Pahl et al. (28) reported that gliotoxin appeared to
prevent IkB degradation rather than mediate its effect at the
level of DNA binding.
In a number of immune cells NF-kB activation by agents
such as TNF-« has been shown to play a central role in regu¬
lating the genes for inflammatory cytokines such as granulo-
cyte/macrophage-colony stimulating factor and TNF-o itself
(14). The importance of this response in vivo is that many of
these factors inhibit granulocyte apoptosis and may therefore
delay inflammatory resolution by enhancing the longevity of
these cells. Indeed, a positive-feedback loop may exist since
many of these inflammatory mediators which protect against
apoptosis in neutrophils and eosinophils also activate NF-kB
(7). Conversely, we have recently shown that NO, a known
inhibitor of NF-kB (52, 53). is a potent inducer of apoptosis in
neutrophils (54). Our cm-rent results suggest that the activa¬
tion of an inducible form of NF-kB represents a powerful sur¬
vival mechanism in granulocytes, and that when this pathway
is inhibited, in both neutrophils and eosinophils, these cells
undergo a greatly augmented rate of apoptotic cell death. It. is
possible that NF-kB performs a similar function in other cell
types that undergo apoptosis in response to gliotoxin.
Enhanced cytotoxic responses to TNF-cy have also been dem¬
onstrated in cells where NF-kB is genetically deficient or inac¬
tivated (19-21) and hepatocyt.es from Rel-A null mice are
known to undergo apoptosis causing death in utero (55). Em¬
bryonic fibroblasts and macrophages from Rel-A-deficient mice
also showed dramatic loss of viability when treated with TNF-«
leading to the suggestion that Rel-A regulates a protective
mechanism against the cytotoxic effects of TNF-n. It would be
of interest to investigate the effects of TNF-o- and gliotoxin on
granulocytes isolated from mice deficient in Rel A; it would be
reasonable to predict that TNF-« will induce a rapid cell death
and gliotoxin and other NF-kB inhibitors would not. have a
dramatic effect on the rate of granulocyte apoptosis. Although
our experiments indicate that gliotoxin does not inhibit the
constitutive form ofNF-kB, at least at early time points, it does
inhibit the activation of an inducible isoform of NF-kB. which
most likely consists of heterodimers containing the Rel-A/p65
protein and therefore could perform a similar anti-apopt.otic
function in neutrophils and eosinophils. While in our hands
TNF-n does not produce significant cytotoxic effects in eosino¬
phils, co-treatment with gliotoxin caused these cells to become
highly responsive to this cytokine producing greatly increased
levels of apoptosis. This suggests that both of these inflamma¬
tory cell types could be stimulated to undergo apoptosis and
hence be cleared rapidly by phagocytes at sites of inflammation
if activation of the inducible NF-kB isoform were inhibited.
The mechanism whereby inactivation of NF-kB induces
granulocyte apoptosis and increases the cytotoxic response to
TNF-n is currently unclear. Since gliotoxin and TNF-n- driven
apoptosis are both inhibited by the caspase-inliibitor zVAD-
fmk, this, together with the synergy for apoptosis observed
with these agents, implies that NF-kB or an NF-kB regulated
step influences granulocyte apoptosis at an intermediate step
between the TNF-n receptor and caspase activation. The pos¬
sibility that NF-kB controls the transcriptional activity of a
gene(s) which induces the synthesis of survival proteins is
supported by the observation that cycloheximide also increases
apoptosis in granulocytes (49). This suggests a strong link
between inducible NF-kB activation and the control of TNF-n-
induced apoptosis, possibly via the production of a protein
inhibitor of this pathway. Indeed, as we have shown, protein
synthesis inhibition enhances the pro-apoptotic effect of TNF-o
as early as 2 h of culture. Indeed, one possible candidate for this
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protein has already been suggested: A20, a protein induced by
TNF-q- activation of NF-kB (56, 57), has been shown to protect
against TNF-a induced cell death by acting at the level of the
TNF-re receptor-associated proteins TRAF-1 and TRAF2 (58).
Although A20 has yet to be demonstrated in neutrophils or
eosinophils, this would represent an attractive candidate pro¬
tein to fulfill such a role.
The ability of gliotoxin to enhance the cytotoxic effects of
TNF-o and itself produce a rapid onset of apoptosis in inflam¬
matory cells such as neutrophils and eosinophils may suggest
NF-kB inhibition as a logical therapeutic target in the treat¬
ment of inflammatory conditions. In a rat model of lung inflam¬
mation. suppression of NF-kB activity has already been shown
to block the development of neutrophil lung inflammation by
inhibiting the synthesis of chemotaxins (59). Our results sug¬
gest that NF-kB inhibition may also be of benefit in enhancing
the resolution of inflammation by allowing a more rapid clear¬
ance of granulocytes. We therefore propose that granulocyte
apoptosis is regulated by an inducible form of the transcription
factor NF-kB and suggest that inhibition of this transcription
factor may be exploited for therapeutic benefit in inflammatory
conditions where granulocytes play a prominent role.
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Abstract
An 11 amino acid HIV-TAT peptide can deliver target proteins into a variety of cells in a
receptor independent manner. To generate a highly specific inhibitor of the transcription
factor NF-kB, we have fused the TAT-peptide to a version of IkBcx that is resistant to
signal-induced degradation. TAT-IicBa(S32A, S36A) inhibited NF-kB dependent
transcription in HeLa and A549 cells by retaining NF-kB p65 in the cytoplasm.
Introduction ofTAT-IkBoc(S32A, S36A) into human eosinophils inhibited the nuclear
translocation ofNF-kB and induced apoptosis. Thus, continuous NF-kB dependent
transcription is important for eosinophil survival. While eosinophils are normally
refractive to standard methods of gene delivery, the ability of TAT fusion proteins to be
taken up by these cells should enable a detailed molecular analysis of survival pathways
in these cells. -
1. Introduction
Excessive eosinophil recruitment and activation at inflammatory sites is likely to cause
surrounding tissue damage by liberation of their toxic granules contents. Toxic granule
proteins are important for defence against parasites, but if they are released in the host
tissue when eosinophils are inappropriately activated, they will contribute to the
progression of inflammatory diseases such as asthma. Thus levels of eosinophilic toxic
granules components such as major basic protein, eosinophil cationic protein, eosinophils
peroxidase and cysteinyl leukotrienes have been found in significantly increased amounts
in the airways of asthmatic patients and animal models suggesting that they may be
responsible for the airway tissue damage and remodelling [1-3]. An additional function
of eosinophils is the production of pro-inflammatory cytokines including IL-1, IL-4, IL-6,
IL-8, TNFa, GM-CSF and IL-5 [4]. Synthesis of these proteins in eosinophils is
dependent on activation of intracellular signalling cascades and key transcription factors.
Some of these proteins trigger the activation of inflammatory cells, including eosinophils
thereby contributing to an amplification of the inflammatory response and disease
progression. Therefore, effective removal of eosinophils from inflammatory sites may be
a key factor for successful resolution of the inflammatory process. As previously shown
from our study [5, 6] and others [7, 8] NF-kB is a key regulator of eosinophil activation
and survival.
NF-kB is a family of transcription factors that regulates survival and inflammatory
responses [9, 10]. The NF-kB family contains the proteins p65IRel A, c-Rel, Rel B, p50/
NF-kB1, and p52/ NF-kB2 in various combinations to form the active transcriptional
dimer. NF-kB transcriptional activity is controlled by the IkB family of inhibitory
proteins which contain ankyrin repeat domains (ARD) and share the function of retaining
NF-kB in the cytoplasm. IkBcx is a 37kDa protein that binds to NF-kB, retaining it in the
cytoplasm and inhibiting DNA binding. The pro-inflammatory cytokines TNFa and IL-
1 (3 initiate a signalling cascade via their receptors on the cell surface and activate the IkB
kinases consisting of subunits, IKK-1 (or IKK-a) and IKK-2 (or IKK-(3), and a structual
subunit IKKy or NEMO. The activated kinase phosphorylates IkBcc on serines 32 and 36
and phophorylated IkBcx is selectively ubiquitinated on lysine 21 and 22 by an SCF E3
ubiquitin ligase contain pTrCP. Poly-ubiquitinated IkBcc is degraded by the 26S
proteasome [11] and the released NF-kB translocates to the nucleus where it activates
transcriptional responsive genes. The pro-inflammatory cytokine TNFa can trigger at
least two antagonistic pathways: a survival pathway via NF-kB transcriptional activation
and a pro-apoptotic pathway via activation of caspase cascades. Thus inhibition ofNF-
kB un-masks the caspase-dependent pro-apoptotic properties of TNFa in many cells [12-
14] including granulocytes [6].
The study of specific intracellular signalling pathways in eosinophils is technically
challenging because they are refractory to many methods of direct molecular
manipulation such as transfection, viral infection or microinjection. Recently an 11 amino
acid HIV-TAT has been highlighted for its ability to deliver target proteins into a variety
of cells in a receptor independent manner. It has been demonstrated that the arginine rich
motif (ARM), corresponding to amino acids 47-57 ofHIV-1 TAT (YGRKKRRQRRR)
could transduce materials such as antibodies and enzymes, nucleic acids and beads into
cells in a receptor and transporter independent manner [15]. Furthermore linkage of TAT
to proteins such as p27 [15], caspase3 [16], GTPase [17] and [3-galactosidase [18]
resulted in almost 100% transduction efficiency in 30 min ofmany cells types including
granulocytes [19-21],
Here, we generated a TAT-IkBcc fusion protein that is resistant to signal induced
degradation and demonstrate that it is capable of inhibiting NF-kB dependent
transcription in a variety of cell types. Introduction of TAT-IkBcc(S32A, S36A) into
human eosinophils inhibited the nuclear translocation ofNF-kB and induced apoptosis,
thus demonstrating the utility of this approach.
2. Materials and Methods
2.1. Cloning TA T-ItcBa and GST- TA T
pcDNA IkBocWT (wild type, full length) and pcDNA S32A, S36AIkBoc were described
[23], The sequence encoding an 11 amino acid TAT peptide (YGRKXRRQRRR) [15]
inserted into pGEX2T (Pharmacia, New Jersey,USA). GST-TAT-IicBa and GST-TAT-
IkBoc (S32A, S36A) and GST-TAT were purified essentially as described [24],
2.2. Labelling TAT with FITC
Fluorescein 5-isothiocyanate (FITC) was incubated with TAT-IkBcx, recombinant IkBoc
or GST-TAT (40-80pg per mg of protein) for 1 hour at room temperature then, overnight
at 4°C in the dark. After coupling, protein was dialysed against buffer (lOmM Tris,
150mM NaCl, pH8.2), at 4°C with four changes of the same buffer and the protein
concentration determined as described [24],
2.3. Luciferase Assay
HeLa cells, 57A [25] containing an integrated NF-kB dependent luciferase reporter were
maintained in 10% FCS in DMEM. Following treatment with TAT-IkBo. or GST-TAT
cells were exposed to TNFa to activate NF-kB and 6 hours later luciferase specific
activity (RLU/mg) was determined described [25],
2.4. Other experimenal methods
Human eosinophils isolation, assessment of eosinophil apoptosis, statistical analysis,
isolation of cytoplasmic and nucleus extract for Western Blotting and fluorescence
microscopy were as described [5], with the following modifications. The images of
fluorescence microscopy were captured using Open Lab software (Improvision,
Coventry, UK) and CoolSnap digital camera (Media Cybernetics, Silver Spring, MD,
USA). To prepare cytoplasmic and nucleus extract for Western Blotting, 5xl06
eosinophils and lxl06 A549 cells were used for each condition, and were analysed with
anti-IicBoc (Cell Signalling Technology, Manchester, UK) and anti-p65 antibodies (Santa
Cruzu Biotechonology Inc, California, USA).
3. Results
3.1. Inhibition ofNF-kB Activation by TAT-IkBcc
The 11 amino-acid TAT peptide (YGRKKRRQRRR) can mediate uptake of coupled
molecules into cells. Therefore, to generate a cell permeable molecule capable of
specifically inhibiting NF-kB the TAT peptide was fused to IkBoc, the natural inhibitor of
NF-kB and IkBoc (S32A, S36A) (figure 1A) that is resistant to signal induced
degradation [26]. As a negative control the TAT peptide was also fused to GST. These
proteins and recombinant IkBoi lacking the TAT peptide were expressed in bacteria and
purified as described [24], MALDI- TOFF mass spectrometry confirmed that the proteins
were of the predicted molecular mass (TAT-IicBa(S32A, S36A); 37570 a.m.u. and
recombinant IkBoc (rlxBa); 35471 a.m.u.) and SDS-PAGE followed by Coomassie blue
staining indicated that they were essentially homogenous (figure IB).
To determine the ability of the TAT-IxBa fusion to block NF-kB activation, recombinant
proteins were applied to a HeLa cell line (57A) containing an integrated NF-kB
luciferase reporter gene [25] and preincubated for 30 min prior to addition of TNFa.
After a further 6 hours cells were harvested and luciferase activity was determined.
TNFa alone induces a large (approximately 100-fold) activation ofNF-kB dependent
reporter activity and this was substantially inhibited by addition of TAT-lKBa(S32A,
S36A), but not by GST-TAT or rficBa (figure 1C). To compare the efficiency with which
TAT-lKBa(S32A, S36A), and TAT-lKBa(WT) inhibit NF-kB activation, a range of
concentrations of the proteins were preincubated with HeLa 57A prior to addition of
TNFa and reporter activities determined. While TAT-IkBoc(WT) displays some
inhibitory potential. It is clear that TAT-IkBo,(S32A, S36A) is considerably more
efficient at inhibiting NF-kB dependent transcription (figure ID). Even at a low dose
(0.03 pg/ml) TAT-1kB(x(S32A, S36A) reduces TNF-a-activated luciferase activity by
61%. Therefore, TAT-IkBoi(S32A, S36A) was chosen for further study.
3.2. Mechanism ofInhibition ofNF-kB by TAT-IkBcc
To investigate the mechanism by which TAT-IkBcx inhibits signal induced activation of
NF-kB, the alveolar epithelial cell line A549 was preincubated with TAT-hcBa(S32A,
S36A) prior to addition of TNFa, cells were lysed and iKBa levels determined by
Western Blotting (WB) analysis. In the absence of TAT-lKBa(S32A, S36A), TNFa
induces the degradation of endogenous IKBa (figure 2A, lanes 1 and 2). Exogenous
TAT-lKBa(S32A, S36A) is resistant to TNFa induced degradation, but does not protect
endogenous IKBa from signal induced degradation (figure 2A, lanes 3 and 4). GST-TAT
does not influence TNFa induced degradation of IKBa (figure 2A, lanes 5 and 6).
To determine the influence ofTAT-lKBa(S32A, S36A) on TNFa-induced nuclear
translocation ofNF-kB, cells were pretreated with TAT fusion protein and the subcellular
localisation ofNF-kB determined by immuofluorescence microscopy.
In untreated cells, p65 is predominantly cytoplasmic but after treatment with TNFa
translocates to the nucleus (figure 2B, left panels). However, pre-treatment of cells with
TAT-IkBoc(S32A, S36A) blocks TNFa induced nuclear translocation ofNF-kB p65. Pre-
treatment of cells with GST-TAT did not influence TNFa induced nuclear translocation
ofNF-kB p65 (figure 2B, right panels). Thus, TAT-IicBa(S32A, S36A) does not inhibits
TNFa-induced degradation of endogenous IicBa but blocks nuclear translocation of the
released NF-kB.
3.3. TAT-IkBci Transduction Into Eosinophils
Unlike established cell lines, eosinophils are refractory to most forms of transfection or
viral infection. To investigate the possibility that eosinophils could take up exogenously
added protein TAT-h<Ba(S32A, S36A) and rlKBa were conjugated to FITC to allow
their direct visualisation. TAT-hcBa(S32A, S36A)-FITC was efficiently taken up by
eosinophils whereas rlKBa-FITC showed no evidence of uptake into eosinophils. To
establish the ability of TAT-hcBa to inhibit NF-kB in eosinophils, TAT-lKBa(S32A,
S36A) was preincubated with eosinophils prior to treatment with TNFa. Cells were
fractionated into nucleus and cytoplasm and analysed by WB with iKBa and p65
antibodies respectively. As in A549 cells, TNFa induced degradation of endogenous
IKBa in eosinophils, irrespective of the presence of TAT-hcBa(S32A, S36A) (figure 3B
upper panel).
In the absence ofTAT-lKBa(S32A, S36A) a significant amount of NF-kB p65 is
detected in the nuclei of eosinophils, suggesting that a fraction ofNF-kB is constitutively
active in these cells. However the nuclear content ofNF-kB p65 is dramatically increased
after treatment with TNFa (figure 3B, lower panel). In the presence of exogenous TAT-
IkBcc(S32A, S36A), the eosinophil nuclear extract is cleared of constitutively active NF-
kB p65 and TNFa induced nuclear accumulation ofNF-kB p65 is substantially reduced
(figure 3B, lower panel).
To establish the biological consequence of inhibiting NF-kB in human eosinophils TAT-
IicBa(S32A, S36A) was transduced into these cells and half of the cells treated with
TNFa. After 24 hours the proportion of cells exhibiting characteristic apoptotic
morphology was determined. In untreated or GST-TAT treated eosinophils 20% of cells
became apoptotic after 24 hours regardless of the presence of TNFa. In the presence of
TAT-lKBa(S32A, S36A), there is a dramatic increase in the proportion of apoptotic cells
(78%) that is independent of TNFa treatment (figure 3C). These results suggest that the
presence of constitutively active NF-kB is required for eosinophil survival.
4. Discussion
Eosinophils are notoriously difficult cells in which to carry out molecular analysis as they
are refractive to transfection and viral infection. Here we establish the principle ofHIV
TAT Arginine rich motif peptide (YGRKKRRQRRR) mediated uptake of proteins into
eosinophils and demonstrate that TAT fused to the complete IkBoc protein is efficiently
internalised in these cells. TAT-IkBcx(S32A, S36A) efficiently enters HeLa cells and
blocks signal-induced activation ofNF-kB dependent transcription. In A549 cells
exogenous TAT-IkBcx(S32A, S36A) does not stop TNFa induced degradation of
endogenous IkBoc, but it does inhibit nuclear translocation ofNF-kB p65. Thus it is
likely that NF-kB heterodimers released from endogenous IkBoi are bound by TAT-
IkB(x(S32A, S36A) and retained in a transcriptionally inert state in the cytoplasm. This is
coincident with recently published studies employing various versions of TAT-IkBo.
carried out in HeLa cells, Jurkat cells and bone marrow macrophages [27, 28]. The
biological consequences of introducing TAT-IkBcx(S32A, S36A) into eosinophils are
striking and a dramatic increase in apoptosis is observed, even in the absence of TNFa
(figure 3C) although this is somewhat donor dependent. This suggests that in eosinophils
constitutively active NF-kB is required to maintain a survival response and inhibition of
NF-kB by TAT-h<Ba(S32A, S36A) unmasks a potent pro-apoptotic signal. This is
consistent with the observation that NF-kB p65 is detected in the nuclei of unstimulated
eosinophils and this nuclear p65 is cleared by exogenously added TAT-lKBa(S32A,
S36A) (figure 3B). Given that free IxBa has the ability to translocate to the nucleus,
disengage bound NF-kB from DNA and export the NF-KB/IxBa complex back to the
cytoplasm [29], it is likely that exogenously added TAT-IkBcx(S32A, S36A) inhibits NF-
kB dependent transcription in eosinophils by this mechanism. A requirement for
constitutive activation ofNF-kB to provide a survival response was also evident from
previous studies in eosinophils where pharmacological inhibitors ofNF-kB activity such
as gliotoxin and Mgl32 induced apoptosis [5].
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Figure legends;
Figure 1; A. Schematic diagram representing the structure of TAT-hcBa(S32A, S36A).
B. The indicated purified proteins were analysed by SDS-PAGE followed by Coomassie
Blue Staining. C. HeLa 57A cells containing an NF-KB-dependent luciferase reporter
were incubated with recombinant IkBcx (rhcBa ), GST-TAT or TAT-IkBcx(S32A, S36A)
at 30pg/ml for 30 min prior to treatment with TNFa (5ng/ml). After a further 6 hours
luciferase activity was determined and expressed as fold activation relative to the activity
in cells that were not exposed to TNFa. D. The effect of TAT-hcBa(S32A, S36A) and
TAT-lKBa(WT) on NF-KB-dependent reporter activation. HeLa 57A cells were
incubated with the indicated TAT-h<Ba (S32A, S36A) or TAT-lKBa(WT) for 30 min at
37°C and exposed to TNFa (5ng/ml) for further 30 min. Error were not shown as they
were within the range of the symbols.
Figure 2. Inhibition ofNF-kB by TAT-hcBa in A549 cells. A549 cells were incubated
with TAT-lKBa(S32A, S36A) (30pg/ml) and GST-TAT (30pg/ml) for 30 min at 37°C
and then treated with TNFa (5ng/ml) for 30 min. A. Cytoplasmic extract was analysed by
WB with anti IxBa antibody. B. Cells were stained with anti-p65 antibody and viewed
by fluorescence microscopy as indicated in materials and methods.
Figure 3. A. TAT-IxBa transduction into eosinophils FITC conjugated TAT-IxBa or
rlKBa (both at 30pg/ml) were incubated with purified human eosinophils for 30 min at
37°C in the dark. After extensive washing to remove unbound material, FITC conjugated
proteins were visualised by fluorescence microscopy. B. Eosinophils were incubated with
TAT-IkBo.(S32A, S36A) (30pg/ml) for 30 min at 37°C and further treated with TNFa
(5ng/ml) for 30 min, prior to preparation of nuclear and cytoplasmic extracts. IkBcx levels
in cytoplasmic extracts and p65 levels in nuclear extracts were determined by WB. C.
Eosinophils were treated with TAT-IkB(x(S32A, S36A) (30p.g/ml) and GST-TAT
(30pg/ml) for 30 min at 37°C and further treated with TNFa (lOng/ml) as indicated. At
24 hours, apoptosis was determined morphologically. All values represent mean ± S. E.







































+ + + +














Figure 3. Fujihara et al.,
















no TAT TAT-IicBa GST-TAT
(S32A, S36A)
